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ABSTRACT 
 
 
Bacterial secondary metabolites have historically been a rich source of antibiotic compounds. The 
genomic era has shown that bacteria harbor the potential to produce even more natural products 
that could be developed into new antibiotic agents to combat the alarming rise in antibiotic-
resistant pathogens. Ribosomally synthesized and post-translationally modified peptide (RiPP) 
natural products are genetically encoded peptide-derived secondary metabolites whose structures 
can be predicted based on gene sequence and identity of tailoring enzymes within the biosynthetic 
gene cluster. Post-translational modifications installed by the tailoring enzymes in a site-selective 
manner endow the compounds with structural rigidity and, in many cases, interesting biological 
activities. Once genome mining has been used to select RiPPs gene clusters, chemical and 
microbiological techniques are employed to characterize the structure, biosynthesis, antibiotic 
activity, and mode of action of newly discovered RiPPs.  
Plantazolicin (PZN) is a RiPP natural product with a rigid, polyheterocyclic structure and 
a remarkably species-specific antibiotic activity, targeting the pathogen Bacillus anthracis. While 
the highly modified natural product bears the characteristic heterocycles of a linear azol(in)e-
containing RiPP, N-terminal dimethylation after cleavage of the leader peptide is also essential for 
bioactivity. The methyltransferase responsible for this post-translational modification is highly 
evolved for PZN-like substrates, with very little tolerance to mutant sequences.  
The underlying cause of the ultra-narrow spectrum bioactivity was investigated using a 
broad range of chemical and microbiological techniques. PZN was not found to have a 
proteinaceous target; instead, the bioactivity was found to be dependent on the 
diphosphatidylglycerol lipid cardiolipin. PZN is thought to localize to weakened sections of the B. 
anthracis membrane that contain aggregates of cardiolipin. These lipid aggregates create regions 
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of membrane instability in B. anthracis, and PZN is able to insert into these regions, causing 
membrane depolarization and eventual cell lysis. Exogenous cardiolipin synergizes with PZN to 
enhance antibiotic potency. 
The citrulassin sub-family of lasso peptides contain a citrulline post-translational 
modification which inspired reactivity-based screening for additional citrullinated natural products 
from bacteria. While ubiquitous in eukaryotes, deamination in bacteria is poorly characterized and 
exceedingly rare. Surprisingly, the peptidyl arginine deiminase responsible for the modification of 
arginine to citrulline in bacteria is not known. Comparative genomics was employed to find a 
putative PAD enzyme, which was subsequently heterologously expressed and tested for arginine 
deiminase activity. The scope of citrulline post-translational modifications in the citrulassins was 
further investigated, and the utility of the probe to label citrulline-containing natural products in 
complex biological extracts was studied. The bacterial arginine deiminase responsible for the 
modification of peptidic substrates was investigated. The citrulline-specific reaction is useful for 
labeling of not just RiPPs, but other citrulline-containing natural products as well.  
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CHAPTER 1: INTRODUCTION 
 
 
1.1 Genomics-driven antibiotic discovery  
 
1.1.1 The golden age of antibiotics and the rise of antibiotic resistance 
 
Historically, bacterial infections were portents of death. With treatment options limited to synthetic 
compounds of particularly harsh natures, even medical aid was not a guarantee for survival. 
However, the discovery of penicillin in 1928 ushered in a revolution in modern medical treatment. 
When penicillin began to be used as a treatment for infections in the 1940s, the drug seemed to 
promise the end of the fear surrounding disease.1 Alexander Fleming’s discovery of penicillin from 
the fungus Penicillum notatum inspired the hunt for additional bacterial and fungal compounds 
with potent antibiotic activity. During the so-called golden age of antibiotic discovery, many such 
compounds heralded a future free from pathogens.  
Unfortunately, bacteria have rapidly acquired resistance to all clinically relevant classes of 
antibiotics.2 Alarmingly, many of the more recently FDA-approved antibiotics have had less than 
one year of use prior to observed antibiotic resistance (Figure 1.1).3 While human pathogens are 
not necessarily endogenously resistant to such antibiotics, there is enormous selective pressure to 
acquire means of survival. Human microbiota are known reservoirs of antibiotic resistance genes, 
enabling these organisms to survive even during antibiotic courses. Hence, when pathogens 
interact with the natively resistant microbiome under the stress of antibiotic treatment, horizontal 
gene transfer is hypothesized to provide a mechanism through which pathogens acquire resistance 
genes.4 
To combat the continual threat of resistance, elaboration of the current arsenal of antibiotic 
scaffolds has elongated the utility of the currently available drugs. Throughout the 1970s and 
1980s, chemical derivatization of antibiotics was targeted at overcoming the new resistance 
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mechanisms observed. Mechanisms by which bacteria survive in the presence of cytotoxic 
concentrations of antibiotics include expression of drug efflux pumps, acquisition of enzymes that 
degrade the antibiotics, mutation of the target of the antibiotic, or use of alternative metabolic 
pathways that enable survival.5 Thus, the primary modes by which novel second-generation 
antibiotics were developed were derivatization of currently prescribed compounds or through the 
use of synergistic inhibitors, which in combination with the primary antibiotic enhanced efficacy 
by targeting certain metabolic pathways more effectively. However, drug scaffolds that target 
different pathways or have novel modes of action may provide many more years of effective 
antibiotics.6 Increasing structural diversity of antibacterial compounds is an integral part of 
overcoming acquired resistance mechanisms.7 Thus, novel methods of discovering antibiotic 
therapies to combat the rise of these nascent pathogens are necessary.  
1.1.2 Impact of the genomic revolution on antibiotic discovery 
 
Natural products have historically been a rich source of antibiotics (Figure 1.2),8 though the 
traditional method for discovering new bioactive compounds from bacterial sources via 
bioactivity-driven screening of bacterial extracts is plagued by rediscovery.9 Fortunately, the 
genetic revolution heralds a new wave of antibiotic discovery. Sequencing bacterial and fungal 
genomes provides surprising and hopeful insight into the vast number of untapped biosynthetic 
gene clusters predicted to produce secondary metabolites.10 Genomics has been exploited as a way 
to identify novel bacterial targets for antibiotic development; targets that are specific to pathogens 
but are absent in commensals and eukaryotes could decrease the rapidity at which resistance 
develops.7, 11 
With the rapidly declining cost of genomic sequencing, the number of sequenced 
organisms has grown exponentially. Mining the vast array of genomic data has shown the untapped 
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potential of bacteria to produce diverse natural products.12-13 This reverse-genetics approach to 
finding natural products is revolutionizing the manner in which natural products, and in turn 
potential antibiotic scaffolds, are discovered.14-15 Genomics can provide insight into the types of 
natural products an organism may be capable of producing, the potential of those compounds for 
interesting biological activities, and can even guide the isolation and structure elucidation 
process.16-17  
1.1.3 Reactivity-based screening for natural product discovery  
 
A recent advance in natural product discovery that has exploited the recent availability of the 
expontentially increasing collection of genomic data is reactivity-based screening (RBS). The 
main driving force behind RBS is the discovery of novel drug scaffolds, both from well-studied 
and new organisms. Additionally, there is interest in connecting genes to molecules, thereby 
elucidating new biosynthetic pathways and the genetic basis for chemistry taking place in a 
biological context.16 This can, in turn, elucidate ways in which the natural product biosynthetic 
pathway can be altered to produce unnatural compounds and, in turn, libraries of compounds to be 
tested for interesting and potent antibiotic properties.18 
In RBS, a chemical reaction is developed to specifically react with a natural product 
functional group of interest. These functional groups may endow the natural product with 
enhanced stability, improved structural rigidity, an altered conformation, or a specific reactivity. 
Examples of modifications of interest include terminal alkenes and alkynes, thioether bonds, 
aldehydes, and dehydrated amino acids. Reactions that are ideal for RBS are (a) able to specifically 
react with the functional group in a complex sample; (b) not adversely affected by the presence of 
water; (c) simple, one step reactions; (d) easily scalable and easily carried out in parallel; (e) 
compatible with mass spectrometry and (f) possibly extendable to guide purification or enrich for 
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the specific natural product.19 The reaction is developed by testing reaction conditions on purified 
natural product substrates, followed by reactions in cell extracts known to contain natural products 
with the functional group of interest. For example, an aminooxy probe was recently validated by 
first labeling purified streptomycin, an aldehyde-containing aminoglycoside antibiotic. The 
reaction was then confirmed to label streptomycin in an extract from the producing organism, 
Streptomyces griseus.20 
After a functional group has been selected, the enzyme or enzymes responsible for that 
modification are used as diagnostic markers to guide genome mining for suitable organisms. 
Prioritized strains containing the necessary enzymes are then grown, extracted, and a portion of 
the extract is subjected to the reaction with the probe. Using mass spectrometry, the unreacted 
extract is compared with the reacted sample. Mass shifts characteristic of the reaction are used to 
confirm the presence of a biomolecule bearing the functional group of interest. If the reactions 
successfully label a biomolecule, subsequent isolation and characterization can occur (Figure 1.3).   
 RBS has been used to guide the identification and purification of a number of natural 
products with antibiotic activity, demonstrating the utility of the technique in not only connecting 
genes to molecules but also providing potential leads in antibiotic discovery.20-22 For example, 
RBS was used to guide identification and purification of a natural product from Streptomyces 
rimosus subsp. rimosus.21 Bacterial extracts were screened with dithiothreitol, known to react with 
a,b-unsaturated amino acids, and a characteristic mass shift was observed. The isolated natural 
product, cyclothiazomycin C, is a novel thiopeptide with Gram-positive antibiotic activity. 
Cyclothiazomycin C belongs to a much larger family of natural products that are ribosomally 
synthesized and post-translationally modified. These natural products are genetically encoded and 
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have distinct classes of enzymes responsible for post-translational modifications, making them 
ideal candidates for RBS. 
1.2 Ribosomally synthesized and post-translationally modified peptide natural products 
 
The ribosomally synthesized and post-translationally modified peptide natural products (RiPPs) 
are a family of secondary metabolites that is rapidly growing. Due to the vast number of sequenced 
genomes, many newly designed bioinformatics programs have been designed to mine genomic 
databases for recognizable sequences.23-25 Similar to nonribosomal petptide and polyketide 
biosynthetic machinery, there are genetic signatures that can be used to search new genomes for 
RiPP gene clusters and to predict natural product structures.16-17, 26-27 The diversity of post-
translational modifications, such as various cyclizations, dehydrations and oxidations, 
rearrangements, and methylations, create complex scaffolds that have inspired new thinking about 
the untapped chemical potential of bacteria (Figure 1.4).28-30  
Recently, the similarities between biosynthetic gene clusters for the many families of RiPPs 
were characterized and the family was organized into distinct classes based on the posttranslational 
modification machinery involved in production of each RiPP.28 As of 2013, RiPPs are organized 
into 20 classes,28 mostly based on biosynthetic enzymes but in some based grouped around 
historical classifications such as producing organism31 or biological activity.32 The discrete, 
modular modification machinery of RiPPs makes these natural products extremely amenable to 
mutation and library generation. Interestingly, a number of RiPP biosynthetic gene clusters encode 
multiple precursor peptides, suggesting flexibility in the posttranslational machinery to accept 
multiple core peptide sequences.33-34 Ease of genetic mutation has also facilitated the ease with 
which novel RiPP analogs can be generated.18, 35  
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The overarching logic of the biosynthesis of a RiPP is as follows: the precursor peptide is 
a short, 20 – 110 amino acid peptide that is synthesized in the ribosome. Tailoring enzymes have 
a specific RiPP recognition element (RRE)26 that enable them to bind to the leader peptide and 
perform enzymatic modification of the core region of the precursor peptide (Figure 1.5).36 In some 
cases, the core peptide is N-terminal to the leader peptide, which is then referred to as the follower 
peptide.37-38 Proteolytic cleavage of the leader peptide, when not required for certain post-
translational modifications (such as in the case of the cyclization of lasso peptides, for example) 
is required prior to export of the mature natural product. Some post-translational modifications 
also occur after leader peptide cleavage, such as the dimethylation of the nascent N-terminus of 
the linear azol(in)e-containing peptide plantazolicin39-41 and the isopeptide bond macrocyclization 
of lasso peptides.17, 28  
1.2.1 Thiazole-oxazole modified microcins 
 
Linear azol(in)e-containing peptides (LAPs) are a subclass of thiazole-oxazole modified microcins 
(TOMMs), an overarching classification for RiPPs that contain cyclized Thr/Ser and Cys residues, 
including some thiopeptides, cyanobactins, and LAPs.28, 42-43 LAPs are characterized by a lack of 
macrocyclization machinery but the presence of a cyclodehydratase complex that will process 
Thr/Ser and Cys residues into the corresponding (methyl)oxazoline or thiazoline. Occasionally, a 
dedicated dehydrogenase will perform a two-electron oxidation to further elaborate azolines into 
azoles (Figure 1.6).44 The mechanism of cyclodehydration is an ATP-dependent backbone 
activation, followed by subsequent nucleophilic attack from the side chain O/S.45-46 Heterocycle 
formation induces more complex secondary structure which rigidifies the backbone and protects 
the molecule from proteolytic degradation.  
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Some of the earliest-characterized TOMMs are members of the LAP family of TOMMs, 
including microcin B1747 and streptolysin S.48 Plantazolicin (PZN) is a LAP with an unusual 
polyheterocyclic structure discovered through a reverse genetics approach in the soil-dwelling 
bacterium Bacillus velezensis  FZB42.49-50 The two sets of five heterocyclized residues, which are 
all installed by a common cyclodehydratase complex, has inspired multiple total syntheses, 
although thus far none has successfully achieved one-pot cyclization of all ten residues.51-53  
Not only does PZN have an intriguing structure, but its biological activity is also unique. 
PZN selectively targets the native producer of anthrax, Bacillus anthracis, in a species-specific 
manner.54 Determination of the mode of action of PZN through standard microbiological assays 
was unsuccessful, but through a combination of chemical and microbiological strategies, it was 
determined that PZN specifically kills B. anthracis by interacting with unusual lipid aggregates in 
the cell membrane. Cardiolipin creates regions of increased fluidity and destabilization that enable 
PZN to insert in the membrane and cause cell lysis.54-55 Like PZN, other TOMMs have antibiotic, 
antiviral, or anticancer activity, or act as virulence factors and signaling molecules.43 At least 700 
TOMMs have been identified bioinformatically, suggesting the family has great potential for 
future structural and functional analysis.16, 29, 56 
1.2.2 Lasso peptides 
 
Compared to the TOMMs, lasso peptides have very small biosynthetic gene clusters and only two 
necessary tailoring enzymes, a leader peptidase and a lasso cyclase. After leader peptide cleavage, 
the C-terminal tail region of the core peptide is encircled by a macrocycle formed between the 
nascent N-terminus and an Asp/Glu side chain, creating a locked lariat topology (Figure 1.6). High 
sequence variation within the bioinformatically characterized precursor peptides allows for a vast 
array of naturally occurring lassos in three different families, and suggests great potential for lasso 
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peptide library generation.57 Interestingly, lasso peptides are particularly resistant to proteolysis 
due to the complex three-dimensional structure, which may also endow many lasso peptides with 
antimicrobial activity.58-59 
Lasso peptides were recently subject to extensive bioinformatic investigation as a test case 
for developing an ORF recognition and natural product structure prediction program.60 Rapid ORF 
Description and Evaluation Online (RODEO) showed the previously-unknown biodiversity of 
lasso producers and was used to map over 1400 lasso peptide biosynthetic gene clusters and 1300 
precursor peptides. In the course of validating the core sequence and structure prediction portions 
of the program, six lassos were selected for isolation, structural confirmation, and bioactivity 
testing. Surprisingly, one lasso peptide was found to have an additional post-translational 
modification not predicted based on the biosynthetic gene cluster.60 Citrulassin A contains an Arg-
to-Cit modification, causing a mass increase of 1 Da and the loss of a net positive charge at neutral 
pH.61 A distally arginine deiminase is hypothesized to perform the post-translational modification, 
and evaluation of this enzyme is revealing the biosynthetic potential of bacteria to install citrulline 
residues into proteins and peptide-derived natural products. Intriguingly, however, citrulassin A 
does not appear to have antibiotic activity, calling into question the role of this PTM in not just 
lasso peptides, but other bacterially produced citrulline-containing natural products.60 RODEO 
uncovered many lasso peptide gene clusters containing phosphorylation and adenylation domains 
involved in bacterial signaling pathways, which suggests that deimination may also be important 
for signaling.60 
1.3 Determining antibiotic mode of action 
 
While knowledge of the mode of action is not required for the clinical deployment of an antibiotic, 
as in the case of daptomycin,62 such information could play a critical role in determining useful 
 9 
combination therapies and efficient structural elaboration for subsequent generations of drugs. For 
instance, if the target of an antibiotic is known, the interaction can be used to guide structure-
activity relationship studies to improve binding to the target or diminish off-target interactions. 
Most of the commonly prescribed antibacterials kill bacteria by targeting cell wall biosynthesis, 
protein biosynthesis, or nucleic acid biosynthesis.63 Therapeutic agents that can work in tandem to 
resensitize pathogens to commonly used antibiotics may provide the next set of useful antibiotics. 
However, this requires a deep understanding of not only drug interactions with targets, but how 
different modes of action can antagonize or synergize with one another. Alternatively, drug 
scaffolds that are entirely different from currently used drugs may target bacteria through other 
essential pathways for which bacteria have not acquired resistance mechanisms. 
 Chemical methods to determine the mode of action of antibiotic agents generally rely on 
substrate modification, such as the attachment of affinity tags for affinity purification or 
fluorescent molecules for microscopy-guided localization. These techniques can complement the 
microbiological techniques of RNA-Seq,64 resistant mutant generation and sequencing,65 and 
macromolecular synthesis assays, to name a few. 
1.3.1 Affinity purification 
 
A common first approach to determining antibiotic mode of action is affinity purification, which 
can provide relatively direct evidence to its binding ligands and hence, target information.66 A 
position in the molecule that is amenable to modification is labeled with an affinity probe, such as 
biotin. The compound is dosed into cell lysate and allowed to bind to its target, and then isolated 
from the cell lysate. The tagged antibiotic and its target interact with a resin bearing the binding 
partner of the tag molecule, such as streptavidin for biotin tags or glutathione for GST tags, and 
the pair are specifically eluted after washing away noninteracting biomolecules.67 Using 
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proteomics and mass spectrometry, the target can then be identified and subsequently validated 
through additional biochemical and microbiological investigation.68   
Affinity purification is particularly designed for molecules that covalently modify their 
target biomolecule, as the drug-target bond cannot be broken during the washing and purification 
steps. However, there are significant drawbacks to affinity purification, limiting its utility,  
especially for compounds that interact in a noncovalent manner with the cellular target.69 Indeed, 
the many strategies available for target identification suggest that no one technique is capable of 
elucidating all compound-target interactions, due to complexities that may be inherent in the 
compound-target interaction.70 First, the target must remain stable in cell lysate and folded 
correctly for the interaction to occur. Second, the drug molecule must be amenable to derivatization 
without significantly affecting binding to the target.71-72 Third, the drug-target interaction must be 
strong enough to persist through stringent washing protocols. Some of the difficulties can be 
alleviated with the use of photoaffinity reagents to covalently attach the biomolecule to the drug.66, 
73-74 
1.3.2 Fluorescence microscopy 
 
Evaluation of antibiotic-treated cells by microscopy can be used to determine the mode of action 
of antibiotics through the observation of phenotypic changes. For example, cell lysis can indicate 
pore formation and subsequent membrane depolarization, leading to lytic activity, such as in the 
case of nisin.75-76 Morphological changes of resistant mutants may signify that certain pathways 
are negatively affected by a drug. Streptomonomicin resistance induces a chaining phenotype in 
B. anthracis, which suggests that the lasso peptide interacts with cell wall biosynthesis.77 In 
addition, localization of a fluorescent antibiotic can inform on its action within the bacterium. 
Vancomycin and ramoplanin each stain cells at sites of active peptidoglycan biosynthesis, 
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including the cell poles and in helical patterns across the side walls of bacilli.78 Two-component 
action of haloduracin α/β was confirmed through labeling of both molecules and using 
fluorescence resonance energy transfer microscopy.79 Similar to affinity purification, fluorescent 
tagging of antibiotics is limited by the fact that the fluorophore must not interfere with the ability 
of the antibiotic to bind to its target.80 
More precise fluorescence microscopy in recent years has enable improved spatial 
localization of antibiotics, especially with the development of super-resolution microscopy to 
bypass the diffraction limit of traditional microscopy. Crucial to the technology is a 
photoswitchable dye such as Cyanine5, which can be sent into a dark or nonfluorescent state, 
enabling activation of only a very small subset of dye molecules at any one time.81-82 Stochastic 
optical reconstruction microscopy (STORM), which can achieve resolution to 20 nm,82-83 recently 
demonstrated that a fluorescent PZN derivative formed aggregates within the B. anthracis cell 
envelope, leading to cell lysis.54 Due to the small size of bacterial cells (1 – 2 µm in diameter for 
many Bacilli), limitations to resolution make subcellular localization difficult without super-
resolution microscopy. However, single molecule fluorescence imaging is a powerful technique to 
directly visualize drug-target interactions in real time.54, 79, 84 
1.3.3 Other methods to determine mode of action 
 
In order to validate an antibiotic mode of action, there must be additional means of implicating a 
connection between drug target and drug molecule. Growing susceptible species in the presence 
of sub-inhibitory concentrations of compound can lead to the evolution of resistant mutants. 
Genomic polymorphisms giving rise to resistance could support the involvement of certain genes 
and biological processes in overcoming antibiotic susceptibility. Daptomycin-resistant 
Enterococci mutate liaF and GdpD, genes which are involved in phospholipid cell wall 
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metabolism, confirming that the antibiotic induces cell envelope stress.85-86 A complementary 
approach involves overexpression of the putative target, resulting in reduced potency of the drug.87 
Transcriptional profiling techniques, such as RNA-Seq, provide a global picture of bacterial 
response to an antibiotic and are also useful in highlighting pathways involved in antibiotic-
induced stress response.88 Similarly, macromolecular synthesis assays show bacterial response to 
antibiotic treatment in real time through measuring alterations in the incorporation of radiolabeled 
precursors into various biomolecules such as peptidoglycan, proteins, and DNA.89 While no one 
assay is sufficient to confirm an antibiotic target, these and many other techniques can be used in 
combination to better understand antibiotic mode of action. Despite the challenges, determining 
mode of action can provide powerful new insight into biological processes in addition to furthering 
the search for new antibiotics and new targets for antibiotic development. 
1.4 Summary and outlook 
 
Natural product discovery is undergoing a revolution due to the advent of next-generation 
sequencing and the proliferation of programs designed to mine genomes for biosynthetic potential. 
Previously, natural products with interesting bioactivities were isolated based on biological 
activity; however, this yielded only high-abundance natural products in certain families. Now, 
however, bioinformatics is shedding light on the potential of organisms to produce compounds 
covering a much broader area of chemical space. These predicted compounds demonstrate the vast 
array of biochemical reactions, provide interesting new scaffolds to inspire the development of 
new antibiotics, and even inspire organic chemists to attempt new chemical reactions.  
 A burgeoning class of natural products benefiting from new genome mining efforts is the 
ribosomally synthesized and post-translationally modified peptide family of natural products. 
Many of these compounds display interesting biological activities and have unique biosynthetic 
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enzymes. Critically, natural product discovery efforts guided the isolation, purification, and 
characterization of the RiPP natural product, plantazolicin. The linear azol(in)e-containing peptide 
has ten nitrogen-containing heterocycles but also requires N-terminal dimethylation for potent 
anti-B. anthracis activity. In Chapter 2, we studied the enzyme responsible for this final post-
translational modification in the biosynthesis of plantazolicin. We investigated the minimal 
substrate necessary for enzyme recognition and determined the kinetics of substrate binding. We 
crystalized the purified methyltransferase with the cofactor inhibitor S-adenosylhomocysteine and 
with PZN substrate analogs in order to better understand the exquisite selectivity of the 
methyltransferase for PZN-like substrates. 
 PZN generated interest not just for its biosynthesis but also its ultra-narrow spectrum of 
bioactivity. In Chapter 3, we covered the scope of PZN bioactivity and demonstrated its species 
selectivity. We investigated the mode of action through extensive bioactivity testing, chemical 
derivatization, genetic analysis of resistant mutants, and additional biochemical assays. While no 
specific target for PZN was definitevely determined, resistant mutants suggested cardiolipin 
misaggregation in the B. anthracis cell membrane was necessary for PZN bioactivity. We validated 
the role of cardiolipin by demonstrating synergy with PZN and studying the effects of exogenous 
cardiolipin on the ability of a fluorescent derivative to label B. anthracis. We finally suggested 
that ultra-narrow antibiotics may be useful in combating the rise of antibiotic resistance. 
 While predicting natural products through genome mining projects demonstrates the 
untapped potential of nature to synthesize complex scaffolds, isolation and purification of those 
compounds for characterization is often the rate-limiting step. Reactivity-based screening takes 
advantage of genomic information about specific enzymatic processes that install functional 
groups of interest onto natural products to streamline extract screening. In Chapter 4, we extended 
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reactivity-based screening to investigate the scope of citrulline modifications in ribosomally 
synthesized and post-translationally modified peptides, in particular the lasso peptides. We used 
the results of reactivity-based screening to inform the search for the bacterial peptidyl arginine 
deiminase responsible for the post-translational modification.  
 Currently, genomics is generating extreme interest in natural product discovery for 
antibiotic development. However, the isolation and subsequent characterization of these 
compounds is necessary to determine their utility as drug scaffolds. The biosynthetic evaluation of 
plantazolicin, determination of its mode of action, and the study of novel post-translational 
modifications onto peptide-derived scaffolds empowers the future of natural product discovery 
and characterization, and supports the continued efforts to prioritize natural products for antibiotic 
development. 
 
 
1.5 Acknowledgement 
 
I am grateful to Christopher Schwalen for his critical review of this introductory chapter. 
 
  
 15 
1.6 Figures 
 
Figure 1.1 Years of antibiotic efficacy prior to clinically observed resistance. Antibiotics are 
ordered by date of release, from left to right. Gradients indicate members of the antibiotic class 
have a range of years of efficacy. Data adapted from Clatworthy, Pierson, and Hung, Nat. Chem. 
Biol. 2007, 3, 541. 
 
 
Figure 1.2 Sources of all clinically relevant antibiotic agents, demonstrating the importance of 
natural products as inspiration for new drug molecules. Data adapted from Newman and Cragg, J. 
Nat. Prod. 2012, 75, 311. 
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Figure 1.3 Workflow of reactivity-based screening. Genome mining for specific modification 
enzymes leads to prioritized strains, which can be cultured and tested with a specific labeling 
reaction for the production of natural products bearing the functional group of interest. If the 
natural product is produced under laboratory conditions, the compound can be isolated and further 
characterized. 
 
 
 
 
 
Figure 1.4 Representative structures of characterized RiPP natural products. Family-defining 
post-translational modifications are highlighted in red. Family names are listed in italics below 
the name of the natural product. 
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Figure 1.5 General scheme for the biosynthesis of RiPP natural products. (A) The RiPP 
biosynthetic gene cluster contains genes for the precursor peptide, tailoring enzymes, and 
additional enzymes involved in immunity, proteolysis, and export. (B) The post-translational 
machinery installs modifications onto the ribosomally produced precursor peptide, composed of a 
leader and a core peptide. After proteolytic cleavage of the leader peptide, the mature RiPP natural 
product is exported from the producing organism. 
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Figure 1.6 Enzymatically driven heterocycle formation in linear-azole containing peptides (LAPs) 
utilizes a cyclodehydratase (D protein) to guide heterocycle formation through backbone activation 
with an intermediate phosphorylated hemi-orthoamide. The cyclodehydratase occasionally is 
paired with a secondary enzyme responsible for leader peptide binding (C protein). Additional 
elaboration with an FMN-dependent dehydrogenase is also possible, leading to the oxidation of 
azolines to azoles and a total mass loss of 20 Da from the natural amino acid. 
 
 
 
 
 
 
 
 
 
 
Figure 1.7 General scheme for the biosynthesis of lasso peptides. Cleavage of the leader peptide 
occurs prior to threading and cyclization of the core peptide, yielding the mature natural product. 
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CHAPTER 2: INSIGHTS INTO METHYLTRANSFERASE SPECIFICITY AND 
BIOACTIVITYOF DERIVATIVES OF THE ANTIBIOTIC PLANTAZOLICIN1 
 
2.1 Abstract 
 
Peptide antibiotics represent a class of conformationally constrained natural products of growing 
pharmaceutical interest. Plantazolicin (PZN) is a linear, polyheterocyclic natural product with 
highly selective and potent activity against the anthrax-causing bacterium, Bacillus anthracis. The 
bioactivity of PZN is contingent on demethylation of its N-terminal Arg residue by an S-
adenosylmethionine-dependent methyltransferase. Here, we explore the substrate tolerances of 
two homologous PZN methyltransferases by carrying out kinetic analyses of the enzymes against 
a synthetic panel of truncated PZN analogs containing the N-terminal Arg residue. X-ray cocrystal 
structures of the PZN methyltransferases with each of these heterocycle-containing substrates 
provide a rationale for understanding the strict substrate specificity of these enzymes. Kinetic 
studies of the structure-guided, site-specific variants allowed for the assignment of residues 
governing catalysis and substrate scope. Microbiological testing further revealed that upon 
demethylation of the N-terminal Arg, a pentaheterocyclized PZN analog retained potent anti-B. 
anthracis activity, nearly equal to that of full-length PZN. These studies may be useful in the 
biosynthetic engineering of natural product analogs with different bioactivity profiles, as 
demonstrated by our identification of a truncated plantazolicin derivative that is active against 
methicillin-resistant Staphylococcus aureus (MRSA). 
                                                
1 Reprinted with permission from Hao, Y.*.; Blair, P.M.*; Sharma, A.; Mitchell, D.A.; Nair, S.K. "Insights into 
methyltranferase specificity and bioactivity of derivatives of the antibiotic plantazolicin." ACS Chem. Biol., 10:1209-
1216 (2015). Copyright 2015 American Chemical Society. Y.H. performed crystallization and biochemical assays. 
A.S. synthesized PZN analogs used in this manuscript. 
*These authors contributed equally to this work. 
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2.2 Introduction 
Ribosomally synthesized and post-translationally modified peptides (RiPPs) encompass a large 
and widely distributed class of bioactive secondary metabolites,1 which include 
the thiazole/oxazole-modifiedmicrocins (TOMMs).2 The natural product plantazolicin (PZN) (1), 
produced by the plant growth-promoting bacterium Bacillus amyloliquefaciens FZB42,3-4 is 
biosynthesized from a 41-residue precursor peptide to yield a product that contains ten azol(in)es, 
produced through the cyclodehydration and subsequent oxidation of Cys/Ser/Thr characteristic of 
TOMMs.5-6 Installation of the heterocyclic moieties is catalyzed by an ATP-dependent 
cyclodehydratase that converts Cys and Ser/Thr to thiazoline and (methyl)oxazoline, respectively,7 
followed by a flavin mononucleotide-dependent dehydrogenation8 to yield the corresponding 
thiazole and (methyl)oxazole. Twelve out of the fourteen residues of the core region of the PZN 
precursor peptide are modified in the fully mature, bioactive natural product. Following the 
proteolytic excision of the 21-residue leader sequence from the deca-heterocyclized peptide, an S-
adenosyl-L-methionine (SAM)-dependent methyltransferase modifies the N-terminus.9 The 
resultant product PZN bears an Nα,Nα-dimethylArg as the N-terminal residue, five contiguous 
azoles, two hydrophobic spacer residues, followed by another stretch of five contiguous 
heterocycles, and terminates with a C-terminal Phe (Figure 2.1). Genome mining has identified 
four other bacterial strains with the capacity to generate PZN-like molecules, with Bacillus 
pumilus being a demonstrated producer of PZN.6 
PZN displays a narrow spectrum of activity. Using the microbroth dilution method, the 
only organism susceptible to the action of purified PZN to date has been Bacillus anthracis, the 
etiological agent of anthrax.6, 10 Using the agar disk diffusion method, which allows unrealistically 
high concentrations of antibiotic to be impregnated into the disk, PZN displayed weak growth 
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inhibitory activity towards other members of the genus Bacillus.4 Notably, the biological activity 
of PZN is contingent on the Nα,Nα-methylation of the terminal Arg, as desmethylPZN activity is 
attenuated.6 Reconstitution experiments demonstrated that recombinant BamL (the PZN 
methyltransferase from B. amyloliquefaciens) and BpumL (the orthologous methyltransferase 
from B. pumilus) can install both methyl groups onto desmethylPZN in an SAM-dependent 
manner.9 Unlike other canonical methyltransferases involved in natural product biosynthesis,11-13 
both BamL and BpumL have highly restricted substrate tolerances, as the unmodified precursor 
peptide, as well as several other peptidic substrates designed to mimic the functionality of 
desmethylPZN, were not substrates for these enzymes.9 BamL can also accept Arg amide (in which 
the α-carboxylate is replaced with an amide) as a substrate, but only so under near-single turnover 
conditions.9 Another study concluded that Arg thiazole (also containing a terminal amide) is the 
minimal substrate for BamL, and found that residues other than Arg are not tolerated by the 
methyltransferase.14 Lastly, BamL reactions with Arg-thiazole yielded mainly monomethylated 
product under stoichiometric (i.e. limiting) concentrations of SAM, and the BamL active site 
mutant Tyr182Phe also yielded monomethylated product using desmethylPZN as substrate.14 
Our prior crystal structures of BamL (PDB Code: 4KVZ) and BpumL (PDB Code: 4KWC) 
in complex with S-adenosyl-L-homocysteine (SAH) revealed a minimalistic methyltransferase 
fold that lacked any additional structural decorations.9 Due to the limited aqueous solubility of 
desmethylPZN, numerous attempts to solve the structures of BamL/BpumL with bound substrate 
were unsuccessful. Additionally, substrate solubility limitations precluded kinetic characterization 
of wild-type and mutant enzymes, as well as determination of binding affinities using isothermal 
titration calorimetry. As the methyltransferase crystal structures revealed a narrow tunnel adjacent 
to the bound SAH, inferred to be the substrate-binding site, whose dimensions were sufficient to 
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accommodate roughly the first 5 residues of desmethylPZN, we initiated the chemical synthesis of 
shorter desmethylPZN fragments (Figure 2.1).15 The largest fragment consisted of the N-terminal 
Arg followed by five azoles (hereafter Arg-Az5, 4), and was shown to convert to the dimethylated 
product, Me2-Arg-Az5, when reacted with BamL and SAM.15 Smaller desmethylPZN fragments, 
consisting of the terminal Arg followed by one (Arg-Az1, 2) or three (Arg-Az3,3) azoles, were also 
accepted as BamL substrates and bound to the enzyme with low micromolar affinity (Figure 2.1). 
Here, we present the cocrystal structures, solved to resolutions between 1.5-1.8 Å, of BamL and 
BpumL in complex with each of the three azole-bearing substrates, as well as cocrystal structures 
of BpumL with two monomethylated products. The enhanced aqueous solubility of these analogs 
compared to desmethylPZN facilitated the determination of the Michaelis-Menten kinetic 
parameters for both the wild-type enzymes with the three truncated derivatives, as well as the 
kinetic characterization of several active site variants designed based on the structural data. We 
also show that both Me2-Arg-Az3 and Me2-Arg-Az5 display antibiotic activity with a broader-
spectrum profile relative to PZN. These combined biophysical and microbiological data provide a 
rare example of a RiPP tailoring enzyme bound to a processed substrate, and provide the chemical 
framework and proof-of-concept for the engineering of PZN derivatives with improved bioactivity 
profiles. 
 
 
2.3 Results 
2.3.1 Kinetic characterization of truncated desmethylPZN substrates 
In order to overcome the poor physicochemical behavior of desmethylPZN in aqueous solution, 
we had previously synthesized three truncated desmethylPZN analogs consisting of an N-terminal 
Arg followed by one, three, or five azoles (Figure 2.1). Each of these compounds was converted 
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to the corresponding dimethylated counterpart, with N-terminal dimethylation determined mass 
spectrometric analysis (Figure 2.2). The aqueous solubility of Arg-Az1 and Arg-Az3, and moderate 
solubility of Arg-Az5, allowed for kinetic characterization of each of these substrates in a coupled 
assay using SAH nucleosidase to monitor SAM turnover (the pfs SAH nucleosidase has a catalytic 
efficiency of 11.6 × 106 M−1s−1,16 which is greater than that of BamL and BpumL). The catalytic 
efficiency of BamL toward the truncated desmethylPZN substrates increases with the number of 
heterocycles (Arg-Az1, 3.46 × 103 M−1s−1; Arg-Az3, 5.75 × 103 M−1s−1; Arg-Az5, 7.53 × 103 M−1s−1, 
Table 2.1). We only tested the kinetic activity of BpumL towards the Arg-Az3 substrate, yielding 
a kcat/KM value of 6.38 × 103 M−1s−1 comparable to that for BamL on the same substrate (Figure 
2.1 and Table 2.1). The values for kcat are similar for all three substrates, with decreases in 
KM values corresponding to increases in the length of the substrates. These data are consistent with 
the notion that the BamL active site likely accommodates the first 5 residues of desmethylPZN. 
2.3.2 Cocrystal structures of plantazolicin methyltransferases 
Given that several other small molecule methyltransferases demonstrate some degrees of substrate 
promiscuity,11-13 it was perplexing that BamL did not accept non-heterocyclized substrates. In 
order to delineate the basis for the strict substrate specificity, we determined the cocrystal 
structures of BamL-SAH and BpumL-SAH with Arg-Az1, and Arg-Az3, to resolutions between 1.5 
Å - 1.8 Å, and the structure of BpumL-SAH with Arg-Az5, to 1.75 Å resolution. Crystallographic 
phases were determined by the molecular replacement method, and relevant data collection and 
refinement statistics are provided in Table 2.2. In each ternary complex structure, clear and 
continuous electron density for the N-terminal Arg and all of the azoles of Arg-Az1 and Arg-
Az3 was observed; however, the Arg-Az5 structures show strong density for only the first four 
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heterocycles, with much weaker electron density for the fifth heterocycle, which resides outside 
of the binding pocket (Figure 2.3). 
The BamL and BpumL cocrystal structures recapitulate the core class I methyltransferase 
Rossmann fold consisting of six α-helices and seven β-strands.17 The SAH byproduct is bound 
across the interior in a bent manner, which would dispose the electrophilic methyl group of SAM 
adjacent to the α-amine of Arg in each of the (poly)azolic substrates (Figure 2.4). The (poly)azolic 
substrates bind in an extended configuration, perpendicular to the plane of the β-strands, in a 
narrow tunnel formed by the helices that cap the Rossmann fold core (Figures 2.5-2.7). The N-
terminal Arg of the substrate is nestled in this pocket and is situated orthogonally to SAH (Figure 
2.4). BamL residues Leu162 and Tyr187 are along one face, and a short 310 helix between Phe134 
through Phe137 buttresses the opposing side. The guanidinum side chain of the substrate is held 
in place through hydrogen bonding interactions with the side chains of Asp161, Gln186, and 
Ser190, and the backbone carbonyl of Gln186 (BamL numbering). This combination of van der 
Waals contacts and hydrogen bond interactions establishes a planar, coaxial orientation for the 
substrate Arg. 
The azole rings are all cradled within a hydrophobic tunnel situated along the width of 
BamL and are encapsulated by several residues within a large α-helix that spans the length of the 
enzyme (Figure 2.3). A number of hydrophobic residues surround the first two azole rings of the 
substrate, and these include Tyr33, Leu132, Ile141, Val160, Leu162, Tyr182, Leu183, and Tyr187 
(Figures 2.5-2.7). The Thr-derived methyloxazole ring at position 3 of the peptide substrate 
(RCTCTT) makes favorable van der Waals contact with Leu132, and Leu258, but we predict that 
steric clashes would preclude binding of desmethylPZN analogs containing Thr at position 4 (Cys 
in the native substrate, RCTCTT). The third (and presumably) fourth, and fifth rings of Arg-
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Az3 and Arg-Az5 (RCTCTT) are enclosed by a capping loop that spans BamL residues Thr244 
through Ala257, and includes Met255 that makes contacts with the terminal azole in each substrate 
(vide infra) (Figure 2.4). 
To determine structures of a product-bound ternary complex, BpumL was incubated with 
SAM and Arg-Az3 and Arg-Az5. However, the structures reveal BpumL-SAH in complex with 
monomethylated Me-Arg-Az3 (1.5 Å resolution) and Me-Arg-Az5 (1.75 Å resolution) (Figure 2.8). 
Subsequently, we carried out liquid chromatographic and mass spectrometric analyses 
demonstrating that monoalkylated intermediates are indeed observed under pseudo-single turnover 
conditions, which was consistent with prior experiments on truncated PZN derivatives carried out 
under limiting concentrations of SAM (Figure 2.9).14 The cocrystal structures of BpumL-SAH in 
complex with Me-Arg-Az3 and Me-Arg-Az5 reveal that the monomethylated products are situated 
within the active site with a nearly identical orientation as the corresponding desmethyl substrates. 
A comparison of the pre- and post-methyl transfer structures suggest that the α-amino group of 
Arg is positioned in a relatively hydrophobic environment formed by Phe20, Leu130, and Leu134. 
Two polar residues (Asp33 and Tyr180) are in the vicinity of the α-amino group, and the contours 
of the pocket are sufficient to accommodate dimethylation on the Arg of the substrate (Figure 2.8). 
2.3.3 A polymorphic capping region undergoes structural changes in response to 
(poly)azolic substrate  
As noted, in BamL, the (poly)azolic substrate-binding tunnel is flanked by a region of the enzyme 
encompassing Thr244 through Ala257. In the absence of the substrate, this region in BamL and 
BpumL forms a loop that links the central Rossmann fold core to a flanking helix (Figure 2.10). 
The co-crystal structures of BamL with the various substrates show that this region is polymorphic 
and can undergo structural changes to accommodate the length of the bound ligand (Figure 2.10). 
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The most drastic rearrangement is seen in the BamL/SAH/Arg-Az1 ternary complex in which 
Gly247 through Met255 reorganize to form an α-helix (Figure 2.10). Similarly, in the SAH/Me-
Arg-Az3 ternary structure, Ser245 through Gly248 form a one-turn helix that precedes the loop 
(Figure 2.10). The net result of these conformational movements is the displacement of Met255 to 
facilitate the packing of the terminal azole in the respective substrate. Conformational 
displacement of this region results in the formation of a hydrophobic pocket that is optimized for 
the appropriate truncated substrate. These residues are located at the C-terminus of the 
methyltransferase, and are among the least conserved amongst BamL and BpumL. Other suspected 
PZN methyltransferases completely lack the C-terminal extension that contains these residues 
(Figure 2.10). 
2.3.4 Kinetic analysis of active site variants with Arg-Az3 as substrate 
The ternary complex structures reported here suggest potential catalytic roles for a number of 
residues that are in the vicinity of the bound substrate. Prior functional analysis of BamL and 
BpumL were limited due to issues with substrate solubility and could only be characterized using 
semi-quantitative mass-spectrometric analysis of product yield (9). Based on the structures of the 
ternary complex, several individual site-specific variants of BamL were generated and kinetic 
parameters were determined using Arg-Az3 as the substrate. Thr38 is located on a helix that runs 
parallel to the trajectory of the (poly)azolic substrates and is in van der Waals contact with the first 
two heterocyclized residues (RCTCTT). The T38F mutation results in a 17-fold decrease in kcat/KM 
(Table 2.2). Similarly, mutation of either Leu132 (in van der Waals contact with ring 2), or Leu162 
(contact with ring 1) to Phe results in a decrease in kcat/KM by a factor of 16 and 48, respectively. 
Two other variants of BamL were of further interest and thus were kinetically characterized. In the 
cocrystal structures, Arg42 is involved in an ionic interaction with the SAH carboxylate, and the 
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R42A mutation resulted in a 12-fold decrease in kcat/KM (Table 2.3). Likewise, Tyr182 is in the 
vicinity of the α-amino group and the Y182F mutation results in a 17-fold decrease in kcat/KM. The 
effects of these mutations are consistent with roles for both residues in catalysis, as direct or 
indirect constituents in acid-base chemistry. Methyltransferases from the biosynthetic clusters for 
two other PZN-like molecules bear a Phe at this position but contain a neighboring Tyr that may 
similarly facilitate deprotonation of the α-amine.9 
2.3.5 The molecular basis for substrate specificity 
 
The PZN methyltransferases demonstrate narrow tolerance for substrates,9 which is unexpected as 
natural product methyltransferases, in general, are broadly substrate-tolerant,11-13 and the 
methyltransferase that catalyze similar Nα,Nα-dimethylation of α-amino groups (e.g. during the 
biosynthesis of linaridins) are fairly tolerant of substrates.18-19 An examination of the active site in 
the cocrystal structures of BamL and BpumL with SAM/SAH and each of the (poly)azolic 
truncated desmethylPZN derivatives provides a rationale for this specificity. For example, in order 
to accommodate unmodified peptide substrates, the residue following the Arg must be in 
the cis conformation to avoid steric clashes. In addition, steric constraints would result in 
energetically unfavorable Ramachandran torsion angles for the second residue, permitting only a 
Gly at this position. Conceding all of the steric requirements would still be unfavorable due to the 
placement of the charged C-terminal carboxylate in the hydrophobic binding tunnel. Finally, the 
active site contours of BamL and BpumL are constricted in a manner that could only accommodate 
heterocyclic substrates, and kinetic analysis of site-specific mutations at residues that line the 
binding site suggest that the changes in the contours of the substrate-binding tunnel are not well 
tolerated and that the pocket around the first azole is the least resistant to alterations in volume. 
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The prevalence of hydrophobic residues that line the substrate-binding tunnel provide a 
rationale for understanding why Arg thiazole (bearing a terminal amide) represents the minimal 
competent substrate for BamL.14 Similarly, Arg amide is a poorer substrate that is turned over by 
BamL but only under single-turnover conditions.9 In contrast, the amino acid Arg, which bears a 
charged α-carboxylate, is not accepted as a substrate, probably for the same electronic reasons 
noted above. Structure-activity studies demonstrate that an Arg at the amino terminus of substrate 
is a strict requirement, and this constraint can be understood in the context of the structural data. 
Both BamL and BpumL make extensive hydrogen bonding contacts with the Arg guanidino group, 
consistent with the observation that substrate containing either ornithine or lysine are not 
processed. Likewise, homoArg is a poor substrate because the steric limitations of the active site 
is adapted for Arg and could not accommodate the extra methylene group of this side chain.14 
2.3.6 Antibacterial profile of truncated PZN derivatives 
We have previously shown that potent antibacterial activity of PZN is dependent on the 
dimethylation of the N-terminus. As BamL and BpumL could effectively methylate the truncated 
PZN derivatives, we characterized the activity of these compounds. As expected, all desmethyl 
compounds were inactive towards the B. anthracis Sterne indicator strain at concentrations of up 
to 48 µM, underscoring the importance of N-terminal dimethylation for antibiotic activity (Table 
2.4). Following enzymatic dimethylation and purification of each derivative, these resultant 
compounds were tested for bioactivity against a panel of ten diverse bacterial strains (seven 
Firmicutes, three Proteobacteria). As with all of the desmethyl compounds, Me2-Arg-Az1 did not 
show any appreciable bioactivity against any strain. However, both Me2-Arg-Az3 and Me2-Arg-
Az5 displayed minimum inhibitory concentrations (MICs) in the low micromolar range against B. 
anthracis Sterne, with Me2-Arg-Az5 being nearly as potent as PZN. 
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Surprisingly, both Me2-Arg-Az3 and Me2-Arg-Az5 demonstrated broader-spectrum activity 
relative to PZN (Table 2.4). While PZN is not active up to 48 µM against other representative 
members of the genus Bacillus, both Me2-Arg-Az3 and Me2-Arg-Az5 were active against these 
PZN-insensitive strains. In all tested species, Me2-Arg-Az3 showed reduced bioactivity relative to 
Me2-Arg-Az5. Importantly, the bioactivity profile of Me2-Arg-Az5 was extended to include S. 
aureus oNRS384 (a USA300 community acquired-MRSA strain), against which this derivative 
demonstrates an MIC comparable to that against B. anthracis Table 2.4). Inhibition of B. 
anthracis is similar for PZN and Me2-Arg-Az5 in a microbroth dilution assay, but only Me2-Arg-
Az5 results in inhibition of S. aureus NRS384 (Figure 2.11). However, unlike PZN, which induces 
major cell lysis above the MIC, the treatment of mid-exponential B. anthracis with Me2-Arg-
Az5displayed less extensive lysis Figure 2.11). A compound structurally similar to Me2-Arg-Az5, 
but instead bearing a C-terminal amide, has been recently shown by the Süssmuth group to be 
inactive towardsBacillus megaterium in an agar diffusion assay when 6 µg of the pure compound 
was spotted.14 
 
2.4 Conclusions 
Based to their relaxed specificity for B. anthracis, PZN and the truncated analogs may not share 
the same molecular target(s), but confirmation of this will require extensive additional study. 
Interestingly, Me2-Arg-Az5 retains nearly the same potency as full-length PZN against B. 
anthracis. Hence, it is possible that the bioactive portion of PZN is located in the N-terminal half 
of the molecule, while the C-terminal half may govern species specificity. An alignment of the 
five known PZN precursor peptides shows that the N-terminal portion is considerably more 
conserved than the C-terminal portion, which could support the previous conjecture.6 
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Nevertheless, some modifications to the C-terminus are detrimental to the anti-B. 
anthracis activity.20 The combined biochemical, and microbiological analyses of PZN 
methyltransferase specificity sets the framework for future studies aimed to engineering non-
natural PZN variants with expanded and/or orthogonal bioactivities. 
 
 
2.5 Methods 
2.5.1 Protein expression and crystallization 
The gene for E. coli adenine deaminase was amplified using primers based on the published DNA 
sequence, and inserted into the pET28b vector. Details for the cloning, expression and purification 
of BamL and BpumL have already been reported.9 Briefly, the coding region for BamL and 
BpumL were inserted into a modified pET28-MBP vector for production as a C-terminal fusion. 
Protein was purified by nickel affinity chromatography, and following removal of the affinity tag, 
was further purified by ion exchange and size-exclusion chromatography. Mutant proteins were 
generated using oligonucleotide sequences provided in Table 2.5, and the resultant proteins were 
purified in a similar manner. Sample purity was assessed by Coomassie-stained SDS-PAGE 
chromatography (Figure 2.12). The (poly)azolic substrates Arg-Az1, Arg-Az3, and Arg-Az5 were 
synthesized as previously described. SAM was either prepared enzymatically using SAM synthase, 
or purchased from Sigma immediately prior to use. The integrity of SAM was routinely monitored 
by mass spectrometry and HPLC analysis prior to biochemical experiments. Crystals of the 
BpumL or BamL/SAH/Arg-Azx complexes were grown using the hanging drop method. Briefly, 
a 50 µL aliquot of protein (in a buffer of 0.5 M NaCl, 20 mM Tris pH=8.0, and 10% glycerol, at a 
concentration of 10 mg/mL) was incubated with 2 mM SAM/SAH and 2 mM of the (poly)azolic 
substrate for 1 h on ice prior to crystallization. Commercially available sparse matrix screens were 
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used to identify initial crystallization conditions that were subsequently refined to yield samples 
suitable for diffraction experiments. Plate-like crystals were grown using 100 mM Bis-Tris 
propane, pH=5.5, 200 mM Li2So4, and 22-26% polyethyleneglycol 3350. Crystals were transiently 
submerged in the crystallization medium supplemented with 10% glycerol prior to vitrification by 
direct immersion in liquid nitrogen. 
2.5.2 Data collection, integration and structure determination 
All diffraction data were collected at the Life Sciences Collaborative Access Team (LS-CAT; 
Sector 21) at the Advanced Photon Source (Argonne, IL) using MAR charge coupled device 
detectors. The diffraction data were indexed and scaled using HKL200021 or XDS22 to the 
appropriate limiting resolution. Initial crystallographic phases were determined by the molecular 
replacement method23 as implemented in the Phenix software suite,24 using the coordinates of 
unliganded BamL (PDB Code: 4KVZ) as a search probe. Rounds of manual rebuilding using 
COOT25 were interspersed with crystallographic refinement using REFMAC526 until the free R 
factor dropped below 30%. All ligands and solvents were incorporated into the model at this stage, 
with further refinement and rebuilding of the model until convergence. Cross-validation, using 5% 
of the data for the calculation of the free R factor, was utilized throughout the model building 
process in order to monitor building bias. The validity of all models were routinely determined 
using PROCHECK,27 MOLPROBITY, 28 and by using the free R factor28 to monitor improvements 
during building and crystallographic refinement. 
2.5.3 Kinetic analysis of BamL and BpumL methyltransferases 
 
Kinetic analysis of BamL and BpumL utilized a coupled spectrophotometric assay. Reaction 
mixtures typically consisted of 50 mM Tris, pH=7.8, 200 µM MnSO4, 5 µM E. coli pfs 
nucleosidase, 5 µM B. subtilis adenine deaminase, 80 µM SAM, and varying concentrations of the 
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Arg-Az1, Arg-Az3, and Arg-Az5. The reaction progress was monitored at 310 K and utilized 0.5 
µM of either MBP-tagged wild-type BamL or BpumL. Concentrations for the mutant enzymes are 
as follows: 1.4 µM R42A, 1.325 µM T38F, 1.34 µM L132F, 1.36 µM L162F, and 1.8 µM Y182F. 
Reaction progress was monitored as changes in absorption at a wavelength of 265 nm. Initial 
velocity data were calculated and fitted to the Michaelis-Menten equation using the Origin 
software package. Due to absorption by substrate at 265 nm, reaction rate using high 
concentrations (> 80 µM) of peptide substrate failed to yield reliable data. 
2.5.4 Antibacterial assays 
Microbroth dilution assays were performed as previously described.6 Briefly, 10 mL stationary 
phase cultures (two for each bacterial species) were adjusted to OD600 of 0.01 in the appropriate 
medium and added to 96-well plates. Two-fold dilutions of each compound (stock solution at 4 
mM in DMSO) were added to the cultures (0.375 µM – 48 µM). Plates were covered and incubated 
at 37 °C for 12 h before determination of the MIC based on culture turbidity. The cell densities 
after 12 h were determined for MRSA and Sterne. Vehicle (DMSO)-treated, 24 µM PZN-treated, 
and 24 µM Me2-Arg-Az5-treated wells were analyzed in duplicate on a FilterMax F5 Multi-mode 
Microplate Reader (Molecular Devices) using sterile LB as the plate blank and measuring cell 
density at 595 nm. Error bars indicate standard deviation. P-values were calculated using a two-
tailed t-test between DMSO-treated and PZN- or Me2-Arg-Az5-treated cells of the same bacterial 
species. 
2.5.5 Microscopy 
 
200 µL aliquots of a stationary phase culture of B. anthracis Sterne was used to inoculate 5 mL 
fresh LB. The culture was grown to OD 0.5 and 1 mL aliquots were harvested by centrifugation 
(8,000 × g, 2 min). Bacterial pellets were resuspended in 100 µL PBS supplemented with vehicle 
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(DMSO), 4 µM PZN or 12 µM Me2-Arg-Az5. After mixing at 22 °C for 30 min, cells were washed 
with PBS and resuspended in 200 µL PBS. 10 µL aliquots of each cell suspension were mixed with 
10 µL 2% liquefied low gelling temperature agarose (Sigma-Aldrich) on microscope slides. 
Differential interference contrast microscopy analyses were conducted at the Core Facility at the 
Institute of Genomic Biology (University of Illinois) using a Zeiss LSM 700 confocal microscope 
outfitted with a 405 nm laser. Linear contrast was applied when deconvoluting images in Zen 2012 
software. 
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2.7 Figures 
 
Figure 2.1 (A) Chemical structures of PZN and the three (poly)azolic truncated methyltransferase 
substrates. (B) Enzymatic conversion of Arg-Az3 into the corresponding dimethylated compound 
by BamL, as analyzed by HPLC. *, internal standard. (C) Michaelis-Menten curves for the 
conversion of each of the (poly)azolic substrates catalyzed by BamL using a fixed SAM 
concentration of 5 mM. The concentration of SAM is 80 µM. The ITC data in the previous paper 
says the Kd is around 8 µM, so 80 µM should still be saturated.   
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Figure 2.2 Fragmentation of the products of the enzymatic reactions confirms BamL N-terminally 
dimethylates the PZN substructures, yielding (A) Me2-Arg-Az1, (B) Me2-Arg-Az3, and (C) Me2-
Arg-Az5. 
 
  
Figure S1. Fragmentation of the products of the enzymatic reactions confirms BamL N-
terminally dimethylates the PZN substructures, yielding (A) Me2-Arg-Az1, (B) Me2-Arg-Az3, 
and (C) Me2-Arg-Az5.  
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Figure 2.3 Cut-away surface view of BpumL (colored in purple) viewed parallel to the axis of the 
Arg-Az5 binding site. The ligand is shown as ball and stick with carbon, nitrogen, sulfur, and 
oxygen atoms colored in yellow, blue, green, and red, respectively. The fourth and fifth azoles of 
the substrate are exposed to solvent, relative to the first three azoles. Atoms comprising the C-
terminal ester of Arg-Az5 are disordered. 
 
 
 
  
 
 
 
 
 
Figure S3. Cut-away surface view of BpumL (colored in purple) viewed parallel to the axis of 
the Arg-Az5 binding site. The ligand is shown as ball and stick with carbon, nitrogen, sulfur, and 
oxygen atoms colored in yellow, blue, green, and red, respectively. The fourth and fifth azoles of 
the substrate are exposed to solvent, relative to the first three azoles. Atoms comprising the C-
terminal ester of Arg-Az5 are disordered.  
 43 
Figure 2.4 (A) Structure of the BamL (purple) in complex with SAH (gray), and Arg-Az3 (cyan) 
with the capping loop colored in green. (B, C) Difference Fourier electron density maps of (B) 
BamL-Arg-Az1 and (C) BamL-Arg-Az3 contoured at 2.5σ (blue) and 8σ (red), calculated with 
coefficient (Fobs – Fcalc), with phases derived from the final structure with the coordinates of the 
substrate removed for one round of simulated annealing refinement. The SAH is colored in gray, 
the substrates are colored in cyan, and important active site residues are shown as yellow ball-and-
stick. 
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Figure 2.5 LIGPLOT diagram (1) showing the interaction between BamL and Arg-Az1 with the 
bound ligand shown in purple. Carbon, nitrogen, and oxygen atoms are shown as black, blue, and 
red balls, respectively. Hydrogen bonds are shown as green dashed lines with indicated distances. 
Residues within van der Waals contact distance are represented by spiked red semicircles. 
 
 
 
 
 
Figure S4. LIGPLOT diagram (1) showing the interaction between BamL and Arg-Az1 with the 
bound ligand shown in purple. Carbon, nitrogen, and oxygen atoms are shown as black, blue, and 
red balls, respectively. Hydrogen bonds are shown as green dashed lines with indicated distances. 
Residues within van der Waals contact distance are represented by spiked red semicircles. 
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Figure 2.6 LIGPLOT diagram showing the interaction between BamL and Arg-Az3 with the 
bound ligand shown in purple. Carbon, nitrogen, and oxygen atoms are shown as black, blue, and 
red balls, respectively. Hydrogen bonds are shown as green dashed lines with indicated distances. 
Residues within van der Waals contact distance are represented by spiked red semicircles. 
 
 
 
 
  
 
 
 
 
 
Figure S5. LIGPLOT diagram (1) showing the interaction between BamL and Arg-Az3 with the 
bound ligand shown in purple. Carbon, nitrogen, and oxygen atoms are shown as black, blue, and 
red balls, respectively. Hydrogen bonds are shown as green dashed lines with indicated distances. 
Residues within van der Waals contact distance are represented by spiked red semicircles. 
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Figure 2.7 LIGPLOT diagram (1) showing the interaction between BamL and Arg-Az3 with the 
bound ligand shown in purple. Carbon, nitrogen, and oxygen atoms are shown as black, blue, and 
red balls, respectively. Hydrogen bonds are shown as green dashed lines with indicated distances. 
Residues within van der Waals contact distance are represented by spiked red semicircles. 
 
 
 
 
 
Figure S6. LIGPLOT diagram (1) showing the interaction between BpumL and Arg-Az5 with the 
bound ligand shown in purple. Carbon, nitrogen, and oxygen atoms are shown as black, blue, and 
red balls, respectively. Hydrogen bonds are shown as green dashed lines with indicated distances. 
Residues within van der Waals contact distance are represented by spiked red semicircles. 
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Figure 2.8 (A,B) Active site views of the structures of BpumL in complex with SAH (gray) and 
either (A) Me-Arg-Az3 or (B) Me-Arg-Az5. The substrates are colored in cyan, and important 
active site residues are shown as yellow ball-and-stick. The superimposed electron density maps 
are calculated and contoured as in Figure 2.4. 
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Figure 2.9 ESI-MS spectrum of a 30 min enzymatic reaction of 50 µM wild-type MBP-BamL, 10 
µM Pfs, 50 µM Arg-Az5, and 50 µM SAM in 50 mM Tris-HCl (pH 7.5) shows mono- and 
demethylation of Arg-Az5. 
 
 
 
  
 
 
Figure S7. ESI-MS spectrum of a 30 min enzymatic reaction of 50 µM wild-type MBP-BamL, 
10 µM Pfs, 50µM Arg-Az3, and 50 µM SAM in 50 mM Tris-HCl (pH 7.5) shows mono- and 
dimethylation of Arg-Az3. 
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Figure 2.10 (A-C) Views showing that the capping region (colored in green) is polymorphic and 
changes from (A) a long loop in the BamL structure without substrate to (B) an α-helix in the 
BamL-SAH-Arg-Az1 structure, and (C) a short helix-loop in the BamL-SAH-Arg-Az3 structure. 
(D) The capping region is located in the poorly conserved C-terminus of BamL and is missing in 
methyltransferases from related biosynthetic clusters. Residues conserved among all sequences are 
shaded in black and those that are similar are shaded in light blue. The C-terminal extension is 
missing in CurL and BlinL and is designated by a series of periods. 
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Figure 2.11 (A) Treatment with 24 µM PZN or Me2-Arg-Az5 is bactericidal against B. 
anthracis Sterne. However, Me2-Arg-Az5 but not PZN displays antibiotic activity against MRSA, 
as evidenced by cell density measurements after 12 h treatment (595 nm). Error bars, standard 
deviation. *, P<0.01 vs DMSO-treated B. anthracis st. Sterne. #, P<0.01 vs DMSO-treated MRSA. 
(B-D) Me2-Arg-Az5 displays antibiotic activity against B. anthracis but unlike PZN does not 
massively induce cell lysis of mid-exponential phase cells after 30 min. Scale bars, 5 µm. (B) 
Vehicle (DMSO)-treated B. anthracis vegetative cells. (C) B. anthracis treated with 4 µM PZN 
shows cell lysis. (D) B. anthracis remained mostly intact after treatment with 12 µM Me2-Arg-Az5. 
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Figure 2.12 Relative purities (as determined by Coomassie-stained 10% SDS-PAGE) of wild-type 
and mutant BamL proteins used for experiments. Full-length maltose-binding protein (MBP)- 
tagged BamL and variants (76 kDa) were purified by Ni-NTA affinity chromatography and, 
following removal of the MBP tag by tobacco etch virus protease cleavage, further purified by size 
exclusion chromatography. Roughly 10 µg of protein was loaded in each lanes from 2 through 7. 
Lane 1: Molecular weight ladder, Lane 2: wild-type MBP-BamL, Lane 3: MBP- BamL-T38F, 
Lane 4: MBP-BamL-R42A, Lane 5: MBP-BamL-L132F, Lane 6: MBP-BamL- L162F, and Lane 
7: MBP-BamL-Y182F.  
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Figure S2. Relative purities (as determined by Coomassie-stained 10% SDS-PAGE) of wild-type 
and mutant BamL proteins used for experiments. Full-length maltose-binding protein (MBP)-
tagged BamL and variants (76 kDa) were purified by Ni-NTA affinity chromatography and, 
following removal of the MBP tag by tobacco etch virus protease cleavage, further purified by 
size exclusion chromatography. Roughly 10 µg of protein was loaded in each lanes from 2 
through 7. Lane 1: Molecular weight ladder, Lane 2: wild-type MBP-BamL, Lane 3: MBP-
BamL-T38F, Lane 4: MBP-BamL-R42A, Lane 5: MBP-BamL-L132F, Lane 6: MBP-BamL-
L162F, and Lane 7: MBP-BamL-Y182F. 
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2.8 Tables 
 
Table 2.1 Steady state kinetic parameters for BamL and BpumL against truncated PZN substrates. 
 
 BamL KM (µM) kcat (10–2 s–1) kcat/KM (M–1 s–1) 
 Arg-Az1 26.8 ± 3.3 9.3 ± 0.4 3.46 × 103 
 Arg-Az3 18.3 ± 0.5 10.5 ± 0.1 5.75 × 103 
 Arg-Az5 14.6 ± 2.0 11.0 ± 0.4 7.53 × 103 
 Arg-Az3 (BpumL) 22.5 ± 2.3 14.4 ± 0.7 6.38 × 103 
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Table 2.2 Data collection, phasing, and refinement statistics. 
 
 
  
Table S2. Data collection, phasing and refinement statistics 
 
  BamL     BpumL   
 Arg-Az1 Arg-Az3 Arg-Az1 Arg-Az3 Arg-Az5 
        
Data collection      
Space Group P21 P212121 P21212 P21212 P21212 
 a, b, c (Å), β (o) 39.7, 71.4, 48.8, 107.5 48.8,96.5, 132.6 67.5, 78.6, 44.7 68.1, 78.8, 44.9 67.8, 78.8, 44.7 
Resolution (Å)a 50-1.5 (1.6-1.5) 50-1.75 (1.78-1.75) 50-1.8 (1.83-1.8) 50-1.5 (1.6-1.5)  50-1.75 (1.78-1.75) 
Rsym (%)b 6.0 (34.4) 11.1 (70.8) 7.4 (66.7) 5.4 (67.1) 7.5 (59.3) 
I/σ(I) 15.6 (3.8) 17.0 (2.5) 23.3 (2.6)  23.2 (1.7) 27.0 (3.7) 
Completeness (%) 96.1 (93.9) 100 (100) 99.7 (99.3)  96.6 (81.0) 100 (100) 
Redundancy 4.7 (4.0) 6.9 (6.4) 6.6 (6.5) 5.6 (3.1) 8.0 (8.1) 
 
Refinement 
    
 
Resolution (Å) 25.0-1.5 25.0-1.75 25.0-1.8  25.0-1.5 25.0-1.75 
No. reflections 38,011 60,530 21,423 36,228 23,630 
Rwork / Rfreed (%) 20.6/23.7 18.6/21.2 19.9/23.9  20.6/23.9 20.1/24.3 
 
Number of atoms 
  
  
 
Protein 2133 4311 2071  2087  2080 
(Poly)azole 20 70 26 37 44 
SAH 26 52 26 26 26 
Water 237 518 518 236 186 
 
B-factors 
  
  
 
Protein 16.5 21.3 20.5 16.9  19.7 
(Poly)azole 14.7 21.2 18.1 17.3 25.7 
SAH 13.5 19.9 13.9 11.2 14.3 
Water 25.9 31.3 29.9 29.1 30.9 
 
R.m.s. deviations 
  
  
 
Bond lengths (Å) 0.006 0.007 0.006 0.006 0.006 
Bond angles (°) 1.19 1.51 1.19 1.49 1.77 
 
a. Highest resolution shell is shown in parentheses. 
b. Rsym = Σ |(Ii - <Ii> | Σ Ii where Ii = intensity of the ith reflection and <Ii> = mean intensity. 
c. Mean figure of merit (acentric and centric). 
d. R-factor = Σ(|Fobs|-k|Fcalc|)/Σ |Fobs| and R-free is the R value for a test set of reflections consisting 
of a random 5% of the diffraction data not used in refinement. 
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Table 2.3 Steady state kinetic parameters for BamL variants against Arg-Az3. 
 
BamL kcat/KM (M−1s−1) 
Wild-type 57.5 × 102 
T38F 3.3 × 102 
R42A 4.7 × 102 
L132F 3.5 × 102 
L162F 1.2 × 102 
Y182F 1.7 × 102 
 
 
 
 
 
 
 
 
 
Table 2.4 Bioactivity of PZN truncations compared to PZN. Values reported as minimum 
inhibitory concentrations (µM). 
 
Organism Me2-Arg-Az1 Me2-Arg-Az3 Me2-Arg-Az5 PZN 
Bacillus anthracis Sterne >48 12 3 0.75-1.5 
Bacillus megaterium 7A1 >48 12 3 >48 
Bacillus subtilis 168 >48 24 6 >48 
Enterococcus faecium U503 >48 >48 >48 >48 
Listeria monocytogenes 4b F2365 >48 >48 >48 >48 
Staphylococcus aureus NRS384 >48 >48 3 >48 
Streptococcus pyogenes M1 >48 >48 >48 >48 
Escherichia coli DH5a >48 >48 >48 >48 
Neisseria sicca ATCC 29256 >48 >48 >48 >48 
Pseudomonas putida KT244 >48 >48 >48 >48 
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Table 2.5 Oligonucleotides (primers) used for cloning and site-directed mutagenesis of BamL. 
Primers ending with _f and _r correspond to the forward and reverse direction, respectively. 
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CHAPTER 3: PLANTAZOLICIN IS AN ULTRA-NARROW SPECTRUM ANTIBIOTIC 
THAT TARGETS THE BACILLUS ANTHRACIS MEMBRANE2 
 
3.1 Abstract 
 
Plantazolicin (PZN) is a ribosomally synthesized and post-translationally modified natural product 
from Bacillus methylotrophicus FZB42 and Bacillus pumilus. Extensive tailoring to 12 of the 14 
amino acid residues in the mature natural product endows PZN with not only a rigid, 
polyheterocyclic structure, but also antibacterial activity. Here we report the remarkably 
discriminatory activity of PZN toward Bacillus anthracis, which rivals a previously described 
gamma (γ) phage lysis assay in distinguishing B. anthracis from other members of the Bacillus 
cereus group. We evaluate the underlying cause of this selective activity by measuring the RNA 
expression profile of PZN-treated B. anthracis, which revealed significant up-regulation of genes 
within the cell envelope stress response. PZN depolarizes the B. anthracis membrane like other 
cell envelope-acting compounds but uniquely localizes to distinct foci within the envelope. 
Selection and whole-genome sequencing of PZN-resistant mutants of B. anthracis implicate a 
relationship between the action of PZN and cardiolipin (CL) within the membrane. Exogenous CL 
increases the potency of PZN in wild type B. anthracis and promotes the incorporation of 
fluorescently tagged PZN in the cell envelope. We propose that PZN localizes to and exacerbates 
structurally compromised regions of the bacterial membrane, which ultimately results in cell lysis.  
                                                
2 Reprinted with permission from Molohon, K.J.*.; Blair, P.M.*; Park, S.; Doroghazi, J.R.; Maxson, T.; Hershfield, 
J.; Flatt, K.; Schroeder, N.; Ha, T.; Mitchell, D.A. "Plantazolicin is an ultra-narrow spectrum antibiotic that targets 
the Bacillus anthracis membrane." ACS Infect. Dis., 2:207-220 (2016). Copyright 2016 American Chemical Society. 
K.J.M. performed RNA-Seq, mutational studies, and spectrum of bioactivity assays; S.P. performed STORM; J.R.D. 
performed RNA-Seq analysis; T.M. created knockouts; J.H. performed BSL3 bioactivity assays; K.F. performed 
nematode killing assays. 
*These authors contributed equally to this work. 
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3.2 Introduction 
 
The current practice of employing broad-spectrum antibiotics to treat bacterial infections 
contributes to the rise of antibiotic resistance.1 As a countermeasure, species-selective and narrow-
spectrum antibacterial compounds are garnering increased attention in the medical community for 
their potential as therapeutics and/or diagnostics.2-3 Plantazolicin (PZN) is a polyheterocyclic, 
linear compound of the ribosomally synthesized and post-translationally modified peptide (RiPP) 
natural product family with narrow-spectrum antibiotic activity (Figure 3.1).4 More specifically, 
PZN is a member of the thiazole/oxazole-modified microcins (TOMMs), a recently grouped and 
rapidly expanding RiPP class with ∼1500 identified gene clusters.5-6 Previously, PZN was 
described as an antibiotic compound that inhibits Gram-positive organisms closely related to its 
producing organism, Bacillus amyloliquefaciens FZB424 (this organism has recently been 
taxonomically reclassified as Bacillus velezensis FZB42).7 In 2011, by screening a small panel of 
microorganisms, we described PZN as having potent activity toward Bacillus anthracis, but not 
other Gram-positive pathogens.8 Several additional PZN-like gene clusters have been identified in 
six distinct bacterial genera (from three phyla) through genome mining, but experimental data on 
antibiotic specificity has so far been limited to PZN.4, 8 Although PZN has been the subject of total 
synthesis,9-11 heterologous expression,12 and enzymological studies,13-15 insight into the mode of 
action (MOA) of PZN has not been reported in the eight years since the discovery of its 
biosynthetic gene cluster.16 
B. anthracis, the causative agent of anthrax and a category A priority pathogen, is a Gram-
positive bacterium and a member of the B. cereus sensu lato group, which includes B. cereus, B. 
anthracis, B. thuringiensis, and B. mycoides.17 Microbiologists have debated whether these 
organisms should be considered as one species, given that some strains share >99% DNA sequence 
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identity. Despite being grouped with other Bacillus species, B. anthracis harbors a number of 
distinguishing features compared to other members of the B. cereus group. Fully virulent B. 
anthracis contains two conserved plasmids, pXO1 and pXO2, which harbor the genes responsible 
for producing the anthrax toxin and poly-D-glutamic acid capsule, respectively. However, 
homologous plasmids are also found in certain B. cereus strains.18 Beyond characteristic plasmid 
content, B. anthracis, unlike other members of the B. cereus group, harbors a nonsense mutation 
in plcR (phospholipase C regulator), rendering B. anthracis nonmotile and nonhemolytic.18 The 
unambiguous differentiation of B. anthracis from other nonpathogenic B. cereus species is 
critically important from a public health perspective, especially as it pertains to bioterrorism. 
Other defining features of B. anthracis that may facilitate species selectivity are exterior to 
the cell wall. B. anthracis displays a two-dimensional protein lattice called the surface layer (S-
layer). Decorated with surface-associated proteins in a csaB (cell surface attachment)-dependent 
manner,19 the S-layer is noncovalently attached to the secondary cell wall polysaccharide 
(SCWP),20  which is covalently tethered to the peptidoglycan. The B. anthracis SCWP is 
structurally unique21 and serves as the binding site for gamma (γ) phage22-23 and previously 
described B. anthracis typing antibodies.24 γ phage produce a peptidoglycan hydrolase, PlyG, 
which specifically recognizes the terminal galactoses of the B. anthracis SCWP, allowing efficient 
digestion of the cell wall.22 Similarly, typing methods using monoclonal antibodies to the SCWP 
also exploit differences in the terminal sugar unit. However, there exist atypical B. anthracis strains 
that would constitute false negatives in any diagnostic assay based on these methods.24-25 Wip1, 
another B. anthracis-specific phage, is even more selective than γ phage, yet certain B. 
cereus strains remain sensitive.26 Thus, the species specificity of PZN is intriguing not only from 
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a MOA standpoint but also as a rapid means to discriminate B. anthracis from other B. cereus 
sensu lato members. 
Here we describe PZN as a remarkably selective small molecule antibiotic toward B. 
anthracis. The specificity of PZN was first examined by gene expression profiling, which yielded 
an expression signature distinct from broader spectrum antibiotics. We have identified and 
characterized a set of resistant mutants and evaluated their role in PZN resistance, which led us to 
further investigate the bacterial membrane as the most probable target of PZN. Using fluorescence-
based approaches, we confirmed that PZN localizes to the cell envelope in a species-selective 
manner. PZN binding was associated with rapid and potent membrane depolarization. Taken 
together with the observation that PZN interacts synergistically with the negatively charged 
phospholipid, cardiolipin (CL), we propose that PZN localizes to and aggravates transient 
weaknesses present in the B. anthracis cell membrane. 
 
 
3.3 Results 
 
B. anthracis, the causative agent of anthrax, can often be mistaken for other members of the B. 
cereus group. As a bacterium with a history of use in bioterrorism, there is an urgent homeland 
security need for highly accurate and rapid identification of B. anthracis. We therefore set out to 
characterize and understand the selectivity of PZN. 
3.3.1 Defining the species selectivity of PZN 
PZN was originally described as a Gram-positive antibiotic, inhibiting the growth of B. subtilis, B. 
cereus, and B. megaterium.4 It is important to note, however, that the spot-on-lawn assay employed 
to reach this conclusion used 1 mg of purified PZN per spot. We set out to obtain the minimum 
inhibitory concentration (MIC) of PZN by using a microbroth dilution assay. As expected, the 
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activity of PZN was revealed to be considerably more selective, in that antibacterial activity was 
detected toward only B. anthracis upon screening of a small panel of human pathogens.8 We 
continued to define this unusually narrow spectrum of activity by screening a larger panel of strains 
with various degrees of genetic similarity (Table 3.1). PZN was found to be selective for 
vegetative B. anthracis, including fully virulent biosafety level 3 strains, with MICs between 1 and 
16 µg/mL (0.75–12 µM). Endospores, the dormant phase of the B. anthracis life cycle, were 
resistant to PZN until germination was initiated (Table 3.2). By microbroth dilution, B. subtilis and 
B. cereus were not susceptible to PZN at concentrations up to 64 µg/mL, which contrasts with the 
previous spot-on-lawn assay.4  
To further investigate the selectivity of PZN toward B. anthracis, we conducted a head-to-
head comparison using the γ phage assay. Prior to modern genomic methods, γ phage sensitivity 
and other phenotype testing were popular methods for identifying B. anthracis.25 Notwithstanding 
the reported 96% positive accuracy, non-B. anthracis strains that are sensitive to γ phage and 
true B. anthracis strains that are insensitive have been reported.25, 27-28 We obtained a panel of 
atypical B. cereus strains that are sensitive to γ phage and tested them for PZN susceptibility (Table 
3.3). B. cereus strains that generated a false positive in the γ phage assay were not susceptible to 
PZN.26, 28-29 
To further define the attributes giving rise to the species selectivity of PZN, we procured 
various bacterial strains that address key differences between B. anthracis and B. cereus. plcR, 
encoding the phospholipase C regulator, is nonfunctional in B. anthracis but is intact in B. cereus.18 
Deletion of plcR in B. cereus did not increase its susceptibility to PZN (Table 3.1). Additionally, 
sortase-deficient strains of B. anthracis, which lack the ability to anchor various proteins to the 
cell wall, remain susceptible to PZN.30 The activity of PZN was similarly not dependent on the 
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presence or composition of the B. anthracis S-layer, as strains deficient in S-layer assembly or 
decoration, namely those harboring mutations in csaB, sap, and eag, are equally susceptible to 
PZN.19 We further confirmed that susceptibility to PZN is plasmid-independent given that a 
plasmid-deficient strain (LLNL A0517-1) and strains with both plasmids retained sensitivity 
(Table 3.1; Figure 3.2). Wip1 phage susceptibility and antibody typing have also been used to 
distinguish B. cereus sensu lato strains, but also have known exceptions to their specificity for B. 
anthracis.24, 26 We obtained a “false-positive for B. anthracis” strain for each marker: B. cereus 
CDC32805 for Wip1 and B. cereus ATCC 7064 for antibody typing. We again observed no 
measurable PZN susceptibility for either strain (Table 3.1). 
After extensive susceptibility testing, the only notable exception to the B. 
anthracis selectivity of PZN was B. cereus G9241 (MIC of 8 µg/mL). Strain G9241 encodes the 
genes for an anthrax-like toxin on its pBCXO1 plasmid, which is named for its homology to the B. 
anthracis pXO1 plasmid.31 Because G9241 is encapsulated and toxigenic, it causes an anthrax-
like disease but is undetectable in the γ phage assay.27 Thus, from a pathogen detection perspective, 
the action of PZN toward G9241 could be considered fortuitous if it were to be further developed 
as a rapid diagnostic. Together, these data not only highlight the species discrimination of PZN 
but also rule out plcR-related effects, sortase-mediated proteins, the SCWP, the S-layer, and 
plasmid-borne entities as targets of PZN. 
The spectrum of PZN activity calls into question whether bacteria are the naturally intended 
target. The canonical PZN-producing strain, B. velezensis  FZB42 (formerly amyloliquefaciens), 
is a prolific producer of other natural products with antifungal and nematicidal activities.7, 32 Liu 
et al. ascribed a nematicidal activity to PZN, derived from experiments showing that PZN-deficient 
FZB42 strains exhibit reduced nematicidal activity against Caenorhabditis elegans.33 Because 
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these experiments employed crude cellular extracts, we evaluated purified PZN in a similar 
manner, embedding the compound in agar (“slow killing” assay) or providing PZN in a liquid 
suspension (“liquid fast killing” assay). PZN was found to be no more toxic to C. elegans than a 
vehicle control and is not nematicidal in its own right (Figure 3.3). Purified PZN was also not 
responsible for the antifungal activity of the native producer, leaving the ecological function of 
PZN unknown (Table 3.1). 
After observing the specificity of PZN under one growth medium condition (Luria–Bertani 
broth, LB), we reassessed specificity against a smaller but representative panel of strains in two 
additional growth media (Mueller–Hinton and brain–heart infusion broths, Table 3.4). All tested 
strains of B. anthracis remained equally susceptible, but unexpectedly, some Staphylococcus 
aureus strains were susceptible to PZN under alternative growth media (MICs from 8 to 32 
µg/mL). Only S. aureus showed media-dependent susceptibility to PZN; all other tested strains 
remained nonsusceptible to PZN. 
3.3.2 Assessing potential macromolecules as the target of PZN 
In an attempt to identify the molecular target(s) of PZN by affinity-based purification,34 three PZN 
derivatives were prepared: N-terminal biotinylation, C-terminal biotinylation, and C-terminal 
modification functionalized with aziridinyl and alkynyl groups for photoaffinity capture (Figure 
3.4). Only the C-terminal modifications retained bioactivity, albeit with ∼16-fold reductions; 
therefore, these probes were utilized for affinity-based target identification. Despite numerous 
attempts, we were unable to identify interactions unique to PZN compared to the control (data not 
shown). Because affinity purification-based strategies to identify small molecule targets are most 
successful when the interaction is of high affinity to a protein,35 we considered the possibility that 
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wall, fatty acids, and RNA (as well as protein) using radiolabeled, biosynthetic precursors in the 
presence of PZN. Similar to daptomycin and the nisin-like lanthipeptide Pep5, PZN extensively 
disrupted macromolecular biosynthesis (Figure 3.5).36-37 Interestingly, and in contrast to 
vancomycin and daptomycin, PZN did not significantly block cell wall biosynthesis on the time 
scale of the experiment. 
3.3.3 Gene expression signature of PZN 
Sublethal antibiotic treatment stimulates rapid transcriptional responses in bacteria, and the 
induced/repressed genes may be indicative of MOA.38 We thus performed RNA-Seq to evaluate 
the transcriptional response of B. anthracis following exposure to 0.25 µg/mL (0.25 × MIC) PZN 
for 10 min.39 A total of 74 genes were differentially regulated, including 63 up-regulated and 11 
down-regulated genes, with an adjusted false discovery rate (q value) of 0.01 (Figure 3.6; Table 
3.5). The expression of a subset of these genes was validated by qRT-PCR (Table 3.6, Table 3.7). 
Fourteen of the up-regulated genes were transporter subunits, a common stress response upon 
antibiotic treatment.40 Conversely, PZN treatment led to the down-regulation of genes associated 
with L-lactate metabolism, for which the implications remain unclear. 
The most highly up-regulated B. anthracis genes upon PZN treatment 
were bas1344 andbas1345, which encode a hypothetical protein and a predicted member of the 
PspA/IM30 family, respectively (Table 3.7). These genes are homologous to the B. 
subtilis genes liaI and liaH (lipid II cycle interfering antibiotics), which are involved in the cell 
envelope stress response. Induction of these genes upon antibiotic treatment is well documented 
in B. subtilis, specifically to antibiotics interacting with lipid II in some capacity (e.g., nisin, 
vancomycin, and bacitracin).41 Induction ofliaI and liaH is also seen in B. subtilis after daptomycin 
treatment, despite the lack of any known interaction between daptomycin and lipid II.42 PZN 
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treatment also results in massive up-regulation of bas5200 and bas5201, which are homologous to 
a B. subtilis thermosensor two-component system (TCS), desRK, that regulates the lipid 
desaturase, des.43 Although bas5200and bas5201 have yet to be experimentally interrogated, the 
response regulator and adjacent histidine kinase homologues are 62/89% and 38/71% 
similar/identical at the protein level to B. subtilis, respectively. BLAST-P searches using BAS5200 
and BAS5201 as the query sequences retrieve DesK and DesR as the highest similarity hits in B. 
subtilis; the reverse BLAST-P search (B. subtilis DesK and DesR query sequences) likewise 
retrieves BAS5200 and BAS5201 has the top hits in B. anthracis. Pending experimental validation 
of BAS5200-1 as the bona fide desRKTCS in B. anthracis, PZN would be to our knowledge the 
first compound known to alter the expression of these regulators, which is further suggestive of a 
unique MOA. 
Recently, we reported on the synthesis of a PZN derivative, Me2-Arg-Az5 (Figure 3.1).15 
Chemically, Me2-Arg-Az5 represents the N-terminal half of PZN, but the activity spectrum of Me2-
Arg-Az5 is profoundly broader in LB and includes other Bacillus species as well as methicillin-
resistant S. aureus (Table 3.8). Additionally, the later-described mutations in bas4114 that 
conferred resistance to PZN did not confer resistance to other antibiotics or to Me2-Arg-Az5 
(Tables 3.8 and 3.9). To investigate their differing spectra of activity, we recorded the gene 
expression profile of B. anthracis treated with Me2-Arg-Az5 under otherwise identical conditions 
(0.25 × MIC, 10 min) by RNA-Seq. The two compounds shared a minor portion of their expression 
profiles, but each profile was largely independent (Figure 3.7; Tables 3.10 and 3.11). For example, 
sublethal Me2-Arg-Az5 treatment also induced the desRK TCS, but expression of liaIH remained 
unchanged. Additionally, Me2-Arg-Az5 failed to induce B. anthracis lysis, in contrast to PZN 
(Figure 3.8). A possible explanation for the observed differences between PZN and Me2-Arg-
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Az5 is that the C-terminal portion of the molecule is responsible for the species selectivity of the 
mature molecule and the N-terminal portion harbors the antibiotic activity, although this remains 
to be more extensively investigated. The expression profiles of PZN and Me2-Arg-Az5, together 
with strain susceptibility, suggest that PZN and Me2-Arg-Az5 pursue independent, but possibly 
related, targets. Thus, although Me2-Arg-Az5 is not useful as a mimic for the full-length natural 
product, it represents one strategy to broaden the antibiotic spectrum of PZN. 
3.3.4 PZN depolarizes the B. anthracis membrane 
The induction of liaIH and desRK by PZN suggests a potential relationship with components of 
the cell envelope. To determine if PZN treatment led to the loss of membrane potential, 3,3′-
diethyloxacarbocyanine iodide (DiOC2(3)) was used in a standard flow cytometry-based 
assay.44 We observed a dose-dependent decrease in membrane potential upon treating B. 
anthraciswith PZN, even at concentrations 100-fold below the MIC. These data further suggest 
that PZN exerts its action by disrupting the integrity of the cell membrane (Figure 3.9). 
Destabilization of the bacterial cell membrane is a common MOA for antibiotics; for example, 
both nisin and daptomycin are known to disrupt membrane potential in Gram-positive 
organisms.45-47 By cotreating B. anthracis with either nisin or daptomycin and PZN, the resulting 
isobolograms elicited strong synergistic activity with PZN (Figure 3.9), suggesting independent 
but cooperative activities.48 
3.3.5 Subcellular localization of PZN 
 
With mounting evidence that PZN targets the cell membrane, we determined the subcellular 
localization of PZN by confocal microscopy. Antibiotics derivatized with fluorescent probes have 
previously been used to shed light on their MOAs.49-50 Localization of PZN was established by 
employing a Cy5-labeled PZN derivative (PZN-Cy5) (Figure 3.1, Figure 3.10) that retained much 
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of its anti-B. anthracis activity (MIC of 4 µg/mL, 2 µM). PZN-Cy5 localized to distinct ∼200 nm 
wide foci in B. anthracis Sterne (Figure 3.11). To establish if PZN-Cy5 behaved in a manner 
identical to that of unlabeled PZN, we carried out a competition assay using an excess of unlabeled 
PZN applied toB. anthracis Sterne followed by addition of PZN-Cy5. Due to the extensive cell 
lysis elicited by PZN, we employed a later-described, spontaneous PZN-resistant mutant (PR06) 
for the competition assay. Just as in B. anthracis Sterne, PZN-Cy5 localized to distinct foci in B. 
anthracisPR06, which is consistent with its susceptibility, albeit at higher concentrations of PZN 
(Figure 3.11). Importantly, PZN-Cy5 failed to label strain PR06 when an excess of unlabeled PZN 
was administered first, demonstrating that PZN and the PZN-Cy5 probe identically interact with B. 
anthracis (Figure 3.11). Due to the photoswitching properties of Cy5, we were able to further 
investigate PZN-Cy5 localization using stochastic optical reconstruction microscopy (STORM, 
Figure 3.12).51 Using this super-resolution imaging technique, B. anthracis Sterne cells were again 
confirmed to accumulate PZN-Cy5 at the foci described above. These foci were clearly 
concentrated near the cellular surface, providing additional evidence that a component of the cell 
envelope is the target of PZN (Figure 3.13). B. anthracis cells contain 16 ± 2 foci per cell, each 
with a diameter of 181 ± 7 nm, as determined by analysis of 14 randomly chosen cells treated with 
PZN-Cy5 (Figure 3.13). The labeling pattern of PZN-Cy5 is strikingly different from that of 
BODIPY-vancomycin, which localizes strongly to bacterial septa where peptidoglycan synthesis 
is at a maximum.52 If PZN were acting on the cell wall, sites of active peptidoglycan synthesis or 
the entire cell wall would be labeled with PZN-Cy5. The nonseptal, punctate labeling of PZN-Cy5 
suggests that the target of PZN is neither nascent nor existing peptidoglycan, which is congruent 
with the observation that PZN did not block cell wall biosynthesis (Figure 3.5). PZN-Cy5 also 
does not appear to label nonsusceptible Bacillus species (Figure 3.14). Some modest labeling was 
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found with B. cereus G9241, which aligns with a somewhat elevated MIC for PZN (8 µg/mL). 
Combined with the evidence of PZN-Cy5 labeling PZN-resistant B. anthracis PR06 (Figure 3.11), 
these data suggest that PZN binding to the cell envelope is necessary, but insufficient, for bacterial 
killing. 
3.3.6 Isolation and characterization of PZN-resistant mutants 
An orthogonal strategy for obtaining antibiotic MOA information involves the selection and 
mapping of resistance-conferring polymorphisms.53 The mutated gene(s) can be involved either 
directly in the MOA of the antibiotic or in a target-unrelated mechanism of immunity. We isolated 
PZN-resistant B. anthracis by growing the Sterne strain on agar plates containing PZN at 4 × MIC. 
The resistance frequency was determined to be 2.3 × 10–7, and the resulting mutants exhibited 
MICs that were ≥32 µg/mL. Genomic DNA was isolated and sequenced for six independently 
selected PZN-resistant strains (PR01 through PR06) and the parent Sterne strain. Comparison of 
PR01 through PR06 to the parent revealed that all six polymorphisms were confined to a 50-
nucleotide section of a single gene, bas4114, which is annotated as an AcrR transcriptional 
repressor (Table 3.12).54 This particular AcrR protein is predicted to contain a single 
transmembrane domain near the C-terminus (Figure 3.15), which is precisely where the PZN 
resistance conferring mutations were found, all resulting in premature stop codons. Directly 
downstream of bas4114 are two EmrE-type multidrug resistance efflux pumps, encoded 
asbas4115–4116. We hypothesized that as an AcrR-type transcriptional repressor, BAS4114 
would negatively regulate bas4115–4116 and that mutations near the C-terminus of BAS4114 
would result in regulator mislocalization/dysfunction and derepression of the efflux pumps. This 
in turn would increase resistance to PZN. Multidrug resistant transporters have been shown to 
export membrane-associated antibiotics,55-56 a concept that is consistent with our data supporting 
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the localization of PZN. One prediction is that BAS4115–6 actively efflux membrane-associated 
PZN, which lowers the steady-state membrane concentration of PZN. The MIC for PZN thus 
would increase with the increased expression of bas4115–4116. We employed RNA-Seq to 
compare the mRNA expression profiles of PR06 to the parent Sterne strain. This analysis revealed 
significant up-regulation of bas4114–4116, as well as an unknown gene immediately 
downstream, bas4117 (Table 3.13). PR06 and the Sterne parent were equally susceptible to Me2-
Arg-Az5 (Table 3.8), again underscoring differences between PZN and Me2-Arg-Az5. The 
susceptibility of PR06 to a panel of mechanistically diverse antibiotics, including daptomycin, was 
also assessed (Table 3.9). The mutation present in PR06 did not confer cross-resistance toward 
any other tested antibiotic. We then investigated if bas4114–4117 were constitutively 
overexpressed in nonsusceptible B. cereus strains E33L and ATCC 4342, thereby conferring innate 
resistance to PZN. Using qRT-PCR, we could not identify constitutive overexpression of this locus 
in nonsusceptible B. cereusstrains compared to B. anthracis (data not shown). This suggests that 
the bas4114–4117 locus is not responsible for PZN resistance in nonsusceptible B. cereus strains. 
Frameshift mutations in the predicted transmembrane region of bas4114 are clearly the favored 
route for generating PZN resistance in B. anthracis, as shown by the occurrence of multiple 
independent mutations within the same gene. To subvert this resistance mechanism, and to obtain 
more insightful information about the MOA of PZN, we deleted bas4114–4117 from the parental 
strain by homologous recombination (Figure 3.16). B. anthracis Sterne Δbas4114–4117 thus 
became the new parental strain for isolating second-generation PZN-resistant mutants, as the 
removal of bas4114–4117 rendered this strain as sensitive to PZN as wild type Sterne (1 µg/mL). 
This time, two routes were pursued for obtaining additional PZN-resistant strains. First, we 
selected spontaneous PZN-resistant mutants by challenging Δbas4114–4117 with 4 × MIC PZN. 
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Isolation of the spontaneous mutants resulted in a mutation frequency an order of magnitude lower 
than before (1.3 × 10–8). Two independently selected, modestly resistant strains (PR07 and PR08) 
were subjected to whole-genome sequencing, revealing single missense mutations within 
ftsE (Table 3.14). In Escherichia coli, FtsE is an ATP-binding protein that associates with its 
cognate permease, FtsX, together comprising an ABC transporter that functions during cell wall 
elongation and septum formation.57 The activity of FtsE/X in B. subtilis differs slightly, as it is 
responsible for initiating endospore formation via asymmetric septation.58 Akin to bas4114, 
spontaneous mutations in ftsE alone cannot explain the species selectivity of PZN, as the amino 
acid sequence of B. anthracis FtsE is 100% identical to several nonsusceptible B. cereus strains. 
Other B. cereusstrains, even the PZN-susceptible G9241 strain, are 98–99% identical to B. 
anthracis FtsE. Although there may be an indirect relationship between PZN and FtsE/X, our data 
support a MOA that does not involve a physical association with FtsE. 
As a second strategy to obtain PZN-resistant mutants, we cultured B. anthracis Sterne 
Δbas4114–4117 in the presence of a sublethal concentration of PZN. The concentration of PZN 
was gradually increased with the number of passages.59 We isolated genomic DNA from a first-
passage strain (PR09-1, MIC 16 µg/mL) in addition to two independent fourth passage strains 
(PR09-4, PR10-4, MICs ≥ 64 µg/mL) for whole genome sequencing. PR09-1 contained a missense 
mutation in bas1659, which encodes a predicted CitB-like response regulator (Table 3.14). 
Downstream of bas1659 are genes encoding a predicted histidine kinase (bas1660), ABC 
transporter subunits (bas1661–1663), and a cardiolipin (CL) synthase gene (bas1664). PR09-4 is 
a descendent of PR09-1, and as such, PR09-4 contained the same bas1659 mutation as PR09-1 in 
addition to another missense mutation in bas1662 (the permease domain of the locally encoded 
ABC transporter). PR10-4 contained a similar mutation series (bas1663, a second permease gene 
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for what is presumably a trimeric ABC transporter) but had an additional mutation in bas1842, 
which is implicated in petrobactin biosynthesis.60 Upon further inspection, we found that deletion 
of the petrobactin biosynthetic gene cluster did not decrease susceptibility to PZN; therefore, the 
significance of this missense mutation remains unknown (Table 3.1). 
3.3.7 Exogenous cardiolipin increases sensitivity to PZN 
We hypothesized that the regulatory- and transport-related mutations upstream of the gene 
encoding CL synthase could alter CL concentrations and, thus, CL may be implicated in the MOA 
for PZN. We first examined the effect of exogenous CL on the interaction of PZN with the B. 
anthracis cell membrane. B. anthracis cells were treated with PZN-Cy5 (1 nM, 0.001 × MIC) in 
the presence and absence of exogenous CL (up to 100 µg/mL). PZN-Cy5 treated cells were then 
analyzed by flow cytometry. The extent of PZN-Cy5 binding to B. anthracis was significantly 
increased when cells were cotreated with CL (Figure 3.18). This result is in contrast to that of 
daptomycin, which acts on the bacterial membrane but exhibits an antagonistic relationship with 
CL in Enterococci.61-62 As predicted, co-administration of CL did not increase the labeling 
efficiency of daptomycin-Cy5 on B. anthracis cells (Figure 3.1, Figure 3.17, and Figure 3.18).61 
Congruent with these data was the observation that CL potentiated the killing activity of PZN 
toward B. anthracis, but decreased daptomycin susceptibility 4-fold. Indeed, the strongly 
synergistic behavior with CL enhanced the potency of PZN upward of 16-fold, whereas CL alone 
had no antibiotic activity at the concentrations tested (Figure 3.18). 
3.3.8 PZN Co-localizes with cardiolipin and regions of increased fluidity 
The genetic and functional association with CL implicates the membrane as the most probable 
target for PZN. The lipid dye 10-N-nonyl acridine orange (NAO) approximates regions of the cell 
membrane enriched in CL.63 In B. subtilis and B. cereus, NAO organizes into distinct foci primarily 
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at the septa and the poles (Figure 3.19),64 but it appears that in B. anthracis Sterne, NAO labels 
distinct foci throughout the entirety of the cell membrane (Figures 3.19 and 3.20). CL has the 
potential to dramatically alter membrane architecture and may contribute to the susceptibility of B. 
anthracis through punctate localization throughout the cell. We therefore treated B. anthracis cells 
with PZN-Cy5 and NAO to investigate if PZN localized to CL-rich regions in the cell membrane. 
There existed a clear but imperfect co-localization of the two dyes, suggesting a possible 
interaction with CL in the bacterial membrane (Figure 3.20). Thus, B. anthracis appears to have a 
unique distribution of CL that facilitates an interaction with PZN and leads to cell death, whereas 
CL localization within other species may not facilitate the lytic activity of PZN. Additionally, 1,1′-
didodecyl-3,3,3′,3′-tetramethylindocarbocyanine perchlorate, (DilC12(3)), is a dye reported to 
associate with regions of increased fluidity (RIF) within cell membranes of B. subtilis and may 
also be indicative of CL localization.65 RIFs are transiently weakened regions within the bacterial 
membrane that affect lipid homeostasis and membrane fluidity. We observed co-localization of 
DilC12(3) and PZN-Cy5, consistent with PZN and CL co-associating with B. anthracis RIFs 
(Figure 3.20). 
The proportion of CL in cell membranes has been reported to increase during growth in 
high-osmolarity medium, especially for B. subtilis.66 We thus tested whether increasing the 
osmolarity of the B. subtilis medium (and thus the CL content) would induce susceptibility to PZN. 
When grown in standard LB supplemented with an additional 1.5 M NaCl (1.67 M final), PZN 
was weakly growth-suppressive toward B. subtilis (Table 3.15). By measuring CL from total lipid 
extractions, CL levels did increase compared to standard growth in LB (Table 3.15). However, 
exogenous CL alone did not induce PZN susceptibility in B. subtilis or B. cereus (data not shown). 
Members of B. cereus sensu lato, including B. anthracis, are not as osmotolerant as B. 
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subtilis;67 the maximum salinity these strains can tolerate in LB is 0.67 M (standard LB 
supplemented with an additional 0.5 M NaCl). When grown under high osmotic stress, both wild 
type and PZN-resistant strains ofB. anthracis display measurable susceptibility to PZN, 
although B. cereus strains remain resistant (Table 3.15). Unlike B. subtilis, CL content does not 
increase significantly when B. anthracis or B. cereus strains are grown in 0.5 M NaCl, suggesting 
that the observed susceptibilities may be due to the harsh growth conditions rather than CL content. 
Cell survival under conditions of increased osmolarity is dependent on membrane fluctuations with 
an increase in unsaturated fatty acid composition.66 Increased CL levels are associated with high 
osmotic stress in B. subtilis, E. coli, Lactococcus lactis, and others.66 Furthermore, excess CL 
within the membrane results in increased fluidity and lipid bilayer deformation, as observed 
when B. subtilis is grown in a high-osmolarity medium (Figure 3.21).68 By increasing the 
osmolarity of the growth medium, we can induce a modest increase in the potency of PZN toward 
B. anthracis (Table 3.15). The resultant increase in CL, together with the activation of the des TCS, 
presumably shifts the lipid profile to a more fluid composition, which negatively affects membrane 
integrity. This phenotype is readily observed by confocal microscopy (Figure 3.21).69 We 
hypothesize that PZN takes advantage of an already weakened B. anthracis membrane to elicit its 
selective antibacterial activity. 
As stated previously, the stepwise-selected PZN-resistant strains accumulated mutations in 
genes upstream of one of five CL synthase genes (cls, bas1664). We analyzed the transcriptional 
response within the bas1664 locus, including the upstream regulators/transporters, and observed a 
dramatic increase in the expression of several genes in PR09-1 and PR09-4, 
including bas1664itself and the nearby ABC transporter genes (bas1661–1663), but not the locally 
encoded response regulator and histidine kinase genes (bas1659–1660, Table 3.16). In stark 
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contrast, there was no differential expression of any tested gene in the PR10-4 strain. Although 
these results may seem contradictory, PR10-4 did acquire an additional mutation in a gene 
responsible for the production of the siderophore petrobactin (Table 3.14).70 Given that it is well 
established that B. subtilis experiences iron limitation when grown under high osmotic stress,71-
72 it is possible that PR10-4 handles stress induced by PZN or high NaCl concentrations differently 
from PR09-1 and PR09-4. Furthermore, CL levels do not necessarily correlate to the number 
of cls transcripts (and there are multiple cls genes), which is suggestive of other regulatory 
mechanisms to avoid overproduction of CL.73 With respect to PR09-1, PR09-4, and PR10-4, there 
is a complex relationship between CL content and PZN susceptibility. On the basis of our findings, 
we expect that in addition to CL, other membrane-associated biomolecules may also contribute to 
the ability of PZN to destabilize B. anthracis cell membranes.  
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3.4 Conclusion 
 
Due to advances in genomics, B. anthracis, the causative agent of anthrax, can be distinguished 
from the other members of the B. cereus sensu lato group by whole genome sequencing, multilocus 
sequence typing, the presence of chromosomal lambdoid prophages, and the presence of a 
characteristic nonsense mutation in plcR.18, 29 An alternative approach to B. anthracisidentification 
now includes susceptibility to PZN, which is a natural product exhibiting potent and selective 
bactericidal activity for B. anthracis under standard laboratory conditions. Our data demonstrate 
that the species selectivity of PZN is even more discriminating than that of the reputedly selective 
γ phage.25, 28-29, 74 Additionally, PZN on its own does not contribute to B. methylotrophicus FZB42 
antifungal or nematicidal activity. B. anthracis is nearly identical to other members of the B. cereus 
sensu lato family and, remarkably, strains of B. anthracis selected to interrogate key genetic 
differences retain their respective susceptibility to PZN. Gene expression analysis, together with 
confocal and super-resolution microscopy, reveals that PZN operates by a different MOA than 
previously described cell envelope-targeting antibiotics. Thus, we present a model for PZN activity 
wherein PZN takes advantage of a locally weakened cell membrane, whether due to RIFs, CL-
dependent membrane deformation, or some combination thereof. PZN accumulates to such 
membrane defects, resulting in membrane depolarization and lysis of B. anthracis in a species-
specific manner. The activity of PZN suggests an immediate homeland security application, where 
it could be developed into a rapid B. anthracis detection test. 
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3.5 Methods 
3.5.1 Strain and growth conditions 
All strain references are displayed in Table 3.1. All strains were grown in LB broth unless 
otherwise described (10 g/L tryptone, 5 g/L yeast extract, 10 g/L (0.17 M) NaCl). Biosafety level 
3 strains of B. anthracis were grown on Mueller–Hinton agar. Neisseria strains were grown in 
gonococcal medium base supplemented with Kellogg’s I and II.75 Streptomyces endospores were 
isolated on mannitol soybean flour agar (20 g/L mannitol, 20 g/L soybean flour, 1.5% agar) and 
used to determine PZN susceptibility in ISP2 (4 g/L yeast extract, 10 g/L malt extract, 4 g/L 
dextrose). Yeast strains were grown in YPD medium (10 g/L yeast extract, 20 g/L peptone, 20 g/L 
dextrose). C. elegans was cultured on nematode growth medium with E. coli OP50. Cultures were 
supplemented with 1.25 mM CaCl2 when assaying daptomycin susceptibility. In cases when 
increased osmolarity was desired, the LB was supplemented with additional NaCl (final 
concentration of 1.67 M). 
3.5.2 PZN production  
Stationary phase cultures of RSpMarA2 (Δsfp, yczE, degU) (1) were grown in Luria-Bertani (LB) 
broth supplemented with 7 µg/mL kanamycin and 7 µg/mL chloramphenicol. Sterilized aluminum 
trays (12.75 × 9 in) were prepared with M9 agar medium supplemented with BME vitamin mix 
and ATCC trace mineral solution and the aforementioned antibiotics. Trays were inoculated with 
1.5 mL stationary phase RSpMarA2 and incubated for 48 h at 37 °C. Bacterial lawns were loosened 
from the agar with a razor blade and resuspended in Tris-buffered saline (TBS) (150 mL/tray). The 
bacteria were then harvested via centrifugation (11,000 × g, 20 min, 4 ˚C). The supernatant was 
decanted and the cell pellets were stored at -20 °C until extraction.  
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3.5.3 PZN purification  
PZN was extracted by resuspending the bacterial pellets in 150 mL MeOH/tray with intermittent 
vortexing for 15 min at 22 °C. The cells were then harvested by centrifugation as above. The 
supernatant was vacuum-filtered using Whatman filter paper, rotary evaporated, and subsequently 
lyophilized to dryness. The dried, crude PZN was resuspended in MeOH (1 mL/tray of extract) 
and centrifuged to remove insoluble debris (4,000 × g, 10 min, 4 ˚C). The supernatant was then 
injected onto a RediSep Rf High Performance 15.5 g HP C18 cartridge (Teledyne Isco) and 
purified by MPLC using a Combiflash Rf 200 system (25-100% MeOH/10 mM aqueous 
NH4HCO3 over 120 column volumes). The fractions containing PZN were pooled, rotary 
evaporated, and lyophilized to dryness, which yielded roughly 5 mg/tray. Purity was confirmed by 
analytical HPLC-ESI-MS (Agilent) inline with a BETASIL C18 column (Thermo, 250 mm × 4.6 
mm, 5 µm particle size). On a 35 min gradient from 40-95% MeCN/10 mM aqueous NH4HCO3, 
the sample was monitored for absorption at 220 and 260 nm, all ions 400 – 2000 Da and the 
[M+2H]2+ of PZN. After confirmation of purity, PZN was dissolved in DMSO at concentrations 
of 30-50 mg/mL and stored at -80 ˚C for later use.  
3.5.4 Bacterial endospore preparation and susceptibility screening  
B. anthracis Sterne 77022 endospores were prepared as described previously.76 Briefly, B. 
anthracis Sterne 7702 cells were incubated overnight in LB at 37 °C. Difco Sporulation Media 
agar plates (8 g/L Nutrient Broth, 1 g/L KCl, 0.25 g/L MgSO4•7H2O, and 17 g/L agar) was 
inoculated with 150 µL of the stationary phase culture and incubated at 30 °C for 5 d. Lawns were 
recovered by resuspension in sterile H2O and filtered using 3.1 and 1.2 µm filters to remove 
vegetative cells and aggregated endospores. Endospore filtrate was incubated at 65 °C for 1 h to 
remove any remaining vegetative cells. Endospores were harvested by centrifugation (8,000 × g, 
 79 
25 min, 4 °C). After decanting the supernatant, the endospores were washed 3 times with 40 mL 
of H2O, harvesting by centrifugation. Endospores were stored at 4 °C in H2O and quantified by 
plating. Endospores were screened for PZN activity by incubating 1 × 109 endospores with PZN 
(0-16 µg/mL) in H2O for 20 h at 37 °C. Endospores were incubated at 65 °C for 1 h to destroy any 
remaining vegetative cells, followed by a 4 h recovery step at 4 ˚C, and then finally by serial 
dilution onto LB agar plates to assess germination. Plate counts represent the average of two trials.  
3.5.5 PZN bioactivity 
PZN and Me2-Arg-Az5 bioactivities were determined via microbroth dilution assay as described 
in the Clinical and Laboratory Standards Institute manual.77 The optical density (OD600) of a 
stationary phase culture was adjusted to 0.01 and added to a microtiter plate containing serially 
diluted PZN. Wells were visually inspected for turbidity, and the MIC was determined as the 
lowest compound concentration that incurred no growth after 16 h. MICs were determined in LB 
unless growth conditions required an alternative medium (see above). The S. aureus media-
dependent PZN susceptibility was analyzed using LB, brain–heart infusion (BHI, Bacto), and 
Mueller–Hinton (BBL) broths. When indicated, CL was added to the medium at 100 µg/mL. 
A B. anthracis growth curve was generated using Tecan Infinite M200 Pro. B. anthracis Sterne 
7702 cultures were grown in LB to stationary phase at 37 °C. Cultures were diluted to OD600 of 
0.05 with fresh LB and allowed to recover to an OD600 of 0.35. Cultures were aliquoted into 96-
well plates containing PZN and incubated at 37 °C with orbital shaking. OD600 was measured every 
2 min. Values were normalized to an initial OD600 of 0.35 and adjusted to a 1 cm path length. Error 
bars represent standard deviation of two independent experiments. 
A growth curve in the presence of Me2-Arg-Az5 was generated as described above with the 
following differences: B. anthracis Sterne 7702 and cultures were grown in duplicate to OD600 1.0 
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and aliquoted into 96-well plates. Wells were treated with 1:1 dilutions of Me2-Arg-Az5 at a 
maximum concentration of 12 µM. The plate was incubated at 37 °C with orbital shaking, and 
OD600 was measured every 2 min. Values were normalized to an initial OD600 of 1.0, adjusted to a 
1 cm path length, and averaged at each time point. 
3.5.6 Gamma (γ) phage sensitivity 
γ phage are propagated as described previously25 using B. anthracis Sterne 7702 cells on BHI agar 
plates, with no visible loss in infectivity. Phage infectivity was tested against a panel of B. 
cereus and B. anthracis strains using a serial dilution assay. Stationary phase cultures were 
adjusted to an OD600 of 0.1, and 100 µL was plated on BHI plates. Five microliters of phage stock 
(2.6 × 108 plaque-forming units/mL) was serially diluted (2-fold) and spotted onto the plates and 
allowed to dry. After incubation at 37 °C for 16 h, plates were removed and visually inspected for 
plaques. 
3.5.7 RNA isolation and transcriptional profiling of PZN-treated Sterne cells 
For the compound-treated samples, independent 3 mL cultures of B. anthracis Sterne 7702 cells 
were grown to an OD600 of 0.4, and 0.25 × MIC of PZN, 0.25 × MIC Me2-Arg-Az5,15 or an 
equivalent volume of DMSO was added and allowed to incubate for 10 min at 37 °C. Together 
with resistant mutant PR06, RNA was isolated and prepared as described previously.4 RNA-Seq 
libraries were created using the TruSeq Stranded RNA Sample Prep kit (Illumina, San Diego, CA, 
USA) after rRNA depletion using the RiboZero Bacteria kit (Epicenter, Madison, WI, USA). 
Sequencing was performed for 1 × 100 cycles on a HiSeq 2000 with version 3 Chemistry. 
Transcriptomic data were processed with the Rockhopper version 1.30 pipeline78 using B. 
anthracis Sterne and B. anthracis Ames Ancestor plasmid pXO1 (NC_007322.2) as references. 
Default values (allowed mismatches 0.15, minimum seed length 0.33, minimum expression of 
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UTRs and ncRNAs 0.5) were used, with the exception that reverse complement reads were used 
for mapping. The RNA-Seq data discussed in this publication have been deposited in NCBI’s Gene 
Expression Omnibus and are accessible through GEO Series accession no. GSE73343 
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE73343). 
3.5.8 Membrane depolarization 
Three independent stationary phase cultures of B. anthracis Sterne 7702 were used to inoculate 
fresh LB and grown to OD600 of 0.5 at 37 °C with shaking. Aliquots (10 µL) were diluted to 1 mL 
in PBS containing 0.1 µM DiOC2(3) and compounds (DMSO, vehicle; 5 µM carbonyl cyanide m-
chlorophenyl hydrazone (CCCP), 3.0 µM daptomycin, 0.5 µM PZN, 1.0 µM PZN). Cells were 
mixed at 21 °C for 30 min prior to analysis by flow cytometry (BD LSR II Flow Cytometry 
Analyzer). Voltages for fluorescein isothiocyanate (FITC) and propidium iodide (PI) fluorescence 
were set so that average counts per cell were between 103 and 104. Geometric means for 
fluorescence ratios were normalized to the control DiOC2(3) samples. 
3.5.9 Confocal microscopy 
In general, cells were prepared by inoculating 5 mL of LB with 200 µL of a stationary phase 
culture. After growing to an OD600 of 0.5 at 37 °C with shaking, 1 mL aliquots were centrifuged 
(3 min, 8000g), decanted, and resuspended in sterile PBS. Slides were prepared by mixing 1:1 
(v/v) cell suspensions in PBS and liquefied low gelling temperature agarose (Sigma-Aldrich, 2% 
w/v in water). All microscopy images were obtained using a Zeiss LSM 700 confocal microscope 
with a 63×/1.4 Oil DIC objective and processed using Zen 2012 software. Laser intensity and gain 
were kept at a minimum and held constant for all experiments. Linear contrast was equally applied 
during image processing. To localize PZN, B. anthracis Sterne 7702 was treated in PBS with 0.2 
µM PZN-Cy5 for 30 min at 22 °C. After washing in PBS (3 × 500 µL), cells were resuspended in 
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a final volume of 250 µL of PBS. Competition experiments were performed using PR06 (PZN-
resistant) in PBS treated with DMSO (vehicle) or 1 µM PZN for 20 min at 22 °C before the addition 
of 0.05 µM PZN-Cy5. After 20 min at 21 °C, the cells were washed in PBS (3 × 500 µL) and 
resuspended in a final volume of 250 µL of PBS. Sterne underwent cotreatment in PBS with 0.2 
µM PZN-Cy5 for 25 min before the addition of other fluorescent compounds. After 5 min of 
additional treatment, cells were washed in PBS (5 × 500 µL) and resuspended in a final volume of 
250 µL of PBS. Concentrations used were as follows: NAO (Sigma-Aldrich), 1 µM; DilC12(3), 1 
µM. For CL experiments, cells were treated with EtOH (vehicle), 10 µg/mL CL, or 100 µg/mL CL 
in addition to 0.2 µM PZN-Cy5 for 30 min. For high-osmolarity samples, cells were grown to 
stationary phase in standard LB and diluted into high-osmolarity medium (an additional 1.5 M 
NaCl was added to B. subtilis cultures; 0.50 M for B. anthracis and B. cereus). 
3.5.10 Super-resolution microscopy (STORM) 
Cells for 3D super-resolution microscopy were grown and treated with PZN-Cy5 as described for 
confocal microscopy. The cells were immobilized on a Nunc Lab-Tek 8-well chambered 
coverglass (Sigma-Aldrich) coated with 0.1% (w/v) poly-L-lysine (Sigma-Aldrich). After 10 min 
of incubation, unattached cells were removed by washing chambers with sterile PBS. Chambers 
were filled with 500 µL of imaging buffer (10 mM NaCl, 50 mM Tris-HCl (pH 8.5), 10% w/v 
glucose). Immediately prior to imaging, cysteamine (Sigma-Aldrich, 10 mM final concentration), 
catalase (EMD Millipore, 909 U/mL), and pyranose oxidase (Sigma-Aldrich, 4.44 U/mL) were 
added to the imaging buffer. 3D super-resolution microscopy was performed as described 
previously.79-80 Briefly, samples were imaged using an Olympus IX-71 inverted microscope 
outfitted with a 100× NA 1.4 SaPo oil objective. Mechanical shutters (LS6T2, Unibliz) were used 
to alternatively excite the sample with a red laser (DL640-100-AL-O, Crystalaser) and reactivate 
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Cy5 with a violet laser (405 nm, 20 mW, Spectra Physics Excelsor). The lasers were expanded by 
7.5×, reflected by a dichoroic mirror (Semrock FF408/504/581/667/762-Di01-25X36), and sent to 
the sample chamber with a focusing lens that also creates an incidental angle slightly smaller than 
the total internal reflection angle, reducing the background signal while allowing illumination of 
several hundred nanometers along the z-axis. The emission signal from the sample was passed 
through an emission filter (Semrock FF01-594/730-25) and two additional notch filters (Semrock 
NF01-568/647-25X5.0 and NF01-568U-25) and was imaged on an EMCCD camera (DV887ECS-
BV, Andor Tech). A cylindrical lens (SCX-50.8-1000.0-UV-SLMF-520-820, CVI Melles Griot, 
2 m focal length) in the emission beam path induced astigmatism for 3D detection.51 ASI CRISP 
(Applied Scientific Instrumentation) and a piezo-objective (PI P-721.10) were used to compensate 
for vertical drift during data collection. The horizontal drift was corrected in the post data 
acquisition step by the analysis software utilizing the correlation function.81 The data analysis 
software was provided by Xiaowei Zhuang79 and modified for 3D imaging. 
3.5.11 2D projection analysis  
2D projection analysis was used to determine spatial localization of PZN on B. anthracis Sterne 
7702 cells. A total of 11 cells imaged by super-resolution microscopy were aligned lengthwise 
along the y-axis, and then sectioned to remove poles and septa. Cells were projected onto the XZ 
plane and divided into units of 30 × 30 nm2. Within each unit, spot density was determined and 
color-mapped. The probability of finding a dye molecule at distance R from the y-axis was 
calculated for radial windows with a 20 nm bin size and normalized to the area of the radial 
window.  
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3.5.12 PZN-Cy5 cluster analysis 
A density-based clustering analysis algorithm, DBSCAN,(8) was used as previously reported(9, 10) 
to analyze super-resolution images of PZN-Cy5-treated B. anthracis Sterne 7702. Briefly, spots in 
super-resolution images of 14 cells were grouped into clusters based on spatial density. The 
required Npts and Eps parameters were set to 19 and 40 nm, respectively, and used to identify core 
points in high density spots. Parameter values empirically set such that core points within a cluster 
were within Eps distance of each other and surrounded by at least Npts points. Cluster borders 
were defined by points located with Eps distance to any core point. Cluster size was calculated as 
twice the average distance between the cluster center and every point in the cluster.  
3.5.13 Selection of spontaneous PZN-resistant mutants 
Spontaneous PZN-resistant mutants were generated by plating 2 × 108 B. anthracis Sterne 7702 
cells grown to stationary phase onto a PZN plate containing 4 × MIC PZN. Surviving colonies 
were tested for sustained PZN resistance via microbroth dilution as described above. Resistant 
mutants PR01, PR02, PR05, and PR06 were subjected to genomic DNA isolation as follows: 3 × 
10 mL cultures of each strain were grown to stationary phase, harvested, and resuspended in 400 
µL of water. Cells were lysed with 50 µL of 10% SDS and 5 µL of 20 mg/mL RNase solution at 
22 °C for 5 min. DNA was isolated via 25:24:1 phenol/chloroform/isoamyl alcohol extraction, 
followed by addition of 24:1 chloroform/isoamyl alcohol. DNA precipitation via cold isopropyl 
alcohol and a subsequent 70% ethyl alcohol wash resulted in purified genomic DNA. 
After genetic deletion of bas4114–4117, a second round of spontaneously resistant mutants 
to PZN was selected and isolated as above. Serial-passage mutants were isolated as previously 
described,59 starting with three independent cultures of an OD600 of 0.1 B. anthracis Sterne 7702 
Δbas4114–4117 in 0.25 µg/mL (0.25 × MIC) PZN LB. Cultures that grew were diluted to an 
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OD600 of 0.1 and subjected to increased concentrations of PZN until cultures were resistant to 64 
µg/mL. Cultures were serially passaged onto PZN-free medium to confirm mutant stability. 
Genomic DNA was isolated as described above. All mutants derived from the Δbas4114–
4117 deletion strain were sequenced as described and assembled via CLC Genomics Workbench, 
and SNP analysis was performed with Mauve version 2.3.1. 
3.5.14 Whole genome sequencing and assembly 
Genomic libraries for resequencing were prepared using the TruSeq DNaseq Sample Prep Kit 
(Illumina). Sequencing was performed on a HiSeq 2000 with version 3 Chemistry for 1 × 100 
cycles. SNP and DIP discovery was performed with two different methods. Regarding PR02, 
PR05, and PR06, CLC Genomics Workbench SNP and DIP discovery pipelines were employed 
using with the publicly available B. anthracis str. Sterne genome NC_005945.1 as a reference. 
PR01 required de novo assembly with IDBA UD version 1.0.9, followed by whole genome 
alignment and SNP discovery using Mauve version 2.3.1. Resistant mutants PR03 and PR04 were 
selected separately and underwent Sanger sequencing after PCR amplification of bas4114and 
sequencing with the BamHI-BAS4114-f primer (Table 3.6). The WGS data discussed in this 
publication have been deposited in NCBI’s GenBank and are accessible via BioProject accession 
no. PRJNA295544. Within this BioProject are individual accession numbers for each B. 
anthracisstrain (taxId: 1392) for which whole genome sequencing was performed: CP012720, 
PR01; CP012721, PR02; CP012722, PR05; CP012723, PR06; CP012724, PR07; CP012725, 
PR08; CP012726, PR09–1; CP012727, PR09–4; CP012728, PR10–4; CP012730, Parent1 (for 
PR01 through PR06); CP012729, Parent2 (for PR07 through PR10-4). 
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3.5.15 Effect of cardiolipin on fluorescence intensity 
Three independent stationary phase cultures of B. anthracis Sterne 7702 were used to inoculate 
fresh LB (200 µL into 5 mL of LB), and the new cultures were grown to OD600 of 0.5 at 37 °C 
with shaking. Samples were prepared by diluting 10 µL aliquots of culture to 1 mL in PBS 
containing 1 nM PZN-Cy5 and vehicle (EtOH), 10 µg/mL CL (Sigma-Aldrich), or 100 µg/mL CL. 
After mixing at 22 °C for 30 min, cells were analyzed by flow cytometry as described above for 
differences in PZN-Cy5 fluorescence intensity. Geometric means were normalized to the control 
samples. 
3.5.16 Cardiolipin quantification from total lipid extracts 
Cultures of B. anthracis Sterne 7702, B. anthracis Δbas4114–4117, B. anthracis PR09-4, B. 
anthracis PR10-4, B. subtilis 168, E. faecium U503, and S. aureus USA300 (three independent 10 
mL cultures for each strain) were grown for 20 h at 37 °C. LB containing an additional 1.5 M NaCl 
was inoculated with 200 µL aliquots of stationary phase cultures of B. subtilis 168 or 0.5 M NaCl 
for B. anthracis and B. cereus (three independent 10 mL cultures for each strain) and grown for 
40 h at 37 °C. The cells were harvested by centrifugation (4000g, 10 min, 4 °C) and resuspended 
in 5 mL of 2:1 CHCl3/MeOH and 1.25 mL of PBS and then extracted for 1 h at 22 °C. The 
supernatant was removed after centrifugation (4000g, 10 min, 4 °C), and layers were washed with 
1 mL of CHCl3 and 1 mL of PBS. The organic layer was removed and dried by speed vacuum. 
The crude lipids were redissolved in 200 µL of CHCl3 and transferred to microfuge tubes and then 
dried again. The lipids were then dissolved in 20 µL of CHCl3, spotted (2 µL) onto Merck Silica 
Gel 60 F254 analytical TLC plates, and separated using 80:20:5 CHCl3/MeOH/AcOH. Pure CL was 
used as a standard. The plates were imaged using a Bio-Rad ChemiDoc XRS+. ImageJ was used 
to subtract background and measure spot density to determine percent CL out of total lipid content. 
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3.5.17 C. elegans nematicidal assays  
Wild-type N2 Caenorhabditis elegans were cultured on Escherichia coli OP50 using standard 
techniques.32 Eggs were isolated from gravid hermaphrodites using standard bleaching protocols82 
and incubated for 18 h at 20 °C to obtain synchronized L1 larvae. Cultures were then transferred 
to new nematode growth media (NGM) plates seeded with OP50 E. coli and incubated for 48 h at 
25 °C. Resulting L4 larvae were used for assays adapted from Liu et al.33 S3 Slow killing assays 
were performed using 12-well culture dishes with wells containing 1 mL NGM agar amended with 
64 µg/mL PZN dissolved in DMSO or an equivalent volume (2 µL) of DMSO alone. One half of 
the slow killing assay wells were also seeded with 10 µL of OP50 E. coli. Subsequently, 40-60 L4 
hermaphrodites were transferred to each well, incubated at 25 °C and assessed every 24 h for 3 d. 
Each treatment was performed with two biological replicates, each having three technical 
replicates. Liquid fast killing assays were also performed using 12-well cell culture dishes with 
wells containing 1 mL M9 buffer combined with 64 µg/mL PZN dissolved in DMSO or DMSO 
alone. 40-60 L4 larvae were transferred into each well and incubated at 25 °C for 24 h. Fast killing 
assays were replicated similarly to the slow killing assay (two biological, three technical 
replicates). For the duplicate assay, an additional control of M9 buffer was included. In both fast 
and slow killing assays, animals were scored according to criteria shown in Liu et al. Mortality 
rates were also calculated using identical ratios.  
3.5.18 cDNA construction and qRT-PCR analysis  
cDNA was generated using the published protocol from the Promega Improm-II system, replacing 
the reverse transcriptase with Invitrogen m-MLV reverse transcriptase. qRT-PCR was performed 
with iTaq universal SYBR Green Supermix and following manufacturer’s instructions using a 
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Roche Lightcycler 480 System. Fold changes upon PZN treatment were calculated as described 
previously.8 
3.5.19 Compound preparation  
Me2-Arg-Az5  
Me2-Arg-Az5 was synthesized as previously described.14  
PZN-Cy5 
PZN (500 µg, 3.74 × 10-7 mol) in 20 µL dimethylformamide (DMF) was mixed with 5 µL N,N’-
diisopropylethylamine (DIPEA), 10 µL of a 190 mM solution of 1-hydroxybenzotriazole (HOBt) 
in DMF, and 10 µL of a 190 mM solution of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide 
(EDC) in DMF for 15 min at 21 °C. Then 29.3 µL of a 10 µg/µL solution of Cy5 amine 
(Lumiprobe) in DMF was added. The reaction was protected from light and stirred at 22 °C for 24 
h. The sample was dried by speed vacuum, redissolved in 5% MeOH, and purified on a Sep-Pak 
C18 cartridge (Waters) on a gradient from 0 – 100% MeOH. Fractions containing PZN-Cy5, as 
determined by matrix-assisted, laser desorption/ionization time-of-flight (MALDI-TOF) mass 
spectrometry (MALDI-TOF-MS), were combined and their purity assessed by analytical HPLC 
(Thermo BetaSil C18 column [250 mm × 4.6 mm], 40 – 95% MeOH). Concentration was 
determined using the extinction coefficient of Cy5 in DMSO (ε646 = 250 L cm-1 mmol-1).  
Daptomycin-Cy5 
A 1 mg/mL solution of daptomycin in DMSO was prepared and 33 µL was mixed with 2 µL of 10 
mM Cy5 NHS ester (Lumiprobe) and stirred at 22 °C, protected from light, for 4 h. Labeled 
compound was purified by reverse-phase chromatography on a Perkin Elmer Flexar HPLC 
outfitted with a Thermo Scientific BetaSil C18 column (250 mm × 4.6 mm I.D., 5 µm particle 
size) using 10 mM NH4HCO3 as the aqueous phase on a 45 min gradient from 25 – 95% MeCN at 
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a flow rate of 1 mL/min. Absorbance monitoring at 647 nm was used to identify the fraction 
containing daptomycin-Cy5, which was confirmed by MALDI-TOF mass spectrometry. Purity 
was determined by a second analytical HPLC run using the same solvents on a 30 min gradient 
from 40 – 95% MeOH. Concentration was determined using the extinction coefficient of Cy5 in 
DMSO.  
Biotin-PZN (N-terminal label)  
A 100 mM solution of EZ-link N-hydroxysuccinimide (NHS) Biotin (Thermo Scientific) in 80% 
MeCN, 10 mM 3-(N-morpholino)propanesulfonic acid (pH 8.0) was prepared. DesmethylPZN 
(200 µg, 1.53 × 10-7 mol) was dissolved in 24 µL of the same buffer and treated with 6 µL EZ-link 
NHS biotin solution for 4 h at 22 °C. The solvent was removed by speed vacuum and the sample 
was dissolved in MeOH for purification by HPLC (BetaSil C18 column, 250 mm × 4.6 mm, 1 
mL/min, 50 – 95% MeOH over 60 min, 10 mM NH4HCO3 aqueous phase, S4 monitored at 254 
nm). Fractions containing purified biotin-PZN, as determined by MALDI-TOFMS, were 
combined, dried, and redissolved in DMSO. B. anthracis Sterne 7702 susceptibility was 
determined to be >32 µg/mL using a standard microbroth dilution assay.  
PZN-Biotin (C-terminal label) 
PZN (500 µg, 3.74 × 10-7 mol) was dissolved in 10 µL DMF and 1 µL DIPEA was added to the 
sample. A solution of 2.0 mM EDC and 2.0 mM HOBt in DMF was prepared and 2 µL was added 
to the PZN. After 5 min stirring, 1.0 mg biotin cadaverine was added to the reaction and allowed 
to proceed at 22 °C for 30 h. The reaction was dried by speed vacuum, redissolved in MeOH, and 
purified by HPLC (BetaSil C18 column, 250 mm × 4.6 mm, 1 mL/min, 50 – 95% MeOH over 60 
min, 10 mM NH4HCO3 aqueous phase, monitored at 254 nm). Fractions containing purified PZN-
biotin, as determined by MALDI-TOF-MS, were combined, dried, and redissolved in DMSO. B. 
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anthracis Sterne 7702 susceptibility was determined to be 32 µg/mL by a standard microbroth 
dilution assay.  
PZN-diazirine-alkyne 
PZN (6.68 mg, 5.0 × 10-6 mol) was dissolved in 75 µL DMF and 1.4 µL Et3N was added with 
stirring. The sample was cooled in an ice bath to 0 ˚C. HOBt (0.95 mg, 0.007 mmol) and EDC (1.1 
mg, 0.007 mmol) were dissolved in 100 µL DMF and added to the PZN. 2- (2-azidoethyl)-2-(but-
3-ynyl)-1,3-dioxolane (0.96 mg, 0.007 mmol)83 was dissolved in 200 µL DMF and 24 µL was 
added after 10 min at 0 ˚C with stirring, protected from light. The reaction was allowed to warm 
to 22 ˚C and proceeded for 24 h. The solvent was removed by speed vacuum and the sample was 
redissolved in MeOH. The sample was purified by HPLC (BetaSil C18 column, 250 mm × 4.6 
mm, 1 mL/min, 50 – 95% MeOH over 60 min, 10 mM NH4HCO3 aqueous phase, monitored at 
254 nm). Fractions containing purified PZN-diazirine-alkyne, as determined by MALDI-TOF-MS, 
were combined, dried, and redissolved in DMSO. B. anthracis Sterne 7702 susceptibility was 
determined to be 32 µg/mL using a standard microbroth dilution assay.  
3.5.20 Structural characterization of PZN derivatives  
Purified samples were dried by speed vacuum and dissolved in 50% MeCN supplemented with 
1% (v/v) acetic acid. The diluted samples were directly infused using an Advion Nanomate 100 to 
an LTQ-FTMS/MS (ThermoFisher) operating at 11 T. The MS was calibrated weekly using 
calibration mixture following the manufacturer's instructions, and tuned daily with Pierce LTQ 
Velos ESI Positive Ion Calibration Solution (ThermoFisher). Spectra were collected in profile 
mode with a resolution of 100,000. The singly charged ions were targeted for CID using an 
isolation width of 5 m/z, a normalized collision energy of 35, an activation q value of 0.4, and an 
activation time of 30 ms. Data analysis was performed using Thermo Xcalibur software.  
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3.5.21 Affinity purification using PZN-Biotin  
LB (200 mL) was inoculated with 10 mL stationary phase B. anthracis Sterne 7702. The culture 
was grown with shaking at 37 °C to OD600 of 0.5. Samples were divided into 100 mL aliquots, 
harvested by centrifugation, and individually resuspended in 1.5 mL lysis buffer (50 mM Tris, 500 
mM NaCl, 2.5% v/v glycerol, 0.1% v/v Triton X-100, pH 7.5) with 500 mU mutanolysin. After 
equilibrating for 30 min at 22 °C, the cells were disrupted by sonication (4 × 30 s, 50% amplitude) 
and harvested by centrifugation (17,000 × g, 10 min). The insoluble fractions were resuspended in 
1.5 mL 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) buffer (50 mM 
Tris-HCl, 150 mM NaCl, 1% w/v CHAPS, pH 7.5) and disrupted by sonication (10 s, 50% 
amplitude). One sample was treated with 1.0 × 10-7 mol PZN-biotin and the other was treated with 
vehicle (DMSO). The samples were treated for 30 min at 22 °C before the addition of 100 µL 
streptavidin-agarose resin suspension (pre-equilibrated with Tris buffer, 50 mM Tris-HCl, 150 
mM NaCl, pH 7.5). After mixing for 3 h at 22 °C, samples were applied to Bio-Rad spin columns 
and the flow through was collected. The resin was washed (5 × 4 mL Tris buffer). The resin was 
then resuspended in 200 µL 1% SDS in PBS and incubated at 95 ˚C for 10 min. After cooling, the 
S5 eluent was collected and analyzed by SDS-PAGE for the presence of unique bands in the 
sample containing PZN-biotin. Unique bands, as visualized by Coomassie and silver stain, were 
not found compared to the vehicle-treated sample (data not shown). Samples were also analyzed 
by Western blot using the following procedure: proteins were transferred by electroblot to a 
polyvinylidene fluoride (PVDF) transfer membrane (EMD Millipore). The membrane was blocked 
overnight at 4 °C in TBS containing 0.1% (v/v) Tween-20 (TBS/T), treated for 1 h at 4 °C with 
1:3,000 dilution of streptavidin-horseradish peroxidase (HRP) in TBS/T, and then washed (2 × 30 
s then 5 × 5 min) with TBS/T. After washing once in PBS (1 × 30 s), the membrane was treated 
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with 1:1 hydrogen peroxide solution:luminol solution (Bio-Rad) for chemiluminescent imaging on 
HyBlot CL autoradiography film (Denville Scientific) using a Futura 2000K Film Processor.  
3.5.22 Photoaffinity purification using PZN-diazirine-alkyne  
The procedure used for photoaffinity purification studies was similar to that of affinity purification 
experiments, except that the samples were incubated with PZN-diazirine-alkyne or vehicle 
(DMSO) for 4 h at 4 °C, protected from light. The cells were then exposed to UV (4 W, 365 nm) 
for 15 min at 22 °C to induce crosslinking. The samples were pelleted and resuspended in PBS 
containing 1 mM CuSO4, 128 µM tris(3-hydroxypropyltriazolylmethyl)amine, 1.2 mM sodium 
ascorbate, and 50 µM biotin-azide for 1 h at 22 °C. The cells were then harvested by centrifugation 
(4,000 × g, 2 min, 22 ˚C), the supernatant was decanted, and the cells resuspended in PBS 
supplemented with 200 U/mL mutanolysin. After digestion proceeded for 1 h at 37 °C, cells were 
sonicated as previously described. The insoluble fraction was separated by centrifugation and 
resuspended as previously described. Clarified lysates and insoluble fractions were all enriched 
with streptavidin-agarose resin as previously described, and eluents were compared by SDSPAGE 
followed by Western blot and mass spectrometric analysis.  
3.5.23 Macromolecular synthesis assay  
Radiolabel incorporation into cellular macromolecules was carried out as previously described.36 
Briefly, identical B. anthracis Sterne 7702 cultures were grown to an OD600 of 0.6 in LB and 
diluted to a final OD600 of 0.3. Radiolabelled precursor was to 0.1 µCi, and compound (either 
PZN or control) was added to 1 ×, or 2 × the minimum inhibitory concentration (MIC). Samples 
were taken at 1 h post-PZN addition. OD600 at each time point was determined using identically 
treated cultures lacking radioactive precursor compound. The macromolecules of the cultures 
treated with radiation were precipitated using trichloroacetic acid on glass filter disks and washed 
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with 10% and 5% trichloroacetic acid and ethanol successively. The filters were placed in 
scintillation vials with Ultima Gold scintillation cocktail. Radioactive counts were determined 
using a liquid scintillation analyzer (PerkinElmer Tri-Carb 2910 TR). The macromolecules, 
radiolabelled precursors, and their corresponding control antibiotics were as follows: cell wall: 
[1,6- 3 H (N)] N-acetyl-D-glucosamine (ARC, ART 0142), vancomycin control protein: [U- 14C] 
L-amino acid mixture (MP, 1014750), chloramphenicol control RNA: [14C(U)] uridine (ARC, 
ARC 0154), rifampicin control fatty acid: acetic acid [1- 14C] sodium salt (ARC, ARC 0101A), 
triclosan control. 
3.5.24 Genetic deletion of bas4114-bas4117 
 
Markerless genetic deletions were created in B. anthracis Sterne 7702 as described previously.4 
The 500 base pairs upstream of bas4114 and 500 base pairs downstream of bas4117 were Gibson 
cloned into the homologous recombination vector pBKJ236 (New England Biolabs) using the 
BamHI and NotI restriction sites. The pBKJ236 constructs were transformed into the E. coli dam-
/dcm- strain SCS110. Stationary phase cultures of pBKJ236-transformed SCS110 grown in LB 
with 500 µg/mL erythromycin were used for conjugation along with stationary phase cultures of 
the conjugation helper strain E. coli SS1827 grown in LB with 200 µg/mL ampicillin and B. 
anthracis Sterne 7702 grown in brain-heart infusion (BHI) broth. From the stationary phase 
cultures, 400 µL were removed and washed by two rounds of centrifugation and resuspension in 
500 µL of LB to remove residual antibiotic. The pellets were ultimately resuspended in 200 µL of 
LB, then mixed thoroughly in equal volumes, and 150 µL of the mixture was inoculated onto a 
BHI agar plate without spreading. The inoculum was allowed to dry and the plate was incubated 
at 22 °C for 24 h. The entire culture was then carefully removed from the plate, resuspended in 
200 µL of LB, and spotted onto a BHI agar plate containing 5 µg/mL erythromycin and 60 U/mL 
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polymyxin B (BHIep). The culture was allowed to dry and then subsequently replated and 
incubated at 22 °C until single colonies of B. anthracis Sterne 7702 were visible (~48 h). A single 
colony was used to inoculate a 2 mL culture of BHI-containing 5 µg/mL erythromycin, and the 
culture was incubated with shaking at 22 °C overnight. The saturated culture was used to inoculate 
a fresh culture of BHI containing 5 µg/mL erythromycin at a 1:1000 dilution. This culture was 
incubated at 37 °C with shaking until saturation (~8 h), then 150 µL of the culture was spotted 
onto a BHIep plate and allowed to dry. The spot was streaked for single colonies and the plate was 
incubated at 37 °C overnight. A single colony was picked and used to make competent cells as 
previously described.84 Briefly, a colony was used to inoculate a 1 mL culture of LB containing 
0.1% glucose (LBG). The culture was incubated at 37 °C without shaking for 10 min, and then 
used to inoculate 25 mL of LBG in a 250 mL sealable Erlenmeyer flask. The culture was incubated 
with shaking at 100 rpm at 37 °C until it reached an OD600 of 0.20, at which point it was transferred 
to a 50 mL conical tube and pelleted at 4000 × g at 4 °C for 10 min. The spent media was discarded 
and the pellet was washed with ice cold electroporation buffer (EB; 10% w/v sucrose, 15% v/v 
glycerol, 2 mM potassium phosphate, pH 7.8) twice. The cells were resuspended in 400 µL of cold 
EB, transferred to a 0.4 cm gap electroporation cuvette (USA Scientific), and incubated on ice for 
10 min. A plasmid encoding the I-SceI restriction enzyme, pSS4332,85 was added as 10 µL of a 
500 ng/µL stock and the cells were pulsed one time at 2.5 kV, 25 µF, 200 Ω (mean time constant 
of 4.4 ms). The cells were then placed on ice for 10 min before being diluted with 600 µL LBG. 
The cells were recovered at 37 °C for 2 h and then plated on LBG agar plates containing 25 µg/mL 
kanamycin. Colonies were pooled and passaged repeatedly on BHI agar plates containing 25 
µg/mL kanamycin until erythromycin sensitive colonies could be isolated. Sensitive colonies with 
the desired genes deleted were determined by PCR amplification with the cloning primers and 
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were then repeatedly streaked on antibiotic free BHI agar plates until kanamycin sensitive colonies 
were isolated. Gene deletion was confirmed by PCR amplification with gene specific primers 
(Figure 3.13) and the strains were confirmed to be sensitive to both kanamycin and erythromycin 
by plating on the appropriate antibiotic containing BHI agar plates.  
  
 
 
3.6 Figures 
 
Figure 3.1  Chemical structures of PZN (A), Me2-Arg-Az5 (B), Biotin-PZN (C), PZN-Biotin (D), 
PZN-photoaffinity probe (E), PZN-Cy5 (F), daptomycin (Dap)-Cy5 (G), NAO, 10-N-nonyl 
acridine orange (H), and DilC12(3) perchlorate (I).  
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Figure 3.2 Confirmation of plasmid loss in B. anthracis 34F2 LLNL A0517-1. (Top) PCR of a 
conserved chromosomal gene, bas4114. (Bottom) pXO1 encoded gene lef is not present in A0517-
1 or the select B. cereus strains. 
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Figure 3.3 Purified PZN is not toxic to Caenorhabditis elegans using three different survival 
assays. (A) The liquid fast killing assay monitors survival for 24 h in minimal broth medium. Solid 
agar slow killing assays analyzes survival for 72 h without (B) and with E. coli (C). Animals were 
treated with 64 µg/mL PZN and analyzed by live/dead screening over the course of the 
experiments. P-values were generated using the Log-rank (Mantel-Cox) test. NC, no compound.  
 
 
 
  
S30 
 
 
 
Figure S3. Purified PZN is not toxic to Caenorhabditis elegans using three different survival 
assays. (A) The liquid fast killing assay monitors survival for 24 h in minimal broth medium. Solid 
agar slow killing assays analyzes survival for 72 h without (B) and with E. coli (C). Animals were 
treated with 64 µg/mL PZN and analyzed by live/dead screening over the course of the 
experiments. P-values were generated using the Log-rank (Mantel-Cox) test. NC, no compound. 
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Figure 3.4  Mass spectrometry-based structural characterization of PZN derivatives used in 
affinity purification. (A) Structure, exact mass, and MS/MS fragmentation determined from the 
collision-induced dissociation (CID) spectrum (B) of the singly charged N-biotinylated PZN ion 
acquired by LTQ-FT-MS/MS. (C) Structure, exact mass, and MS/MS fragmentation determined 
from the CID spectrum (D) of the singly charged C-terminally biotinylated PZN ion. (E) Structure, 
exact mass, and MS/MS fragmentation determined from the CID spectrum (F) of the singly 
charged and MS-induced N2-cleaved PZN-diazirine-alkyne ion.  
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Figure S4. Mass spectrometry-based structural characterization of PZN derivatives used in 
affinity purification. (A) Structure, exact mass, and MS/MS fragmentation determined from the 
collision-induced dissociation (CID) spectrum (B) of the singly charged N-biotinylated PZN ion 
acquired by LTQ-FT-MS/MS. (C) Structure, exact mass, and MS/MS fragmentation determined 
from the CID spectrum (D) of the singly charged C-terminally biotinylated PZN ion. (E) Structure, 
exact mass, and MS/MS fragmentation determined from the CID spectrum (F) of the singly 
charged and MS-induced N2-cleaved PZN-diazirine-alkyne ion. 
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Figure 3.5 PZN treatment results in the inhibition of three out of four analyzed macromolecular 
pathways. B. anthracis cells were treated with 1 × or 2 × MIC PZN and the appropriate 
radiolabelled precursor to the macromolecule of interest. After incubation for 1 h, macromolecules 
were precipitated and the extent of radiolabel incorporated was measured for protein (A), fatty 
acid (B), RNA (C), or peptidoglycan (D) was measured. Each experiment included samples treated 
with a control compound that is known to affect a particular pathway (protein: Chl, 
chloramphenicol; fatty acid: Tri, triclosan; RNA: Rif, rifampicin; peptidoglycan: Dap, 
daptomycin, Van, vancomycin) All compounds were added at 1 × or 2 × MIC, except rifampicin, 
which required significantly lower concentrations to observe incorporation at 1 h. Percent 
incorporation was determined by comparing radioactive incorporation between cells containing 
compound vs. vehicle. Error is reported as standard deviation with n ≥ 3. * indicates p < 0.05 while 
** indicates p < 0.01 compared to vehicle control.  
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Figure S5. PZN treatment results in 
the inhibition of three out of four 
analyzed macromolecular pathways. 
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< 0.01 compared to vehicle control. 
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Figure 3.6 B. anthracis gene expression profile when treated with PZN. A volcano plot represents 
the set of differentially regulated genes in response to a 10 min treatment of PZN at 0.25 × MIC. 
Red (up-regulated) and green (down-regulated) points are  genes with significantly altered 
expression in response to PZN treatment, whereas black genes did not meet the q value (<0.01) 
threshold. Genes with q value = 0 were given an arbitrary value of 1 × 10-105 for graphing purposes. 
Abbreviations: #, hypothetical; *, transporter, ^, transcriptional regulator; bdbD, B. subtilis 
hypothetical homologue, lldP-1, L-lactate permease; ldh2/3,  L-lactate  dehydrogenase; cydA-2, 
cytochrome d ubiquinol oxidase; mmgD, citrate synthase 3; hutHIU, histidine utilization genes; 
gerN, germination genes; gerN, germination protein; kamA, L-lysine 2,3-aminomutase; §, 
remaining up-regulated genes. All differentially expressed genes are further described in Table 
3.5. 
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Figure 3.7 The B. anthracis gene expression profile with Me2-Arg-Az5 differs from PZN 
treatment. (A) A volcano plot represents the set of differentially regulated genes (red, upregulated; 
green, downregulated) in response to treatment with 0.25 × MIC of Me2-Arg-Az5. Black points 
indicate genes that did not meet the q-value (< 0.01) threshold. Genes where the q-value = 0 were 
given an arbitrary value of E-155 for graphing purposes. Abbreviations: #  hypothetical; * 
transporter; ^ transcriptional regulator; atpI, ATP synthase protein I; hmp, nitric oxide 
dioxygenase; lldP-1, L-lactate permease; ldh2/3, L-lactate dehydrogenase; sugE-1, EmrE protein 
(cationic drug membrane transporter); RR, response regulator; HK, histidine kinase; § remaining 
upregulated. All genes are summarized in Table 3.11. (B) Venn diagram demonstrating the 
commonality of the PZN and Me2-Arg-Az5 expression profiles. The compilation of common genes 
is located in Table 3.10. 
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Figure 3.8 Growth curves of PZN and Me2-Arg-Az5 reveal different phenotypes. (A) B. anthracis 
cells treated with PZN undergo rapid decrease in optical density with concentrations above the 
minimum inhibitory concentration (MIC, determined from microbroth dilution assays). Time 
points were collected every two minutes and adjusted to a 1-cm path length. Error is reported as 
standard deviation with n = 3. (B) B. anthracis treated with Me2-Arg-Az5. Reduction in optical 
density is observed briefly at 4 × MIC. Both growth curves were measured in duplicate and 
normalized to OD600 0.35 (A) and 1.0 (B) at t = 0. 
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Figure 3.9 PZN depolarizes the B. anthracis membrane and acts synergistically with cell 
envelope-acting antibiotics. (A) Detection of membrane potential in B. anthracis. Red/green ratios 
were calculated using mean fluorescence intensities of cells treated for 30 min at room temperature 
with 0.1 µM DiOC2(3) and the vehicle of DMSO (negative control), 0.1 µM DiOC2(3) and 5.0 µM 
CCCP (positive control), 0.1 µM DiOC2(3) and 0.5 µM PZN, and 0.1 µM DiOC2(3) and 1.0 µM 
PZN. Data were normalized to the positive control sample of DiOC2(3) and vehicle (DMSO). Error 
is given as standard deviation with n = 3. P values are given relative to the DMSO control with ∗ 
indicating <0.0005 and ** indicating <0.0001. Abbreviations: Dap, daptomycin; DiOC2(3), 3,3’-
diethyloxacarbocyanine iodide; CCCP, carbonyl cyanide m-chlorophenyl hydrazine. (B) 
Isobolograms of the minimum inhibitory concentrations (µg/mL) of PZN with nisin (top) and 
daptomycin (bottom). Interactions taking place below the dotted line with a fractional inhibitory 
concentration index below 0.5 represent synergistic behavior. 
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Figure 3.10 Mass spectrometry characterization of PZN-Cy5. (A) Mass spectrum of the [M+H]2+ 
species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of the singly 
charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to identified fragments of PZN-
Cy5, shown on the structure in panel (C). 
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Figure 3.11 PZN-Cy5 localizes to distinct foci on B. anthracis. (A) Representative fluorescence 
microscopy images are shown for the Cy5, DIC, and merged channels of B. anthracis Sterne 
treated with 0.1 µM PZN-Cy5 (0.05 × MIC) for 30 min. Competition experiments in a PZN-
resistant B. anthracis strain (PR06, vide infra) show (B) robust labeling with 0.05 µM PZN-Cy5 
in the absence of unlabeled PZN and (C) significantly decreased labeling when cells are pretreated 
with 1 µM PZN (0.016 × MIC, resistant strain PR06) for 20 min. Scale bars = 2 µm. 
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Figure 3.12 STORM images of PZN-Cy5-labeled B. anthracis. (A) 3-D super-resolution images 
of 12 representative B. anthracis cells treated with PZNCy5. (B) Two representative cells rotated 
about the z-axis show distinct, nonseptal localization of PZN-Cy5. Green, blue, and yellow circles 
mark three individual foci in each rotated view. Scale bars = 1 µm. 
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Figure 3.13 Density-based clustering analysis of B. anthracis treated with PZN-Cy5 and imaged 
by super-resolution microscopy. (A) Representation of cell alignment used in subsequent analyses. 
(B) PZN-Cy5 color density map of a representative cell projected onto the XZ plane. (C) 
Probability density of PZN-Cy5 increases as distance from the center of the cell (R) increases, 
reaching a maximum at the cell membrane. (D) Cluster analysis of two representative B. anthracis 
cells (top) shows identified clusters (bottom) used in subsequent size calculations. 
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Figure 3.14 Fluorescence microscopy images of B. subtilis, B. cereus E33L, B. cereus 4342 and 
B. cereus G9241 strains treated with PZN-Cy5 under conditions used for observation of PZN-Cy5 
labeling of wild type B. anthracis Sterne 7702. Modest labeling is observed with G9241, which is 
PZN-susceptible.  
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Figure 3.15 Hydropathy plot of BAS4114 reveals a single transmembrane helix. (A) The amino 
acid sequence of BAS4114 was analyzed using SPOCTOPUS, which predicted a transmembrane 
domain from residues 151-171. (B) Primary sequence of BAS4114, color-coded as in panel A.  
 
 
 
Figure 3.16 Confirmation of bas4114-4117 deletion in B. anthracis Sterne. Gene specific primers 
were used to confirm their absence in B. anthracis Sterne 7702 Δbas4114-4117. WT: B. anthracis 
Sterne 7702. KO: B. anthracis Sterne 7702 Δbas4114-4117.  
 
  
 110 
Figure 3.17 Mass spectrometry characterization of daptomycin-Cy5. (A) Mass spectrum of the 
[M+2H]2+ species by LTQ-FT-MS, which was used to calculate exact mass. (B) CID spectrum of 
the doubly charged ion acquired by LTQ-FT-MS. Labeled peaks correspond to identified 
fragments of daptomycin-Cy5, which are structurally overlaid (C). 
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Figure 3.18 Cardiolipin increases PZN-Cy5 interaction with bacterial cells. (A) Mean 
fluorescence intensities of B. anthracis cell populations treated with daptomycin-Cy5 or PZN-Cy5 
in the presence or absence of exogenous cardiolipin (CL) were determined by flow cytometry and 
normalized to cells treated with only the Cy5-labeled compound and vehicle. Error is reported as 
standard deviation with n = 3. The PZNCy5 P values are given relative to the 0 µg/mL control with 
∗ indicating 0.01. (B) Isobologram of the minimum inhibitory concentrations (µg/mL) of PZN and 
CL. The Y-intercept was arbitrarily assigned for CL, which in the absence of PZN was not toxic 
to B. anthracis at concentrations up to 200 µg/mL. Interactions taking place below the dotted line 
with a fractional inhibitory concentration index (FICI) < 0.5 represent synergistic behavior. 
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Figure 3.19 Fluorescence microscopy images of nonyl acridine orange (NAO, top) and 1,1’-
Didodecyl-3,3,3’,3’-tetramethylindocarbocyanine perchlorate (DilC12(3), bottom) localization in 
B. anthracis, B. cereus, and B. subtilis strains, showing approximate cellular distributions of 
cardiolipin64 and regions of increased fluidity65, respectively. Scale bars, 5 µm. 
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Figure 3.20 PZN co-localizes with CL- and RIF-specific dyes. (A) From left to right, the channels 
for NAO, Cy5, DIC, and a merged image are shown to illustrate the false-color co-localization 
(magenta) of NAO (blue) and PZN (red). (B) The same as panel a but with DilC12(3) replacing 
NAO. Scale bars = 2 µm. 
 
 
 
Figure 3.21 Fluorescence microscopy, DIC, and overlay images of B. anthracis Sterne 7702 cells 
grown in a higher osmolarity medium (0.52 M NaCl) and treated with PZN-Cy5 (top) or NAO 
(bottom). Scale bars, 5 µm.  
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3.7 Tables 
 
Table 3.1 The antimicrobial spectrum of plantazolicin (PZN). 
 
Strain 
 
MIC 
(µg/mL) 
MIC 
(µM) Source 
B. cereus group    
B. anthracis Sterne 34F2 1 0.75 S. Blanke (UIUCb) 
B. anthracis Sterne 7702 1 0.75 USDAb 
B. anthracis Sterne 7702 Δbas4114-4117 1 0.75 This study 
B. anthracis Sterne 7SBON30 1 0.75 30 
B. anthracis Sterne 7SBON40 1 0.75 30 
B. anthracis Sterne 7SDG30 1 0.75 30 
B. anthracis Sterne 7SBTR30 1 0.75 30 
B. anthracis Sterne 7SBONTO 1 0.75 30 
B. anthracis Sterne 7SBTRTO 1 0.75 30 
B. anthracis Sterne 7SBTO30 1 0.75 30 
B. anthracis BSL3 strains 2 – 16 1.5 – 12 USAMRIID 
B. anthracis CDC 684 2 1.5 USAMRIID 
B. anthracis Sterne 34F2 A0517-1 1 0.75 BEI 
B. anthracis Sterne 34F2 A0517-2 2 1.5 BEI 
B. anthracis Sterne 34F2 ΔblsO 1 0.75 86 
B. anthracis Sterne 34F2 ΔcsaB 1 0.75 20 
B. anthracis Sterne 34F2 Δsap 1 0.75 52 
B. anthracis Sterne 34F2 Δeag 1 0.75 52 
B. anthracis Sterne 34F2 Δanthrose 1 0.75 C. Turnbough (U. Alabama Birmingham) 
B. anthracis Sterne 34F2 ΔbclA 1 0.75 87 
B. anthracis Sterne BA850 (Δpetrobactin)  1 0.75 88 
B. anthracis Sterne BA781 1 0.75 BEI 
B. anthracis Weybridge 1 0.75 BEI 
B. cereus 14579 >64 >48 USDA 
B. cereus 541 (ΔplcR) >64 >48 89 
B. cereus ATCC 7064   >64 >48 ATCCb 
B. cereus ATCC 13472   >64 >48 BGSC 
B. cereus BAG4x2-1 >64 >48 BEI 
B. cereus E33L >64 >48 BEI 
B. cereus G9241 8 6 BEI 
B. cereus GP7 >64 >48 BGSCb    
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Table 3.1 (cont.) 
 
B. cereus Rock3-44 
64 48 NMRSb 
 
B. cereus VD014 
>64 >48 BEI 
B. cereus VD115 >64 >48 BEI 
B. mycoides 96/3308 >64 >48 BGSC 
B. samanii C1   >64 >48 BEI 
B. thuringiensis Konkukian 97-27   >64 >48 BEI 
B. thuringiensis israelensis ATCC 35646   >64 >48 BEI 
B. thuringiensis subsp. thuringiensis >64 >48 BGSC 
Atypical gamma phage sensitivity    
B. cereus ATCC 4342   >64 >48 BEI 
B. cereus CDC 32805 >64 >48 27 
B. cereus 2002013145 >64 >48 CDCb 
B. cereus 2002013146 >64 >48 CDC 
B. cereus 2002013100 >64 >48 CDC 
B. cereus 2000031002 >64 >48 CDC 
Non B. cereus group    
B. amyloliquefaciens FZB42   >64 >48 BGSC 
B. amyloliquefaciens B-14393T   >64 >48 BGSC 
B. megaterium 899 32 24 BGSC 
B. pumilus SAFR-032   >64 >48 BGSC 
B. subtilis    
AKP4 (Δdes) >64 >48 D. de Mendoza (U. Nacional de Rosario) 
AKP21 (ΔdesRK) >64 >48 D. de Mendoza (U. Nacional de Rosario) 
BSU-LIKE1 (ΔliaIH) >64 >48 BGSC 
HB0042 >64 >48 Personal Collection 
HB0934 (ΔliaGFSR) >64 >48 J. Helmann (Cornell) 
HB5126 (ΔliaIH) >64 >48 J. Helmann (Cornell) 
str. 168 >64 >48 J. Wells (USCFb) 
Brevibacillus formosus SS 86-3 >64 >48 BGSC 
Brevibacillus laterosporus ATCC 9141 >64 >48 BGSC 
Neisseria meningititis serotype C >64 >48 75 
Neisseria sicca >64 >48 ATCC 
Staphylococcus aureus    
12608 >64 >48 P. Hergenrother (UIUC) 
29213 64 48 P. Hergenrother (UIUC) 
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Table 3.1 (cont.) 
 
S. aureus 33591 
64 48 P. Hergenrother (UIUC) 
 
Staphylooccus aureus 
USA300 
>64 >48 P. Hergenrother (UIUC) 
Streptomyces coelicolor >64 >48 USDA 
Streptomyces lividans >64 >48 USDA 
Eukaryotic organisms    
Caenorhabditis elegans N2 >64 >48 CGCb 
Saccharomyces cerevisiae  >64 >48 H. Zhao (UIUC) 
Talaromyces stipitatus >64 >48 H. Zhao (UIUC) 
 
 
a Minimum inhibitory concentrations (MICs) were measured by microbroth dilution in LB (n ≥ 3 replicates)  
b Abbreviations: UIUC, University of Illinois at Urbana-Champaign; USDA, United States Department of 
Agriculture; USAMRIID, United States Army Medical Research Institute of Infectious Diseases; BEI, 
Biodefense and Emerging Infections Research Resources Repository; ATCC, American Type Culture 
Collection; BGSC, Bacillus Genetic Stock Center; NMRS, Navel Medical Research Center; CDC, Center 
for Disease Control and Prevention; UCSF, University of California San Francisco; CGC, Caenorhabditis 
Genetics Center  
c Susceptibility was assessed at 21 °C, 37 °C, and 42 °C; Susceptibility to PZN was unchanged by 
temperature Strains whose entries are highlighted in yellow were also tested for gamma phage 
susceptibility 
 
 
 
 
 
 
Table 3.2 PZN is not antibacterial against B. anthracis endospores. 
 
[PZN] (μg/mL) CFU/mLa   
Vehicle (DMSO) 9.8 ± 2.0 × 105   
0.5 4.3 ± 0.3 × 105   
1 8.3 ± 1.0 × 105   
2 6.8 ± 0.6 × 105   
4 3.4 ± 1.1 × 105   
8 6.5 ± 0.1 × 105   
16 3.5 ± 1.4 × 105   
aColony forming units per mL of endospore suspension 
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Table 3.3 γ phage sensitivity and PZN susceptibility of Bacillus strains. 
Strain γ Phage Sensitivity PZN MICa Source 
B. anthracis Sterne 7702 +++b 1 USDA 
B. anthracis Sterne 34F2 A0517-1c +++ 2 BEI 
B. cereus 2002013145 +++ >64 CDCd 
B. cereus 2002013146 +++ >64 CDCd 
B. cereus 2002013100 ++ >64 CDCd 
B. cereus 2000031002 +++ >64 CDCd 
B. cereus ATCC 4342 + >64 ATCC 
B. cereus ATCC 7064 + >64 ATCC 
B. cereus CDC 32805 + >64 ref 
B. cereus G9241 - 8 BEI 
B. megaterium 899 - 32 BGSC 
B. mycoides 96/3308 - >64 BGSC 
 
aMIC (Minimum inhibitory concentation) as determined by microbroth dilution, measured in μg/mL. 
b"+" indicate the level of phage sensitivity, with "+++" representing the most sensitive and "-" 
representing no sensitivity 
cLLNL A0517 was obtained from BEI Resources as a mixture of two colony types. A0517_1 was 
confirmed to be devoid of pXO1 (Figure 3.2) 
dStrains identified by Multilocus sequence typing analysis29 
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Table 3.4 MICs of representative strains demonstrating PZN activity in various rich media. 
 MIC (μg/mL)  
Strain LBa MH BHI  
Bacillus anthracis Sterne 1 1 1  
Bacillus cereus CDC32805 >64 >64 >64  
Bacillus cereus ATCC 4242 >64 >64 >64  
Bacillus Al Hakam >64 >64 >64  
Bacillus amyloliquefaciens FZB42 >64 >64 >64  
Bacillus subtilis strain 168 >64 >64 >64  
Enterococcus faecium U503 >64 >64 >64  
Listeria monocytogenes 4b >64 >64 >64  
Staphylococcus aureus ATCC 12608 >64 16 32  
Staphylococcus aureus ATCC 29213 64 8 16  
Staphylococcus aureus ATCC 33591 64 8 16  
Staphylococcus aureus USA300 >64 >64 >64  
     
aLuria-Bertani (LB), Mueller-Hinton (MH), Brain Heart Infusion (BHI) 
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Table 3.5 RNA-Seq analysis of all differentially expressed B. anthracis Sterne 7702 genes after 
PZN treatment.  
Locus Tag Gene Description 
Fold 
Change q-value 
BAS1222 ywcJa formate/nitrite transporter family protein -7 3.19E-38 
BAS0577 lldp-1 L-lactate permease -7 2.14E-24 
BAS4869 ldh3 L-lactate dehydrogenase -6 6.40E-27 
BAS0169  hypothetical protein -6 1.30E-25 
BAS4146  hypothetical protein -5 3.66E-19 
BAS4762 ldh2 L-lactate dehydrogenase -4 1.19E-13 
BAS1089 yjzCa hypothetical protein -4 5.38E-16 
BAS1615 yfmQa hypothetical protein -3 1.49E-05 
BAS3917  hypothetical protein -3 9.12E-04 
BAS4690 cydA-2 cytochrome d ubiquinol oxidase subunit I -3 4.40E-04 
BAS0513 bdbD hypothetical protein -3 1.00E-03 
BAS1942 sdpIa hypothetical protein 2 5.98E-03 
BAS3405  ahpC/TSA family protein 2 6.00E-03 
BAS2363  hypothetical protein 2 1.27E-03 
BAS2776 yetGa hypothetical protein 2 9.17E-04 
BAS1163  hypothetical protein 3 2.06E-03 
BAS0730 yfhCa nitroreductase family protein 3 6.85E-03 
BAS4453  hypothetical protein 3 4.90E-04 
BAS2568  TetR family transcriptional regulator 3 1.43E-03 
BAS2566 kynB hypothetical protein 3 2.83E-03 
BAS0683 yqgIa phosphate ABC transporter permease 3 7.44E-04 
BAS4452  hypothetical protein 3 2.81E-05 
BAS2565 kynA tryptophan 2,3-dioxygenase family protein 3 3.85E-03 
BAS3439 hutGa formimidoylglutamase 3 1.17E-03 
BAS3871  hypothetical protein 3 1.35E-05 
BAS0214 lagB invasion protein LagB 3 2.21E-04 
BAS1691 fabH2 3-oxoacyl-ACP synthase 3 6.35E-04 
BAS4502 ytpIa hypothetical protein 3 2.71E-06 
BAS1573  hypothetical protein 3 8.18E-03 
BAS0849  hypothetical protein 3 1.49E-06 
BAS1346 liaFa hypothetical protein 3 1.77E-04 
BAS0525 yuaGa hypothetical protein 3 6.06E-04 
BAS0610 rocEa amino acid ABC transporter permease 3 1.77E-04 
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Table 3.5 (cont.) 
BAS4777 sodC superoxide dismutase, Cu-Zn 3 6.63E-08 
BAS0524 yuaFa hypothetical protein 4 2.77E-07 
BAS0848 yhaRa enoyl-CoA hydratase 4 1.25E-07 
BAS4173 pstC phosphate ABC transporter permease 4 9.53E-06 
BAS4172 pstA phosphate ABC transporter permease 4 2.15E-07 
BAS4171 pstB phosphate transporter ATP-binding protein 4 7.63E-07 
BAS1307 ilvE1 
branched-chain amino acid 
aminotransferase 4 1.40E-08 
BAS4560 acsA acetyl-CoA synthetase 4 5.09E-06 
BAS3772 ylbPa hypothetical protein 4 2.05E-05 
BAS0464 rocR-1 arginine utilization regulatory protein RocR 4 1.01E-09 
BAS4877 fadNa 3-hydroxyacyl-CoA dehydrogenase 4 1.18E-09 
BAS0624 dppCa oligopeptide ABC transporter permease 4 7.90E-08 
BAS4174 phoX 
phosphate ABC transporter substrate-
binding protein 4 1.87E-08 
BAS5194 fadFa ferredoxin, 4Fe-4S 4 1.32E-07 
BAS1894 dppEa 
oligopeptide ABC transporter substrate-
binding protein 4 1.46E-08 
BAS1070  hypothetical protein 4 1.73E-10 
BAS4778  hypothetical protein 5 5.76E-14 
BAS0681 pstSa 
phosphate ABC transporter substrate-
binding protein 5 1.12E-16 
BAS4512  hypothetical protein 5 1.76E-24 
BAS3440 hutI imidazolonepropionase 5 3.49E-21 
BAS2288  hypothetical protein 6 7.47E-08 
BAS0625 appB, oppBa oligopeptide ABC transporter permease 6 3.26E-20 
BAS2146 yokUa hypothetical protein 6 5.30E-39 
BAS0626 appF, oppFa 
oligopeptide ABC transporter ATP-binding 
protein 6 2.29E-19 
BAS2145 kamA L-lysine 2,3-aminomutase 7 4.12E-35 
BAS3024  arsR family transcriptional regulator 7 1.17E-52 
BAS2188 mmgD citrate synthase 3 8 2.67E-54 
BAS3441 hutU urocanate hydratase 8 5.49E-50 
BAS2649  hypothetical protein 9 5.16E-42 
BAS2650  hypothetical protein 9 2.30E-45 
BAS3442 hutH histidine ammonia-lyase 10 9.17E-104 
BAS0627 appD, oppDa ABC transporter nucleotide-binding protein 11 1.62E-95 
BAS2287 yaaNa hypothetical protein 13 4.38E-93 
BAS1521 gerN germination protein gerN 28 0 
 121 
Table 3.5 (cont.)    
BAS3456  hypothetical protein 40 0 
BAS5200 yvfU, desRa DNA-binding response regulator 49 0 
BAS5201 yvfT, desKa sensor histidine kinase 56 0 
BAS5202 yvfSa ABC transporter permease 130 0 
BAS5203 yvfRa ABC transporter ATP-binding protein 135 0 
BAS1345 liaHa PspA/IM30 family protein 1084 0 
BAS1344 liaIa membrane protein 1407 0 
 
aGenes are annotated by sequence homology to the corresponding Bacillus subtilis gene  
The q-value is an adjusted p-value, taking in to account the false discovery rate 
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Table 3.6 Primers used in this study. 
 
Confirmation of LLNL A0517_1 pXO1 plasmid loss     
pXO1_0172 lef RT-r GATGCGAAAGTAGTGCCAAAGA   
pXO1_0172 lef RT-r CCACAGCATGTCCAAATTCG 		 	
Confirmation of spontaneous mutants           
BamHI-BAS4114-f AAAAGGATCCATGACAGCAAACCGCATTAAAG 
NotI-BAS4114-r AAAAGCGGCCGCTCAGTTTGAAAGGCCTCGC  
Generation and Confirmation of the BAS4114-BAS4117 deletion strain     
G236Tet-up-vec-f TGGAGCTCCACCGCGGTGGCAGGCGTTTGCTGATACAC 
G236Tet-up-down-r TAAAAAAGGACAGTTTCATCCCCTACCTACC 
G236Tet-down-up-f GGGGATGAAACTGTCCTTTTTTATATTCATTCAGAC 
G236Tet-down-vec-r TCGACCTGCAGCCAAGGACGCATCTGTCTTTGTTTCAGTG 
TetR-f GCAAACCGCATTAAAGCTGTAGC  
TetR-r CAGTTTGAAAGGCCTCGCC   
SugE4115-f GGCATGGATTTATGTAATCTTAGCTGG  
SugE4115-r GCCTCCTTCGCTTCTTTTTCTTC   
SugE4116-f GGCTTGGGTATTTTTAATTCTAGCTGG  
SugE4116-r CTTAATAGTTTTAAGCCAACAGCGCC  
BAS4117-f GTGGAAAGAAAAAGGGAAGCAACTG  
BAS4117-r GTTCAGAAGAACTGTCCTTTTTAAATAACTTATTCC 
RT-qPCR             
Banth 16S qRT-f CGGAATTATTGGGCGTAAAG   
Banth 16S qRT-r TCTCCCAGTTTCCAATGACC   
BAS0577 lldp-1 qRT-f TGGTTCACTATTCGCACCAC   
BAS0577 lldp-1 qRT-r TTTGCTATTGTGCCACCAAC   
BAS0627 appD qRT-f ACGAATTATCTGGCGGAATG   
BAS0627 appD qRT-r AGCCGTTGTTGGCTCATC   
BAS1344 liaI qRT-f GGAGCAGGAGTTGTGTACTGG   
BAS1344 liaI qRT-r GATGGACAAGCCGATTAAACC   
BAS1345 liaH qRT-f ATCAAAGCAAGCGCTTATCG   
BAS1345 liaH qRT-r TTCTAATCGAGTTACTTGCCCTTC  
BAS1521 gerN qRT-f ACGAATGACTGGATTTGATGC   
BAS1521 gerN qRT-r GAAAGTCCTGTTCCTGCAATG   
BAS1659 CitB RR qRT-f AACGACGTTCGATGATGATG   
BAS1659 CitB RR qRT-r TTATCGCATCACGAATACGC   
BAS1660 Sensor HK qRT-f TGAAAGCATTCGGATTACATTG   
BAS1660 Sensor HK qRT-r TCATGCTTACTGGCAAATTCC   
BAS1661 ABC trans qRT-f TGCGAAGATGAATATTGGTGTC   
BAS1661 ABC trans qRT-r ACCCGTACAGTCCAGCAAAG   
BAS1662 ABC trans qRT-f CGGTTGTAATGACGACGATG   
BAS1662 ABC trans qRT-r TAGGCGCAGCAATAAGGTG   
BAS1663 ABC trans qRT-f TATGGGAATGTAGGGCAAGG   
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Table 3.6 (cont.)    
BAS1663 ABC trans qRT-r AGAAATTTCACCGTATCATTTGC   
BAS1664 minor cls ClsB qRT-f TGGCACAACAAACTTTACTTCG   
BAS1664 minor cls ClsB qRT-r AACGCCTTATTAACTTGCCCTAC   
BAS1842 asbE qRT-f GGGTATTTGCTTTCTGGTCTTG   
BAS1842 asbE qRT-r TTTCACGGAAGTATGCAAAGG   
BAS1843 asbF qRT-f CAGATCCAGTTGACAGCTTCC   
BAS1843 asbF qRT-r CGGTTCGAACACATGTAAATAATC  
BAS3439 hutG qRT-f TAACGGGCTTTGCAAACAG   
BAS3439 hutG qRT-r CATTTGACGGACCACCATC   
BAS3440 hutI qRT-f TGACCCGCATACTCATCTTG   
BAS3440 hutI qRT-r AAGAATACCTCCGCCTTGTTC   
BAS3441 hutU qRT-f ATTTGTTGGCTTGGTTACGG   
BAS3441 hutU qRT-r CACGACCGATAACGATTGG   
BAS3442 hutH qRT-f TGCGATGGTTGCTCTTACAG   
BAS3442 hutH qRT-r AAAGAACTCCTTGCGCTGTC   
BAS4762 ldh2 qRT-f AATCGTTCGCGGTATTATGG   
BAS4762 ldh2 qRT-r TGGTAGACCAGATTCTTTCCAAG   
BAS4869 ldh3 qRT-f AATCATGAACGTGCAGTTGG   
BAS4869 ldh3 qRT-r TTGCAGTCTTCATAGCTTCCTG   
BAS5033 ftsX qRT-f CGGAAAGACGTTTGAGTTATTTG   
BAS5033 ftsX qRT-r TCGCAATTGTTGCTGTATCTG   
BAS5034 ABC ftsE qRT-f TCTTGAAGATCGTGCAGACG   
BAS5034 ABC ftsE qRT-r ATCGGCAATTACGACTTTCG   
BAS5200 desR qRT-f TTGAAGTAATTGGGCAAGCTG   
BAS5200 desR qRT-r TCTAACCCGCTTTGAATTGG   
BAS5201 desK qRT-f GCAGTGACGAATGTTGTAAAGC   
BAS5201 desK qRT-r CCAATTCCGTTATCTTCTACCG   
BAS5288 TetR reg qRT-f AAGATGAGGAATTGCTTGTTACG   
BAS5288 TetR reg qRT-r CTTGTATAACCGGAATCCTTGG   
BAS5289 transporter qRT-f CGGAGCTCTTGTTGCCTTAC   
BAS5289 transporter qRT-r AAGCACGATTGCGTTTGTTAC   
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Table 3.7 RNA-Seq and qRT-PCR analysis of PZN-treated B. anthracis Sterne 7702. 
	   Fold Change 
Locus Tag Gene Description RNA-Seq qRT-PCR 
BAS0577 lldp-1 L-lactate permease -7 -7 ± 2a 
BAS4869 ldh3 L-lactate dehydrogenase -6 -24 ± 14 
BAS4762 ldh2 L-lactate dehydrogenase -4 -3 ± 1 
BAS3439 hutG formimidoylglutamase 3 3 ± 1 
BAS3440 hutI imidazolonepropionase 5 4 ± 0 
BAS3441 hutU urocanate hydratase 8 3 ± 0 
BAS3442 hutH histidine ammonia-lyase 10 5 ± 2 
BAS0627 appD, oppD ABC transporter nucleotide-binding protein 11 6 ± 3 
BAS1521 gerN germination protein 28 14 ± 9 
BAS5200 yvfU, desRb DNA-binding response regulator 49 37 ± 30 
BAS5201 yvfT, desKb sensor histidine kinase 56 94 ± 36 
BAS1345 liaHb PspA/IM30 family protein 1084 138 ± 10 
BAS1344 liaIb membrane protein 1407 352 ± 191 
     
a Error is defined as one standard deviation, n ≥ 3 
b Genes are derived from sequence homology to the given B. subtilis gene 
 
 
 
Table 3.8 Susceptibility of select bacteria towards Me2-Arg-Az5 reveals a broader spectrum of 
activity relative to PZN. 
 
Strain  MICa (µg/mL) MICa (µM) 
Bacillus anthracis Sterne 7702  2.2 3 
Bacillus anthracis PR06  2.2 3 
Bacillus anthracis A0517-1  2.2 3 
Bacillus cereus ATCC 4342  4.4 6 
Bacillus megaterium 899  2.2 3 
Bacillus subtilis 168  4.4 6 
Escherichia coli DH5a  >35 >48 
Enterococcus faecium U503  35 48 
Listeria monocytogenes 4b  >35 >48 
Neisseria sicca ATCC 29256  >35 >48 
Staphylococcus aureus USA300  2.2 3 
Streptococcus pyogenes M1  35 48 
Pseudomonas putida  >35 >48 
    
a Minimum inhibitory concentrations (MICs) were determined by microbroth dilution assay and are reported 
in µg/mL and μM (the molecular weight of Me2-Arg-Az5 is ~half of PZN). 
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Table 3.9 Antibiotic susceptibility of B. anthracis Sterne and PR06.  
 
 
Compound 
B. anthracis 
Sternea 
B. anthracis 
PR06b 
Plantazolicin 1 64 
Tetracycline 0.125 0.125 
Vancomycin 1 1 
Triclosan 1 1 
Nisin 2 2 
Kanamycin 4 4 
Cerulenin 4 8 
Spectinomycin 8 4 
Chloramphenicol 8 4 
Daptomycin 8 8 
Ethidium Bromidec 16 16 
 
a MICs were measured by microbroth dilution (LB) in 2-fold increments and are reported as µg/mL 
b Strain PR06 derives from Sterne and contains a frameshift mutation leading to a premature stop codon in 
bas4114 (see Table 3.11) 
c Ethidium bromide was included in this assay owing to previous reports that EmrE/SugE-type efflux pumps 
confers resistance to quaternary ammonium compounds and ethidium90 
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Table 3.10 Differentially expressed genes that are common to both PZN and Me2-Arg-Az5 
treatment. 
 
       Fold Change
a 
Locus Tag Gene Description PZN Me2-Arg-Az5 
BAS0169  hypothetical protein -6 -4 
BAS0513 bdbD hypothetical protein -3 -2 
BAS0577 lldp-1 L-lactate permease -7 -7 
BAS1089  hypothetical protein -4 -4 
BAS1222 ywcJb formate/nitrite transporter family protein -7 -7 
BAS1615  hypothetical protein -3 -3 
BAS3917  hypothetical protein -3 -2 
BAS4146  hypothetical protein -5 -5 
BAS4690 cydA-2 cytochrome d ubiquinol oxidase subunit I -3 -2 
BAS4762 ldh2 L-lactate dehydrogenase -4 -4 
BAS4869 ldh3 L-lactate dehydrogenase -6 -4 
BAS5200 ycfU,desRb DNA-binding response regulator 49 6 
BAS5201 yvfT, desKb sensor histidine kinase 56 5 
BAS5202 yvfSb ABC transporter permease 130 13 
BAS5203 yvfRb ABC transporter ATP-binding protein 135 12 
 
a Fold change compared to wild type B. anthracis Sterne using RNA-Seq 
b Genes are annotated by sequence homology to the corresponding Bacillus subtilis gene 
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Table 3.11 RNA-Seq analysis of all differentially expressed B. anthracis genes after Me2-Arg-
Az5 treatment.  
Locus Tag Gene Description Fold Change qValueb 
BAS0577 lldp-1 L-lactate permease -7 5.95E-90 
BAS1222 ywcJa 
formate/nitrite transporter family 
protein -7 1.30E-59 
BAS4134  hypothetical protein -7 1.61E-116 
BAS4146  hypothetical protein -5 6.09E-31 
BAS4711  hypothetical protein -5 3.53E-31 
BAS0169  hypothetical protein -4 9.57E-21 
BAS1089 yjzCa hypothetical protein -4 2.76E-23 
BAS1357 hmp nitric oxide dioxygenase -4 6.57E-12 
BAS4762 ldh2 L-lactate dehydrogenase -4 1.24E-16 
BAS4869 ldh3 L-lactate dehydrogenase -4 3.46E-17 
BAS1023  hypothetical protein -3 3.80E-06 
BAS1349  hypothetical protein -3 1.12E-08 
BAS1615 yfmQa hypothetical protein -3 1.28E-06 
BAS4990 cggR 
gapA transcriptional regulator 
CggR -3 0.004179 
BAS0070 pabC 4-amino-4-deoxychorismate lyase -2 0.003344 
BAS0513 bdbD hypothetical protein -2 8.87E-04 
BAS0547 maeNa 
citrate cation symporter family 
protein -2 0.002003 
BAS0566 rapD, rapIa transcriptional regulator -2 0.004179 
BAS0631 rbsR ribose operon repressor -2 6.17E-05 
BAS1024  hypothetical protein -2 8.87E-04 
BAS1185  hypothetical protein -2 0.007387 
BAS1273  ABC transporter permease -2 8.71E-05 
BAS1666 gltTa 
proton/sodium-glutamate symport 
protein -2 5.37E-04 
BAS2706  hypothetical protein -2 0.003549 
BAS2707  
ABC transporter ATP-binding 
protein -2 8.05E-04 
BAS3173  transcriptional regulator -2 8.18E-07 
BAS3917  hypothetical protein -2 8.14E-04 
BAS4414  
succinate dehydrogenase, 
cytochrome b558 subunit -2 0.003007 
BAS4690 cydA-2 
cytochrome d ubiquinol oxidase 
subunit I -2 0.004179 
BAS4922 nupCa NupC family nucleoside transporter -2 0.004085 
BAS5002 whiA hypothetical protein -2 0.007026 
BAS5316 yycIa YycI protin -2 7.74E-04 
BAS0982 fadR, yvdTa TetR family transcriptional regulator 3 8.50E-04 
BAS4115 sugE-1 sugE protein 4 4.42E-10 
BAS5201 yvfT, desKa sensor histidine kinase 5 2.03E-21 
BAS5200 yvfU, desRa DNA-binding response regulator 6 4.21E-26 
BAS0375 yuxN, yfiRa TetR family transcriptional regulator 8 2.92E-37 
BAS0902 atpIa ATP synthase protein I 8 2.99E-46 
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Table 3.11 (cont.) 
 
BAS5203 yvfRa 
ABC transporter ATP-binding 
protein 12 1.66E-119 
BAS5202 yvfSa ABC transporter permease 13 2.82E-151 
BAS0376 ykuC, yfiSa 
major facilitator family transporter 
protein 181 0 
     
a Genes are annotated by sequence homology to the corresponding Bacillus subtilis gene 
b The q-value is an adjusted p-value, taking in to account the false discovery rate 
 
 
 
 
 
 
 
Table 3.12 Spontaneous PZN-resistance mutations appear exclusively in B. anthracis Sterne 
bas4114, a predicted AcrR family transcriptional regulator gene. 
 
Strainc Mutation Consequencea 
Sterne Wild type DALEAFLCLLDGLMVELLFAGLNRFETRLNASWQVFWRGLSN 
PR01 457G→T DAL* 
PR02 492^T DALEAFLCLLDGLMV* 
PR03 495^AG DALEAFLCLLDGLMVESYYSQV* 
PR04 504^C DALEAFLCLLDGLMVELLFRRFKSL* 
PR05 506^GC DALEAFLCLLDGLMVELLFAQV* 
PR06 507^ATTCGCA DALEAFLCLLDGLMVELLFAIRRFKSL* 
 
a Amino acids 150-191 of BAS4114. Bold residues represent the predicted transmembrane region, as 
defined by Spoctopus (Figure 3.16)25 
Asterisks (*) represent the location of a premature stop codon due to a nonsense mutation 
c MICs for all PZN-resistant mutants here (PR01-06) are ≥ 32 μg/mL PZN, compared to 1 μg/mL for the wild 
type 
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Table 3.13 Expression change of bas4114-4117 in strain PR06 (PZN-resistant mutant). 
Gene Annotation Fold changea 
BAS4114 acrR family transcriptional regulator 34 
BAS4115 emrE drug efflux pump 152 
BAS4116 emrE drug efflux pump 47 
BAS4117 hypothetical protein 62 
 
a Fold change compared to wild type B. anthracis Sterne using RNA-Seq 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 3.14 PZN-Resistant Mutants of B. anthracis Sterne Δbas4114−4117.  
 
Strain Mutation Annotation Consequence MICa 
PR07 bas5034: A425G cell division ABC 
transporter, FtsE 
E142G 8 
PR08 bas5034: G270T cell division ABC 
transporter, FtsE 
L90F 32 
PR09-1 bas1659: G190C CitB RRb /luxR 
family 
V64L 16 
PR09-4 bas1659: G190C CitB RRb /luxR 
family 
V64L >64 
 bas1662: A638G ABC transporter 
permease 
H213R  
PR10-4 bas1659: C248T CitB RRb /luxR 
family 
T83M 64 
 bas1663: C1127T ABC transporter 
permease 
A376V  
 bas1842: A43G petrobactin 
biosynthesis, AsbE 
S15G  
a MICs were determined by microbroth dilution assay, measured in μg/mL.  
b Response regulator. 
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Table 3.15 Effect of B. anthracis Sterne mutations and growth conditions on PZN susceptibility 
and cardiolipin content of bacterial membranes. 
Strain MICa [NaCl]b % CLc 
B. anthracis Sterne 7702 1 0.17 8.8 ± 4.0 
B. anthracis Sterne 7702 0.25 0.67 12.2 ± 3.4 
B. anthracis Sterne 7702 Δbas4114-4117 1 0.17 11.5 ± 1.3 
B. anthracis PR09-4 >64 0.17 14.3 ± 1.7 
B. anthracis PR09-4 32 0.67 16.3 ± 0.9 
B. anthracis PR10-4 64 0.17 10.7 ± 2.3 
B. anthracis PR10-4 16 0.67 11.0 ± 4.3 
B. subtilis 168 >128 0.17 16.7 ± 0.7 
B. subtilis 168 32 1.67 24.1 ± 0.9* 
B. cereus E33L >64 0.17 11.2 ± 2.0 
B. cereus E33L >64 0.67 18.7 ± 2.0* 
B. cereus ATCC 4342 >64 0.17 20.6 ± 5.1 
B. cereus ATCC 4342 >64 0.67 21.6 ± 2.6 
 
a Minimum inhibitory concentrations (MIC) for PZN were determined by the microbroth dilution method and 
are reported as µg/mL 
b The NaCl concentration of the media is given in M (0.17 M is the standard for LB) 
c The percentage of cardiolipin (CL) within the total lipid fraction was determined by a TLC-based 
densitometric assay. Error is given as standard deviation with n = 3. Asterisks indicate P<0.05 relative to 
the same strain grown in LB with 0.17 M NaCl. PZN was absent from CL quantification experiments 
 
 
 
Table 3.16 qRT-PCR of cls locus in step-wise evolved PZN-resistant mutants. 
 
  Fold changea 
Gene Annotation PR09-1b PR09-4c PR10-4d 
bas1659 Response regulator  NS  NS  NSe 
bas1660 Histidine kinase  NS  NS  NS 
bas1661 ABC transporter (ATPase) 21 ± 7 43 ± 20  NS 
bas1662 ABC transporter (permease) 23 ± 13  NS  NS 
bas1663 ABC transporter (permease) 24 ± 9 39 ± 24  NS 
bas1664 Cardiolipin synthase 39 ± 7 77 ± 19  NS 
bas1842 Petrobactin biosynthesis - -  NS 
bas1843 Petrobactin biosynthesis - -  NS 
 
a Error is given as standard deviation with n ≥ 3 biological replicates 
b PR09-1 contains a missense mutation in bas1659 
c PR09-4 contains missense mutations in bas1659 and bas1662 
d PR10-4 contains missense mutations in bas1659, bas1663, and bas1842 
e p < 0.05; NS: Not significant 
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CHAPTER 4: REACTIVITY-BASED SCREENING FOR CITRULLINE-CONTAINING 
NATURAL PRODUCTS REVEALS A FAMILY OF BACTERIAL PEPTIDYL 
ARGININE DEIMINASES3 
 
4.1 Abstract 
Efforts to discover natural products with antibiotic activity traditionally relied on bioassay-guided 
techniques, but such screens were biased toward the most highly produced compounds and missed 
less abundant but potentially useful compounds. The genomic revolution has provided great insight 
into the vast amount of chemical space covered by natural products, and new methods are needed 
to aid in the discovery and isolation of these compounds. A genome-mining tool recently enabled 
extensive bioinformatic characterization of the lasso peptide family of ribosomally synthesized 
and post-translationally modified peptide natural products (RiPPs), and subsequent isolation 
revealed a class of lasso peptides with an unpredicted citrulline modification. Herein we describe 
the use of reactivity-based screening of bacterial extracts to discriminate between arginine- and 
citrulline-containing lasso peptides. This classification enabled the identification of a distally-
encoded protein with putative peptidyl arginine deiminase (PAD) activity. Heterologous 
expression and in vitro enzymatic assays were used to demonstrate the activity of the first bacterial 
PAD of its kind. The family of PADs were then surveyed bioinformatically for deeper 
understanding of its genomic context and potential role in posttranslational modification of RiPPs. 
These data reveal the importance of validating natural product structural prediction software as 
well as demonstrate the prevalence of citrulline modifications in bacterial natural products. 
  
                                                
3 Manuscript in preparation. 
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4.2 Introduction 
 
Natural products of bacterial origin have historically been a fruitful source for antibiotics, but the 
traditional method of antibiotic discovery, bioassay-guided isolation, is limited to high-abundance 
natural products and leads to high rates of rediscovery.1 However, the genomic revolution has 
shown that bacteria have the capacity to produce many more natural products than previously 
predicted.2 Structural prediction programs, relying on analysis of proteins within these biosynthetic 
gene clusters (BGCs), suggest that these natural products cover a broad swath of chemical space, 
and many of these compounds could have great potential as therapeutic agents.2-3 Additionally, by 
connecting genes to molecules, improvements to genome-mining and structure prediction 
programs can be made. New strategies for identifying, isolating, and characterizing the products 
of these gene clusters are needed. 
Reactivity-based screening (RBS) is a recently-developed technique for the rapid discovery 
of natural products bearing specific functional groups in organic extracts of cultured bacteria 
(Figure 4.1). The basis of RBS is the chemoselective labeling of a reactive functional group on 
natural products in in order to rapidly detect if molecules with that functional group are present in 
the sample. The strategy relies on comparing mass spectra of unreacted and reacted cellular 
extracts, searching for differences in the spectra that correspond to the mass of the probe, which is 
selective for the functional group of interest. RBS enabled the discovery and subsequent 
characterization of the thiopeptide cyclothiazomycin C,4 the nonribosomal peptide (NRP) 
deimino-antipain,5 the hybrid NRP-PKS tirandalydigin,6 and the hygrobafilomycin JBIR-100,7 to 
name a few. RBS is a valuable tool for validating bioinformatics-guided natural product 
identification, enabling a more rapid screen for the production of predicted compounds. 
Additionally, RBS is useful for rapid dereplication of already-characterized natural products,4 
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detection of low-abundance species using a sensitive ionization technique, and the facile use of 
more sophisticated probes that enhance detection due to unique isotope patterns of labeled 
compounds or selective enrichment through affinity purification.5, 8-9  
We have previously reported on RBS probes for dehydrated amino acids, aldehydes, and 
ketones. These reactive functional groups are ubiquitous in ribosomally synthesized and post-
translationally modified peptide natural products (RiPPs) as well as other natural products. We 
sought to characterize a more rare functional group in the context of bacterial natural products. 
The modification of arginine to citrulline is an enzyme-dependent deimination of the primary 
guanidinium group on the arginine side chain (Figure 4.2). Although this is a modest chemical 
transformation, isoelectric point of the guanidinium side chain of arginine is 10.76 but drops to 6.1 
upon deimination. The loss of a positive charge at neutral pH can dramatically alter the structure 
and function of the substrate, and is thought to lead to the misfolding of myelin basic protein, 
filaggrin and trichohyalin, leading to rheumatoid arthritis.10 Deimination of proteins has been 
implicated in other human disease states as well, such as Alzheimer’s disease and cancer.11  
To our knowledge, only one bacterial PAD has thus far been characterized, and in the 
context of virulence. The PAD from Porphyromonas gingivalis is a conserved enzyme in the 
family of periodontal pathogens.12 As an essential virulence factor, the P. gingivalis PAD is 
responsible for deimination of human fibrinogen, leading to gingivitis and increasing the risk of 
rheumatoid arthritis.13 The P. gingivalis PAD is omnipresent in the oral pathogen, but is absent in 
even closely related nonpathogenic species.12 Extracellular arginine has been implicated in 
development of biofilm formation, with enzymes dedicated not only to deimination but also 
proteolysis of C-terminal arginine residues.14 Unlike the human PAD, the P. gingivalis enzyme is 
not calcium-dependent and, in addition to accepting a variety of peptide and protein substrates, is 
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able to convert free arginine to citrulline.15 Such substrate promiscuity is likely the result of a 
critical dependance on extracellular concentrations of arginine for P. gingivalis virulence. An 
arginine deiminase (ADI) secreted from Streptococcus intermedius, a commensal oral bacterium. 
S. intermedius inhibits P. gingivalis biofilm formation through decreasing the concentration of 
extracellular arginine. In arginine-starved conditions, the P. gingivalis fimbriae genes fimA and 
mfa1, which are virulence determinants necessary for biofilm formation, are dramatically 
downregulated.16  
In contrast, little is known about the biosynthesis of citrulline in natural products. Few 
primary ureido-containing natural products have been identified. Currently, only 61 entries 
(excluding plant-derived molecules) in the Dictionary of Natural Products contain primary ureido 
groups, and many have not been matched to biosynthetic gene clusters (Figure 4.3). The majority 
are nonribosomal peptide (NRP) natural products such as enduracidin and azotobactin, in which 
the citrulline is thought to be directly installed into the nascent peptide,17-18 but, to our knowledge, 
no PAD has been identified for RiPPs. By identifying natural products with this modification, we 
can gain a broader understanding of the importance of deimination and identify the citrullinating 
enzyme. However, detection of this modification is challenging due to the small mass change 
(NHàO, +0.98 Da) associated with the post-translational modification, a mass which is easily 
overlooked or assumed to be an isotope peak or with the deamidation of the substrate.19 Therefore, 
citrulline-modified natural products are a prime candidate for characterization using RBS. 
Herein, we describe the expansion of RBS as a biological tool to aid in the discovery of the 
enzyme responsible for peptidyl arginine deimination in bacteria. Repurposeing the work of 
Thompson,20-21 the specific labeling of citrulline over arginine with a phenylglyoxal probe is 
rapidly achieved at low pH. We employed this reaction to confirm the presence of citrulline in a 
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subset of lasso peptides, and use the positive hits to conduct a bioinformatic screen to identify 
putative PADs. We compared the PAD enzymes from Streptomyces glaucescens and Streptomyces 
albulus, two confirmed producers of citrulline-containing lasso peptides, and found significant 
differences from the P. gingivalis PAD. We heterologously expressed the S. albulus and S. 
glaucescens PAD enzymes in vitro and tested for arginine deimination of lasso peptide precursors, 
and demonstrate for the first time the activity of a RiPP arginine deiminase. Finally, we conducted 
a bioinformatic survey of bacterial PADs to reveal their taxonomic breadth and the diversity of 
genomic contexts in which the PADs are encoded. 
 
 
4.3 Results 
 
In the course of characterizing lasso peptides as a proof-of-concept for a new natural product 
discovery and mass prediction program, a new family of lasso peptides was defined.22 Lasso 
peptides have a very highly conserved lasso cyclase and highly conserved precursor peptide 
sequences. However, a subset of lasso peptides with a remarkably conserved precursor peptide 
(Figure 4.4) contain an additional modification: an enzymatic arginine deimination resulting in a 
citrulline-containing mature natural product (Figure 4.2). Additional posttranslational 
modifications to lasso peptides beyond isopeptide bond formation have been demonstrated, such 
as in the case of the phosphorylated lasso peptide paeninodin.23 Despite conservation of the 
arginine residue directly C-terminal to the isopeptide bond (Figure 4.4), not all citrulassins contain 
the modified amino acid. High-resolution MS/MS confirmed that of the nine citrulassin producers 
screened, seven exported a lasso peptide that contained citrulline.22  
Heterologous expression of the citrulassin A gene cluster from S. albulus along with 11 
open reading frames (ORFs) upstream and 17 ORFs downstream of the citrulassin BGC resulted 
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in des-citrulassin A (i.e. arginine, rather than citrulline, was present in the natural product, Figure 
4.5). This suggested that either (a) a distally encoded PAD was responsible, or (b) a PAD that was 
locally encoded was is nonfunctional in Streptomyces lividans.22 However, none of the genes near 
the citrulassin BGC are homologous to any known PAD (Figure 4.5 and Table 4.2). We thus set 
out to characterize additional members of the citrulassin family as citrulline- or arginine-
containing lasso peptides in order to determine the prevalence of the posttranslational modification 
and to guide the search the PAD responsible for the citrulline-containing variants. 
4.3.1 Glyoxal probe validation for RBS 
 
We selected a citrulline-specific reaction in order to more easily identify primary ureido-
containing citrulassins by MALDI-TOF-MS. Thompson and coworkers have previously used 
phenylglyoxal probes at low pH to selectively label citrulline over arginine in eukaryotic cellular 
extracts (Figure 4.2).20-21 At low pH, guanidino groups are protonated and thus inaccessible to 
reaction with glyoxal, but the neutral ureido group will react rapidly, resulting in robust labeling 
at 30 min and nearly complete conversion in 60 min at 37 ˚C in the example of histone H3 and 
using 10 molar excess probe.20 The reaction has been further elaborated to more easily identify 
labeled species in complex samples with the use of 3-bromophenylgloyxal, which provides a 
distinct isotopic pattern and whose UV-absorbing properties impart increased signal intensity.24 
The glyoxal labeling reaction, while not suitable for acid-labile natural products, facilitates 
discovery of primary ureido-containing natural products from bacterial extracts, and can easily be 
modified to enrich for labeled compounds using a biotin-conjugated glyoxal probe.20 As predicted, 
the free amino acid L-citrulline was robustly labeled unlike L-arginine under similar conditions 
(Figure 4.6). To test the reaction for selectivity on natural products, purified citrulassin A from 
Streptomyces albulus B-3066 and purified des-citrulassin A (heterologously expressed in S. 
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lividans22) were treated with 5 molar equivalents of 3-bromophenylglyoxyl for 30 min at 37 ˚C in 
75% MeCN with 20% (w/v) trichloroacetic acid. Under these conditions, citrulassin A was robustly 
labeled while no observable product was observed for des-citrulassin A (Figures 4.7 and 4.8). The 
non-ribosomal peptide antipain, a protease inhibitor, was resistant to the probe, unlike deimino-
antipain, a recently-identified citrulline-containing analog of antipain also from S. albulus B-3066 
(Figure 4.9).5 Next, we harvested S. albulus B-3066 cultured for 7 days at 30 ˚C on ATCC172 
media, extracted exported compounds from the cells with MeCN, and tested the probe in the crude 
extract diluted to contain 20% (w/v) trichloroacetic acid. The lasso peptide was in very low 
abundance in the crude extract, but along with the ~1:1 abundance of 79Br:81Br, substantial label-
assisted signal enhancement enabled identification of labeled citrulassin A (Figure 4.7). Thus, 
pramary ureido-containing natural products are an ideal target for RBS, and the glyoxal probe is 
an effective labeling strategy for aiding in the discovery of ureido-functionalized natural products. 
4.3.2 RBS of predicted citrulassin producers 
 
Next, we sought to identify which members of the citrulassin family of lasso peptides were post-
translationally modified with a PAD (Figure 4.2). Previous screening of extracts suggested that 
not all citrulassins contained a citrulline,22 but because of the small mass difference between 
guanidino-containing and ureido-containing products, we elected to test for the presence of 
citrulline using the 3-bromophenylglyoxal probe. We thus obtained a selection of 80 strains from 
the Agriculture Research Service (ARS) Culture Collection and, after a 7 d cultivation at 30 ˚C, 
the bacteria were harvested and metabolites were extracted from the cell surface using MeCN over 
a 24 h time period at 22 ˚C. Reactions were performed directly on crude organic-extracted cell 
surface extracts, desalted, and analyzed by MALDI-TOF-MS for the presence of primary ureido 
groups in the 1500 – 2200 Da mass range. Not all organisms produced an identifiable citrulassin 
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under the growth conditions tested, and extracts of bacteria cultured on ATCC172 media were 
generally most likely to contain detectable levels of natural products in the mass range of interest. 
Those that did produce a predicted citrulassin were screened for the mass of the labeled citrulassin 
(Figure 4.10). Twenty-six strains were confirmed to produce the predicted citrulassin, and of those, 
nineteen were validated with the 3-bromophenylglyoxal probe to contain citrulline.  
4.3.3 Comparative genomics to identify peptidyl arginine deiminases 
 
In order to determine the enzyme responsible for deimination of the citrulassins, we performed 
comparative genomics using the Joint Genome Institute Integrated Microbial Genomes and 
Microbiome Samples Phylogenetic Profiler for Single Genes (https://img.jgi.doe.gov). With the 
subset of citrulline-producing species whose genomes were available in the program, we 
performed partial phylogenetic profiling to compare the genomes of citrulassin producers and des-
citrulassin producers using S. glaucescens GLA.O as the genome against which other species were 
initially compared. None of the homologs unique to the citrulline producers were identified as 
PADs, but the isochorismatase is in the genomic neighborhood of a hypothetical PAD from 
PF03068 in S. glaucescens GLA.O (Figure 4.11, Table 4.3). By performing an iterative BLAST-
P search using the S. glaucescens putative PAD, we confirmed that the strains that strains 
producing arginine-containing citrulassins lacked a homolog to the S. glaucescens PAD. We thus 
set out to bioinformatically characterize the bacterial PAD. 
4.3.4 Comparison with other characterized PADs 
 
While the bacterial PAD is classified within in the same Pfam as eukaryotic PADs (PF03068), the 
sequence identity is only 20 - 28% between each of the six families of Homo sapiens PADs and 
the PAD from S. glaucescens (Table 4.5). Unlike members of PF03068, the P. gingivalis PAD is 
not calcium-dependent and does share a conserved active site with S. albulus, S. glaucescens, and 
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H. sapiens. In contrast, the S. glaucescens and S. albulus PADs have 70% identity and an even 
higher degree of similarity. In spite of the low sequence identity, an alignment of S. glaucescens 
PAD with the H. sapiens PAD4 shows conservation of active site residues (Figure 4.12). The H. 
sapiens PADs are calcium-dependent enzymes with a conserved catalytic Cys645 and stabilizing 
triad of Asp350-His471-Asp473.25  
The P. gingivalis PAD, a member of Pfam PF04371, is responsible for deimination of human 
fibrinogen and is essential for P. gingivalis pathogenesis.12, 26 This enzyme is highly conserved in 
all sequenced strains of P. gingivalis (Figure 4.13), but has no homolog in S. glaucescens or other 
confirmed citrulassin producers. The P. gingivalis PAD has only 18% identity to the S. glaucescens 
PAD, which also has low identity to the S. intermedius PAD involved in inhibiting P. gingivalis 
biofilm formation (Table 4.4). The low degree of identity is also reflected in a lack of alignment 
in the active site residues, and furthermore suggests that the S. albulus and S. glaucescens PADs 
accept different substrates than the P. gingivalis PAD despite a similar enzymatic activity. 
4.3.5 Genetic context of the bacterial PAD 
 
The S. glaucescens hypothetical protein, putatively named a PAD and part of the Pfam PF03068, 
was used to generate a dataset of 224 unique bacterial PADs using an iterative BLAST-P query 
against all bacterial genomes in the nonredundant database in GenBank.27 Protein accession 
numbers were compiled and sequentially analyzed with RODEO,22 and then used to generate a 
sequence similarity network (SSN) in order to illustrate taxonomic relationships and phylogenetic 
distribution (Figure 4.14).28 Diverse phyla (Actinobacteria, Cyanobacteria, Firmicutes, 
Proteobacteria, and Sphingobacteria) are represented, but the PF03068 PAD is not widespread in 
bacteria. In contrast, members of PF04371, of which the P. gingivalis enzyme is a member, are 
pervasive across prokaryotes and especially prevalent in Actinobacteria and Firmicutes, of which 
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P. gingivalis is a member (Figure 4.13). Instead, many PADs closely related to the S. glaucescens 
enzyme are found within Actinobacteria and in particular the genus Streptomyces, but are not 
pervasive within any one genus. Importantly, none of the RBS-confirmed des-citrulassin producers 
are predicted to contain a PAD. 
There is no indication of horizontal gene transfer (HGT), as proteins clustered with other 
PADs from species within the same phylum (Figure 4.14). Additionally, the %GC content is nearly 
identical to the overall organism %GC.29 (Figure 4.15). These data indicate the bacterial PAD is 
not widespread due to HGT, although we cannot rule out the possibility that the gene was acquired 
by organisms having similar GC content. Intriguingly, two outliers contain lasso peptide BGCs, 
but the Leptolyngbya BGC does not encode a citrulassin precursor. Streptomyces sp. NRRL F-
5140, contains a citrulassin BGC and the product was detected from bacteria grown on ATCC172 
(Figure 4.16), indicating an active enzyme. Species with similar GC content in the PAD nucleotide 
sequence are from Cyanobacteria, which may suggest that Streptomyces sp. NRRL F-5140 
acquired the gene from a member of this phylum. 
The co-occurrence analysis of genes (± 8 ORFs) shows an abundance of genes related to 
transport and transcriptional regulation (Table 4.3). However, the PADs do not appear to be 
contained within defined BGCs. Using genome neighborhood network analysis, we compared 
ORFs between PADs that clustered together based on sequence similarity (Figure 4.16). Even 
PADs with a high degree of similarity appear in diverse genome neighborhoods, which do not bear 
resemblance to RiPP biosynthetic gene clusters. Thus, the PAD likely exerts its activity on a 
distally encoded substrate. 
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4.3.6 In vitro reconstitution of the Streptomyces PAD 
 
The S. albulus B-3066 PAD is a predicted cytosolic protein, unlike the exported Streptococcus 
intermedius enzyme, with no transmembrane regions.16, 30We therefore sought to reconstitute the 
enzymatic activity and test the citrulassin A precursor peptide (CitA) as a substrate for the bacterial 
PAD in vitro. CitA was cloned from S. albulus B-3066 (producer of citrulassin A) and S. 
glaucescens B-2900 (producer of citrulassin E) and overexpressed in E. coli with an N-terminal, 
tobacco etch virus (TEV)-cleavable maltose-binding protein (MBP) tag (Figure 4.18). The 
hypothetical PADs (Accession numbers: S. albulus, WP_064069846.1; S. glaucescens, 
AIR96488.1) were also cloned and overexpressed in the pET28 vector.  
The purified enzymes were tested for activity using an enzyme-linked immunosorbent 
assay.31 While the assay does not allow for localization of the newly formed citrulline residue(s), 
it is independent of mass spectrometry techniques which are not highly accurate for such large 
peptides (MBP-CitA has a mass of about 50 kDa). PAD activity was tested both in the presence 
and absence of 5 µM TEV, as flocculent precipitate was observed when the MBP tags were cleaved 
in situ. MBP-CitA was treated with purified PAD, reactions were quenched with an equivalent 
volume of 50% TCA and immediately subjected to probe labeling with a biotin-conjugated glyoxal 
(Figure 4.18). As a control, MBP-tagged CitA was subjected to identical conditions without the 
addition of enzyme. After 1 h at 37 ˚ C, the probe reactions were quenched with a saturated solution 
of citrulline. Proteins were resolubilized with urea, separated by SDS-PAGE and electroblotted. 
PAD activity, indicated by biotin-glyoxal labeling and secondary interaction with Streptavidin-
HRP conjugate, was visualized by enhanced chemiluminsecence (ECL).20 Slight nonspecific 
labeling of the arginine-containing control peptide was observed (Figure 4.18), but notable signal 
enhancement occurred in samples treated with MBP-PAD. Robust labeling is indicative of PAD 
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activity, although the location of the citrulline within the peptide remains to be determined and is 
an ongoing area of investigation. However, MBP does not appear to be the substrate, as cleavage 
of the peptide in situ results in a loss of luminescence associated at the mass of MBP (Figure 4.18). 
Notably, the PAD shows low specificity for the native substrate, as the PAD from S. albulus was 
able to process CitA from S. glaucescens in addition to the Arg-containing substrates MBP-BamA, 
MBP-TbtA A19R, and MBP-TbtA A25R (data not shown). This suggests that citrulassin library 
generation is possible, and that the PAD could be used to install citrullines on the precursor 
peptides of other classes of RiPPs.  
 
  
4.4 Conclusion 
 
In this study, we employed a citrulline-specific probe to selectively label and subsequently identify 
citrulline-containing natural products from bacterial extracts. This technique, called reactivity-
based screening (RBS),4-5, 7 has been previously used to discover and characterize natural products 
modified with aldehydes, ketones, and Michael acceptors, but was expanded to allow for 
identification of the bacterial enzyme responsible for the posttranslational deimination of primary 
guanidino groups. The new family of bacterial PADs appear in diverse genomic contexts rather 
than within RiPP biosynthetic gene clusters. Through heterologous expression and in vitro enzyme 
assays, it was determined that the PAD does act as a peptidyl arginine deiminase, although its 
specificity for specific arginine residues within a peptide remains to be determined. Further work 
will establish rules for enzyme selectivity through extensive MS analysis and additional enzymatic 
assays on alternative arginine-containing RiPP precursor peptides. 
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4.5 Methods 
4.5.1 General materials and methods  
Reagents for molecular biology experiments were purchased from New England BioLabs 
(Ipswich, MA), Thermo Fisher Scientific (Waltham, MA), and Gold Biotechnology Inc. (St. Louis, 
MO). Chemicals were purchased from Sigma-Aldrich (St. Louis, MO) and New England BioLabs. 
Plasmid maintenance and protein overexpression were carried out using Escherichia coli DH5α 
and BL21 (DE3) strains, respectively.  
4.5.2 Bacterial growth and extraction  
Unless otherwise noted, Streptomyces strains were streaked from frozen 50% glycerol backstocks 
onto ATCC 172 plates (15 g/L agar, 10 g/L glucose, 20 g/L soluble starch, 5 g/L yeast extract, 5 
g/L N-Z Amine Type A, 1 g/L CaCO3, autoclaved). Single colonies from plates were used to 
inoculate 5 mL liquid ATCC 172 cultures. Plates and liquid cultures were incubated at 30 ˚C for 
7 days prior to use. Cells were harvested from plates using a sterile razor blade and transferred to 
sterile 15 mL conicals containing 1 – 5 mL MeCN. Compounds were extracted from cells for 16 
h at 22 ˚C with moderate agitation prior to centrifugation (4,000 ´ g, 10 min) and decanting into 
20 mL scintillation vials. Extracts were used immediately or dried by speed vacuum and stored at 
-20 ˚C and redissolved in MeCN prior to use. 
4.5.3 Citrulassin A isolation and purification  
Citrulassin A was extracted from S. albulus B-3066 and purified by high performance liquid 
chromatography as described previously.22  
4.5.4 Citrulline labeling reaction  
In general, reactions were carried out in freshly prepared 20% trichloroacetic acid (TCA) with 50 
– 75% aq. MeCN. Bromophenylglyoxal hydrate was prepared as a stock solution (10 mM in 
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DMSO). Purified compounds were dissolved at a concentration of 10 µM before the addition of 
bromophenylglyoxal hydrate to a concentration of 10 µM. After 30 min at 37 ˚C, reactions were 
quenched by the addition of an equivalent volume of saturated L-citrulline in slightly acidified 
water. Samples were dried by speed vacuum, redissolved in water, and desalted prior to analysis. 
Reactions on crude cellular extracts were performed by diluting 10 µL of cell extract (in MeCN) 
with 10 µL of 40% TCA in 50% aq. MeCN and treating with 1 µL of the bromophenylglyoxal 
hydrate stock solution. 
4.5.5 Molecular biology techniques  
Oligonucleotides were purchased from Integrated DNA Technologies Inc. (Coralville, IA). The 
gene encoding CitA was amplified from S. glaucescens B-2900 and the genes encoding the PAD 
from S. albulus B-3066 and S. glaucescens B-2900 were amplified from genomic DNA using the 
primers listed in Table 4.1. The DNA was purified using a QIAprep Miniprep Kit (Qiagen). The 
purified DNA was digested with BamHI-HF and XhoI-HF, and then purified by gel extraction on 
a 1% (w/v) agarose gel using a QIAQuick gel extraction kit (Qiagen). The pET28 vector, encoding 
an N-terminal MBP tag with at TEV proteolysis site, and an Arg3 motif in the case of the CitA 
precursor, was likewise digested and purified.  digested with BamHI-HF and XhoI-HF and purified 
using a QIAQuick gel extraction kit (Qiagen). Ligation reactions with T4 DNA Ligase (NEB) were 
used to transform chemically competent E. coli DH5α cells. The cells were plated onto Luria-
Bertani (LB) agar plates supplemented with 50 µg/mL kanamycin and grown at 37 ˚C. Resulting 
colonies were propagated in LB broth (50 µg/mL kanamycin) for 16 h at 37 ˚C prior to plasmid 
isolation using a QIAprep Spin Miniprep Kit. The constructs were sequenced using MBP forward 
primer and T7 reverse primer at ACGT Inc. (Wheeling, IL) (Table 4.1).  
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The co-expression of the citrulassin gene cluster and the PAD was achieved by cloning 
into a pCDFDuet vector. The backbone was amplified using the primers listed in Table 4.1 and the 
PAD and gene cluster were amplified from genomic DNA. The inserts and backbone were purified 
using gel extraction as described above. Stepwise insertion of the gene cluster and then the PAD 
was accomplished with Gibson one-step isothermal DNA assembly.32 The resulting constructs (10 
µL) were used to transform E. coli, propagated, and sequenced as described above.  
4.5.6 Expression and purification of MBP-PAD and MBP-CitA  
Chemically competent E. coli BL21 (DE3) cells (50 µL) were transformed with 100 ng purified 
pET28 plasmid constructs using heat shock, and cells were plated onto LB agar plates containing 
50 µg/mL kanamycin. After growing for 12 h at 37 ˚C, single colonies were used to inoculate 5 
mL LB cultures (50 µg/mL each kanamycin and chloramphenicol) and grown for 16 h at 37 ˚C. 
The 5 mL cultures were used to inoculate 500 mL cultures of Terrific Broth (TB) media (24 g/L 
yeast extract, 12 g/L tryptone, 0.4% (v/v) glycerol, 17 mM KH2PO4, 72 mM K2HPO4), 
supplemented with kanamycin and chloramphenicol, and grown to a final OD600 of 0.6 – 0.8. 
Protein overexpression was induced by dropping the temperature of the cultures to 16 ˚C for 16 h 
and supplementing with 0.4 mM isopropyl β-D-1-thiogalactopyranoside (IPTG). Cells were 
harvested by centrifugation (4,000 ´ g, 10 min, 4 ˚C), washed with phosphate-buffered saline 
(PBS, 137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.6) and centrifuged 
a second time. Cell pellets were stored at -20 ˚C for 8 h before use. 
Purification using amylose resin was carried out as described previously.33 Briefly, cell 
pellets were thawed on ice and resuspended in lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM 
NaCl, 2.5% (v/v) glycerol, 0.1% Triton X-100, 4 mg/mL lysozyme, 2 µM leupeptin, 2 µM 
benzamidine, 2 µM E64, 2 µM PMSF). After 15 min at 4 ˚ C, cells were homogenized by sonication 
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(3 ´ 40 s, 10 min apart) and the insoluble fraction was separated by centrifugation (20,000 ´ g, 60 
min, 4 ˚C).  
4.5.7 In vitro PAD activity testing  
100 µM MBP-CitA was treated with MBP-PAD (10 µM) in reaction buffer (50 mM HEPES [pH 
7.6], 50 mM NaCl, 10 mM CaCl2, 2 mM DTT) for 1 h at 37 ˚C or for various lengths of time at 
22 ˚C. Control reactions were set up with an equivalent volume of protein storage buffer in place 
of MBP-PAD. Reactions were quenched with the addition of an equivalent volume of 50% TCA 
and immediately reacted with phenylglyoxal-biotin (final concentration 50 µM) for 1 h at 37 ˚C.  
The reaction was quenched with a solution saturated citrulline.  
Proteins were resuspended by neutralizing the solution and adding 2 volumes of 1 M urea. 
For Western blot detection of PAD activity, 5-10 µg of MBP-CitA was separated on 12% SDS-
PAGE and transferred by immunoblot (Towbin buffer [25 mM Tris, 192 mM glycine, 20% 
MeOH], 45 V, 2 h, 4 ˚ C) to Immobilon-P membrane (EMD Millipore). The membrane was blocked 
with 5% bovine serum albumin in TBS-T (100 mM Tris [pH 7.6], 100 mM NaCl, 0.1% Tween-
20) for 2 h at 22 ˚C prior to treatment with streptavidin-horseradish peroxidase conjugate (0.5 µL, 
1:20,000) in TBS-T for 60 min at 22 ˚C. The membrane was washed with TBS-T (5 mL; 3 ´ 30 s 
and 3 ´ 5 min) before visualization using Pierce ECL Western Blotting Substrate and imaging 
using the Chemiluminsecence HR setting on a Bio-Rad ChemiDoc. 
4.5.8 Phenylglyoxal-biotin preparation  
The phenylglyoxal-biotin probe was prepared from azidophenyglyxoal (1 mM) and biotin-PEG4-
alkyne (1 mM) in 50% DMSO with 10 mM CuSO4, 1 mM tris(3-
hydroxypropyltriazolylmethyl)amine (THPTA), and 10 mM C6H7NaO6. The reaction was stirred 
at 37 ˚C for 1 h and added without further purification to in vitro PAD reactions. 
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4.5.9 Partial phylogenetic profiling  
Differences in genomes of citrulassin producers and des-citrulassin producers were determined 
using the Joint Genome Institute Integrated Microbial Genomes and Microbiome Samples (JGI 
IMG/M) (https://img.jgi.doe.gov).34 The S. glaucescens GLA.O genome was intersected for 
homologs in citrulassin producer species S. albulus, S. griseus, S. orientalis, and A. orientalis. The 
single genes analysis was processed by subtracting genes with homologs in S. avermitilis, S. 
auratus, and S. natalensis. 
4.5.10 Sequence similarity network (SSN) generation  
SSNs were generated using EFI-EST (http://efi.igb.illinois.edu/efi-est/).28 The network was 
generated using an alignment score cutoff of e-150 as a clustering threshold. The network was 
visualized using the Organic layout within Cytoscape v. 3.4.035 and Adobe Illustrator.  
4.5.11 Genome neighborhood network (GNN) generation  
GNNs were generated using EFI-GNT (http://efi.igb.illinois.edu/efi-gnt/index.php). The program 
currently accepts only SSNs generated from Pfam or BLAST searches, not user-generated SSNs, 
so the S. glaucescens PAD was used in a BLAST search for homologous enzymes. The resulting 
SSN (with an alignment score cutoff of e-150 was uploaded to EFI-GNT. Neighborhood size was 
set to 10 and lower limit for co-occurrence was set to 20%. Only bacterial species were included 
in the subsequent GNN analysis (n = 79). 
4.5.12 Analysis of GC content  
The %GC of nucleotide sequences for a representative set of bacterial peptidyl arginine deiminases 
(n = 160) were calculated and plotted against NCBI Taxonomy records of the organism %GC 
content. The best-fit line was drawn using linear regression and had a slope of 0.98 with an R2 of 
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0.98. Outliers with a greater than 5% deviation from the best-fit line (n = 4) were highlighted. 
Program script was written by Parth Patel. 
4.5.13 Sequence logo generation  
The precursor peptides of the 55 characterized citrulassins found using BLAST and RODEO22 
were aligned using MUSCLE v.3.8.3136 prior to sequence logo generation using WebLogo 2.8.2 
(http://weblogo.berkeley.edu/).37 
4.5.14 Percent identity matrix and sequence alignment  
The following accession numbers were used: Homo sapiens, NP_036519.2; P. gingivalis, 
WP_01245737.1; S. intermedius, AFV46229.1; S. albulus, WP_064069846.1; S. glaucescens, 
AIR96488.1. FASTA sequences were analyzed using EMBL-EFI Multiple Sequence Comparison 
by Log-Expectation (MUSCLE) (www.ebi.ac.uk/Tools/msa/muscle).  
4.5.15 MALDI mass spectrometry  
Cell extracts were screened using matrix-assisted laser desorption/ionization time-of-flight mass 
spectrometry (MALDI-TOF MS). After desalting samples, 1 µL aliquots were co-spotted with 1 
µL 50% aq. MeCN (0.1% formic acid) saturated with α-Cyano-4-hydroxycinnamic acid(CHCA). 
4.5.16 High resolution mass spectrometry  
Purified and desalted compounds were dissolved in 75% MeCN with 1% AcOH and subjected to 
centrifugation (17,000 × g, 5 min). Samples were infused onto a ThermoFisher Orbitrap Fusion 
ESI-MS using an Advion TriVersa NanoMate. The MS was calibrated weekly using calibration 
mixture, following manufacturer instructions, and tuned daily with Pierce LTQ Velos ESI Positive 
Ion Calibration Solution (ThermoFisher). Spectra were collected in profile mode with a resolution 
of 100,000. Ions were selected for fragmentation in the Ultra-High-Field Orbitrap Mass Analyzer 
using an isolation width of 2 m/z, normalized collision energies of 20-35, an activation q value of 
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0.4, and an activation time of 30 ms. Data analysis was performed using Thermo Xcalibur 
software. 
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4.7 Figures 
 
Figure 4.1 Strategy for reactivity-based screening (RBS). The gene of interest is used to mine 
bacterial genomes for biosynthetic gene clusters. Prioritized strains are cultured, harvested, and 
extracted with organic solvents. Reactions with the RBS probe are performed in the extract and 
analyzed by MALDI-TOF-MS for new peaks compared to the unlabeled extract that are associated 
with the mass of the probe. Labeled species are selected for further purification and 
characterization.  
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Figure 4.2 PAD enzyme activity and reactivity-based screening strategy for identification of 
citrulline-containing natural products. (A) Proposed mechanism for enzyme-dependent arginine 
deimination. (B) Phenylgloxal probes, such as 3-bromophenylglyoxal (1) selectively react with 
citrulline at low pH.  
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Figure 4.3 Representative structures of primary ureido-containing natural products, generally 
divided into categories based on biosynthetic pathways. The citrulassins, represented by citrulassin 
A (2), are currently the ownly known RiPPs containing citrulline. 
 
 
 
Figure 4.4 Multiple sequence alignment (http://weblogo.berkeley.edu/logo.cgi) of the 55 
bioinformatically-discovered citrulassin precursor peptides shows remarkable sequence 
homology, especially in the core peptide region. Isopeptide bond formation between the side chain 
aspartic acid and N-terminus of the core peptide is indicated with a black bar. Arginine residue 
which is post-translationally modified to citrulline is indicated with an asterisk.  
 
 
*
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Figure 4.5 Genomic context of the citrulassin A biosynthetic gene cluster cloned from 
Streptomyces albulus B-3066 and structural characterization of the heterologously expressed lasso 
peptide. (A) None of the genes within the neighborhood of the citrulassin A cluster, which were 
heterologously expressed in S. lividans, have homology to known peptidyl arginine deiminases. 
(B) High resolution mass of des-citrulassin A (3), extracted from S. lividans. (C) Collision-induced 
dissociation (CID) spectrum of des-citrulassin A with b- and y-ions indicated in blue and orange, 
respectively. (D) Bubble diagram of des-citrulassin A marked with b- and y-ions from (C). (E) 
Mass list of fragment ions from (C) used to confirm the presence of arginine in des-citrulassin A. 
Figure adapted from Tietz & Schwalen, et al (2016).22 
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Figure 4.6 3-Bromophenylglyoxal in 20% (w/v) trichloroacetic acid does not react with (A) the 
free amino acid arginine but will label (B) citrulline under identical conditions. Reactions were 
analyzed by ESI-MS. 
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Figure 4.7 Confirmation of glyoxal reaction selectivity and robustness. (A) MALDI-TOF-MS of 
of purified citrulassin A (unreacted, top) reacted with 3-bromophenylglyoxal (bottom). (B) 
MALDI-TOF-MS of heterologously expressed and purified des-citrulassinA (unreacted, top) and 
reacted under identical conditions as citrulassin A (bottom). (C) MALDI-TOF-MS of 
Streptomyces albulus B-3066 (citrulassin A producer) extract, either unreacted (top) or reacted 
with probe (bottom). The labeled peak is expanded (inset) to show the altered labeling pattern 
resulting from the bromine-containing probe. 
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Figure 4.8 Structural characterization of 3-bromophenylglyoxal labeled citrulassin A. (A) High 
resolution mass spectrum of the [M+2H]2+ of labeled citrulassin A. (B) CID spectrum of the 
[M+2H]2+ ion. Labeled peaks correspond to identified b- and y- ions, identified in the table. (C) 
Schematized bubble diagram of labeled citrulassin A used to confirm the location of the probe.  
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Figure 4.9 3-Bromophenylglyoxal robustly labels natural products containing citrulline such as 
(A) deimino-antipain (5a), but will not react with (B) arginine-containing antipain (6) under 
identical conditions. 
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Figure 4.10 Representative spectra from the screening of citrulassin producers with the 
bromophenylglyoxal probe. Labeled products are highlighted in red, with the corresponding 
citrulline shown in the amino acid sequence. Unmodified arginine residues in the des-citrulassin 
samples are in bold. Extracts from (A) S. aurantiacus B-2806, (B) S. katrae NRRL B-16271, (C) 
S. glaucescens B-2900, (D) S. avermitilis B-16169, (E) S. sp. NRRL S-1813, (F) S. natalensis B-
5314, (G) S. mutabilis ISP-5169, (H) S. alboniger B-1820, (I) S. auratus 8097, and (J) A. orientalis 
B-5485. 
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Figure 4.11 Genomic context of the Streptomyces glaucescens PAD. Arrows indicate open 
reading frames (ORFs) and length of arrow corresponds to gene length. Blue arrow, PAD; gray 
arrow, isochorismatase hit from comparative genomics. DUF, domain of unknown function. 
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Figure 4.12 Protein sequence alignment of the Homo sapiens (NP_036519.2), Streptomyces 
glaucescens (AIR96488.1), and Streptomyces albulus (WP_064069846.1) PADs. *, conserved 
residues; :, strongly similar residues; ., weakly similar residues. Highlighted residues are 
designated as the active site residues in the H. sapiens PAD. Alignment algorithm used was 
MUSCLE with default settings. 
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Figure 4.13 Sequence similarity network28 of the Porphyromonas gingivalis PAD. Each node 
represents a unique PPAD protein, and lines are drawn between nodes if the proteins share a 
BLAST e-value of < e-150. Nodes are colored by phylum, and P. gingivalis strains are further 
colored to show sequence conservation within the pathogen family. Network was created using 
the Enzyme Function Initiative – Enzyme Similarity Tool  (EFI-EST). Image was generated using 
Cytoscape.38 
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Figure 4.14 Sequence similarity network28 of the bacterial protein arginine deiminase. Each node 
represents a unique PAD protein, and lines are drawn between nodes if the proteins share a BLAST 
e-value of at least e-150. Nodes are colored by phylum. Uncharacterized genomes are grouped in 
the Other category. Clusters are labeled if the majority of nodes are from a single genus. Network 
was created using EFI-EST and image was generated using Cytoscape.38 
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Figure 4.15 %GC content analysis for inference of horizontal gene transfer. Linear regression was 
calculated (slope = 0.98) and outliers (>5%) are indicated in blue. 
 
 
 
Figure 4.16 Streptomyces sp. NRRL F-5140, which has a lower %GC content in its PAD than in 
the entire genome, produces a citrulline-containing lasso peptide. High-resolution MS is consistent 
with the modification, and the natural product is labeled within bacterial extracts (not shown). 
 
 
 
 
Figure 4.17 Cytoscape genome neighborhood network (GNN)28 of co-occurring genes with the 
bacterial protein arginine deiminase. (A) Subset of PADs from the SSN from Figure 4.6 that were 
used in the EFI-GNT analysis, arranged as previously shown. As before, each cluster represents a 
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unique PAD protein, and lines are drawn between nodes if the proteins share a BLAST e-value of 
at least e-150. Clusters are labeled if the majority of nodes are from a single genus. (B) GNN of the 
clusters from (A) with the clusters from (A) represented as the central hubs and Pfams with a  co-
occurrence ³20% shown as nodes. Size correlates to co-occurrence value. N-value is the number 
of PADs included in the co-occurrence analysis for each cluster. 
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Figure 4.18 Chemiluminescence immunoassay demonstrating PAD activity. (A) SDS-PAGE of 
purified MBP-CitA (10 µg). (B) SDS-PAGE of purified MBP-PAD from S. albulus and S. 
glaucescens. (C) MBP- MBP-CitA (50 µM) was treated with MBP-PAD (0.1 µM) prior to reaction 
with APG-Biotin and subsequent imaging with Streptavidin-HRP. Grey lines indicate molecular 
weight standards. Cleavage of MBP-CitA results in a loss of luminescence, indicating PAD 
activity is on the CitA precursor. 
 
 
A   B  
 
 
 
 
 
 
C 
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Figure 4.19 Synthesis of the biotin-glyoxal probe (9) used for immunoassays of PAD activity. 
 
 
4.8 Tables 
Table 4.1 Primers used in this study. 
Primer Name Oligonucleotide sequence 
MBP F 
(sequencing)  GAGGAAGAGTTGGCGAAAGATCCACGTA 
T7 F (sequencing) TAATACGACTCACTATAGGG 
T7 R (sequencing) GCTAGTTATTGCTCAGCGG 
PAD F 
(sequencing) CGCGGACGTGAACCGC 
PAD R 
(sequencing) GCACCTCGCCCATGCC 
Salb PAD F AAAGGATCCGTGGTTACGAGCACCACGAGACGAACAGC 
Salb PAD R TTTCTCGAGTCATACGGCTTCCACCACGCGGCG 
Salb CitA F AAAGGATCCATGAAGAAGGCCTACGAGGCGCCGACG 
Salb CitA R TTTCTCGAGTCAGTTCTTGCTGAGGACGAGACGGTCGTTGC 
Sglau PAD F AAAGGATCCATGGTGCGCTCACGTACGCGCATACACC 
Sglau PAD R TTTCTCGAGTCAGCCCCTGGGTGCGGCCC 
Sglau CitA F AAAGGATCCATGAAGAAGGCGTACGAGGCCCCGACG 
Sglau CitA R TTTCTCGAGTCAGTTCTTGCTGAGGATCAGACGGTCGTTGCC 
Salb_cluster ins F ATAATTTTGTTTAACTTTAATAAGGAGATATACCATGAAGCACCATCAGCCCTGCTCAAC 
Salb_cluster ins R GTTGAGCAGGGCTGATGGTGCTTCATGGTATATCTCCTTATTAAAGTTAAACAAAATTAT 
Salb_cluster BB F CCAGCGGTTCTTCATGGTGGACTGAGGCAGCAGCCATCACCATCATCACCACAGCCAGG 
Salb_cluster BB R CCTGGCTGTGGTGATGATGGTGATGGCTGCTGCCTCAGTCCACCATGAAGAACCGCTGG 
Salb PAD ins F TATTAGTTAAGTATAAGAAGGAGATATACATATGGTGGTTACGAGCACCACGAGACGAAC 
Salb PAD ins R GTTCGTCTCGTGGTGCTCGTAACCACCATATGTATATCTCCTTCTTATACTTAACTAATA 
Salb PAD BB F GCCGCGTGGTGGAAGCCGTAGTGGATATCGGCCGGCCACGCGATCGCTGACGTCGGTACC 
Salb PAD BB R GGTACCGACGTCAGCGATCGCGTGGCCGGCCGATATCCACTACGGCTTCCACCACGCGGC 
Abbreviations: F, forward primer; R, Reverse primer; Salb, S. albulus B-3066; Sglau, S. 
glaucescens B-2900; ins, insert; BB, backbone 
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Table 4.2 Genomic context of the citrulassin gene cluster, represented with an ORF diagram in 
Figure 4.5. A co-occurrence analysis of ORFs upstream and downstream of the 55 unique 
citrulassin gene clusters shows no PAD.  
 
Pfam Count Occurrence (%) Pfam Name Pfam Description 
PF00733 56 102 Asn_synthase Asparagine synthase 
PF00005 53 96 ABC_tran ABC transporter 
PF05402 52 95 PqqD Coenzyme PQQ synthesis protein D (PqqD) 
PF00664 51 93 ABC_membrane ABC transporter transmembrane region 
PF13471 51 93 Transglut_core3 Transglutaminase-like superfamily 
PF08544 18 33 GHMP_kinases_C GHMP kinases C terminal 
PF00440 12 22 TetR_N Bacterial regulatory proteins, tetR family 
PF00528 12 22 BPD_transp_1 Binding-protein-dependent transport system inner membrane component 
PF12802 9 16 MarR_2 MarR family 
PF02540 8 15 NAD_synthase NAD synthase 
PF00009 6 11 GTP_EFTU Elongation factor Tu GTP binding domain 
PF00561 6 11 Abhydrolase_1 alpha/beta hydrolase fold 
PF00583 6 11 Acetyltransf_1 Acetyltransferase (GNAT) family 
PF03466 6 11 LysR_substrate LysR substrate binding protein 
PF12697 6 11 Abhydrolase_6 Alpha/beta hydrolase family 
PF00106 5 9 adh_short short chain dehydrogenase 
PF01590 5 9 GAF GAF domain 
 
 
 
Table 4.3 Joint Genome Institute–Integrated Microbial Genomes and Microbiome Samples 
Phylogenetic Profiler results for homologous genes present in citrulassin producers but not in des-
citrulassin producers. The nicotinamidase immediately adjacent to the S. glaucescens PAD is 
italicized. 
 
Gene ID Locus Tag Gene Name Length (AA) % Identity 
2630312895 Ga0069422_121095 Ribosomal protein S18 acetylase RimI 168 59.8 
2630313800 Ga0069422_122005 Ferredoxin-NADP reductase 351 88.4 
2630315137 Ga0069422_123344 Alkaline phosphatase 462 72.2 
2630315277 Ga0069422_123484 Pimeloyl-ACP methyl ester carboxylesterase 287 80.5 
2630315346 Ga0069422_123553 AraC-type DNA-binding protein 139 65.2 
2630315364 Ga0069422_123571 Nicotinamidase-related amidase 196 73.8 
2630315441 Ga0069422_123648 F420-dependent oxidoreductase, G6PDH family 323 61.1 
2630317310 Ga0069422_125526 Signal transduction histidine kinase 401 61.1 
2630317737 Ga0069422_125955 Acetyl-CoA N-acetyltransferase 247 65.7 
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Table 4.4 Co-occurrence analysis shows bacterial PADs are not located in a common genomic 
context. Co-occurrence was calculated for +/- 8 ORFs from the PAD. 
 
Pfam Counts Co-occurrence (%) Pfam Name Pfam description 
PF03068 223 100 PAD Protein-arginine deiminase 
No Pfam match 173 77     
PF00005 56 25 ABC_tran ABC Transporter 
PF13304 46 21 AAA_21 APTases associated with diverse cellular activities 
PF07690 45 20 MFS_1 Major facilitator superfamily 
PF00072 43 19 Response_Reg Response regulator receiver domain 
PF00440 39 17 TetR_N TetR regulatory protein 
PF00583 33 15 Acetyltransf_1 Acetyltransferase (GNAT) family 
PF00196 32 14 Ger_E LuxR-type DNA-binding HTH domain 
PF07730 28 13 HisKA_3 Histidine kinase 
PF02518 28 13 HATPase_c Histidine kinase-, DNA gyrase B-, and HSP90-like ATPase 
PF12802 24 11 MarR_2 MarR family 
PF13673 23 10 Acetyltransf_10 Acetyltransferase (GNAT) family 
PF07719 23 10 TPR_2 Tetratricopeptide repeat 
PF00528 22 10 BPD_Transp_1 Binding-protein-dependent transport system, inner membrane component 
PF12833 22 10 HTH_18 Helix-turn-helix domain 
 
 
 
Table 4.5 Identity matrix of the bacterial PAD enzymes previously determined in P. gingivalis has 
no homology to the S. albulus S. glaucescens PADs, which are in the same Pfam as the H. sapiens 
PADs. Identity and similarity matrix was generated using EMBL-EBI Multiple Sequence 
comparison by Log-Expectation (MUSCLE). 
 
  PF03068 PF03068 PF03068 PF04371 
  H. sapiens S. albulus S. glaucescens P. gingivalis 
H. sapiens 100 21 22 9 
S. albulus 35 100 69 10 
S. glaucescens 34 76 100 9 
P. gingivalis 17 21 20 100 
     
    % identity 
    % similarity 
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APPENDIX A: PDF REPRINTS OF OTHER COAUTHORED PUBLICATIONS 
 
A.1 Structural and functional insight into an unexpectedly selective N-methyltransferase 
involved in plantazolicin biosynthesis 
 
Reprinted with permission from Lee, J.*; Hao, Y.I; Blair, P.M.; Melby, J.O.; Agarwal, V.; 
Burkhart, B.J.; Nair, S.K.; Mitchell, D.A. Structural and functional insight into an unexpectedly 
selective N-methyltransferase involved in plantazolicin biosynthesis. Proc. Natl. Acad. Sci. 2013, 
110, 12954-12959.  
 
The document may be found in the supplemental file named A.1 Structural and functional 
insight into an unexpectedly selective N-methyltransferase involved in plantazolicin 
biosynthesis.pdf. 
 
In addition to contributing to the writing and editing of the manuscript, I aided in site-directed 
mutagenesis, overexpression, and purification of BamL mutants. I performed the experiments to 
determine relative conversion ratios of desmethylplantazolicin (desmethyl-PZN) to plantazolicin 
(PZN). I discovered the Y182F mutant that could be used to monoalkylate desmethyl-PZN. I 
synthesized and purified ethyl-SAM and performed all enzymatic reactions and follow-up 
experiments to characterize the products of the reaction.  
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A.2 Synthesis of plantazolicin analogues enables dissection of ligand binding interactions of 
a highly selective methyltransferase 
 
Reprinted with permission from Sharma A.; Blair, P.M.; Mitchell, D.A. Synthesis of plantazolicin 
analogues enables dissection of ligand binding interactions of highly selective methyltransferase. 
Org. Lett. 2013, 15, 5076-5079.  
 
The document may be found in the supplemental file named A.2 Synthesis of plantazolicin 
analogues enables dissection of ligand binding interactions of a highly selective 
methyltransferase.pdf. 
 
I evaluated the synthetic compounds as substrates for the methyltransferase, which I expressed and 
purified. I performed isothermal titration calorimetry binding experiments to determine how well 
the analogues bound to the protein. 
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A.3 Structure, bioactivity, and resistance mechanism of streptomonomicin, an unusual lasso 
peptide from an understudied halophilic Actinomycete 
 
Reprinted with permission from Metelev, M.; Tietz, J.I.; Melby, J.O.; Blair, P.M.; Zhu, L.; Livnat, 
I.; Severinov, K.; Mitchell, D.A. Structure, bioactivity, and resistance mechanism of 
streptomonomicin, an unusual lasso peptide from an understudied halophilic Actinomycete. Chem. 
Biol.. 2015, 22, 241-250. 
 
The document may be found in the supplemental file named A.3 Structure, bioactivity, and 
resistance mechanism of streptomonomicin, an unusual lasso peptide from an understudied 
halophilic Actinomycete.pdf. 
 
I aided in collection of mass spectrometry data for streptomonomicin. I prepared samples for 
confocal microscopy, took the images, and evaluated the growth phenotypes. 
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A.4 Biological characterization of the hygrobafilomycin antibiotic JBIR-100 and 
bioinformatic insights into the hygrolide family of natural products 
 
Reprinted with permission from Molloy, E.M.; Tietz, J.I.; Blair, P.M.; Mitchell, D.A. Biological 
characterization of the hygrobafilomycin antibiotic JBIR-100 and bioinformatics insights into the 
hygrolide family of natural products. Bioorg. Med Chem. 2016, doi: 10.1016/j.bmc.2016.05.021. 
 
The document may be found in the supplemental file named A.4 Biological characterization of 
the hygrobafilomycin antibiotic JBIR-100 and bioinformatic insights into the hygrolide 
family of natural products.pdf. 
 
For this manuscript, I collected the data for FT-MS/MS analysis and analyzed all mass 
spectrometry data. I assisted in preparation of samples for microscopy, took all confocal and 
fluorescence microscopy images, and analyzed the data. I conducted the membrane depolarization 
assay. I determined the kinetics of growth for the JBIR-100 resistant mutant strains compared to 
wild-type B. subtilis. I performed the PCR to confirm mutations in the JBIR-100 resistant strains, 
determined through microbroth dilution assays the cross-resistance of the mutants to other 
antibiotics, and performed qRTPCR (not included in the final publication). 
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A.5 In vitro biosynthesis and substrate tolerance of the plantazolicin family of natural 
products 
 
Reprinted with permission from Deane, C.D.; Burkhart, B.J.; Blair, P.M.; Tietz, J.I.; Lin, A.; 
Mitchell, D.A. In vitro biosynthesis and substrate tolerance of the plantazolicin. A.C.S. Chem. Biol. 
2016, 11, 2232-2243. 
 
The document may be found in the supplemental file named A.5 In vitro biosynthesis and 
substrate tolerance of the plantazolicin family of natural products.pdf. 
 
I performed the mass spectrometry for all of the compounds, determining the structures of the 
enzymatically treated peptides. This was essential for determining the cyclized residues and thus 
the pattern of enzymatic processing. 
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A.6 A new genome mining tool redefines the lasso peptide biosynthetic landscape 
 
Reprinted with permission from Tietz, J.I.*; Schwalen, C.J.*; Patel, P.S.; Maxson, T.M.; Blair, 
P.M.; Tai, H.-C.; Zakai, U.I.; Mitchell, D.A. A new genome mining tool redefines the lasso peptide 
biosynthetic landscape. 2016. Nature Chem Biol. Accepted.  
 
The document may be found in the supplemental file named A.6 A new genome mining tool 
redefines the lasso peptide biosynthetic landscape.pdf. 
 
I performed the mass spectrometry for the lasso peptides and was involved in determining the post 
citrulline post-translational modification of citrulassin A. I assisted in determining the threading 
of the lasso peptides through analysis of carboxypeptidase-treated samples. 
 
 
